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PART  I 
 
INTRODUCTION 
 
 
 
 
 
 
CHAPTER 1 
 
GENERAL INTRODUCTION AND OUTLINE OF THE THESIS 
 
 
 
 
           
 
“The excursions of the staphylococcus into disease 
production seem to be aberrant activities outside the main 
stream of its existence.” 
R. Williams 1963 
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INTRODUCTION 
Staphylococcus aureus very commonly causes infections in humans: virtually every person 
will have one or more Staphylococcus aureus infections in his or her lifetime. An 
achievement most microbes do not have on their resume. Most infections occur after an 
abrasion or cut of the skin due to (non-) accidental trauma, like a child that falls on the street. 
A lesion of the skin, especially when it has not been cleansed thoroughly, can eventually 
become painful, red, swollen, and warm, after a day or two. These signs are usually 
accompanied by a creamy discharge from the wound, known as purulence. This describes the 
symptoms of an ordinary S. aureus wound infection. If such a wound infection occurs, and is 
cleaned and kept clean, the infection usually subsides and antibiotics are not necessary.  
One of the reasons that S. aureus is a frequent cause of infections, is that it can survive for 
months on any type of surface.1 S. aureus cells also possess a wide armamentarium of 
virulence factors. These virulence factors include factors for adherence, for cell 
internalization, for evasion of host defense mechanisms, and for invasion of host tissue.1 With 
the help of these virulence factors, S. aureus is able to colonize the skin and mucous 
membranes of more than 30% of the human population.2 It can also colonize the skin and 
mucous membranes of several animals. This happens on a global scale. Being surrounded or 
colonized by S. aureus is, however, harmless in most cases for a healthy (immune competent) 
human.  
Occasionally such a simple wound infection can become complicated by invasion of the 
bacteria, where they can cause deep tissue infection and enter the blood stream.3 Once S. 
aureus cells have entered the blood stream, they will be transported to internal organs, skin 
and bone, where they can cause new infections, known as metastatic abcesses.3 This is a 
serious infection with a high mortality rate, and needs prompt antibiotic treatment.3 If these 
infections in healthy humans develop outside the hospital, they are known as community 
acquired infections. In case these infections develop during hospitalization, they are called 
nosocomial infections. 
S. aureus ranks second as the cause of nosocomial blood stream infections, that leads to 
increased morbidity, mortality, hospital stay, and costs.4-7 Patients admitted to the hospital 
are, in general, at increased risk for infection. They are ill and, therefore, moderately to 
severely immune compromised. Hospital treatment usually requires that first line barriers for 
pathogens, of which the skin is an important one, are intentionally breached, as occurs during 
surgery or placing of indwelling devices, such as bladder and intravascular catheters. Surgery 
can result in postoperative wound infections, urine catheterization in urinary tract infections, 
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and intravascular catheters in blood stream infections. Therefore, prevention of these 
infections is important. 
Most of these nosocomial S. aureus infections are caused by the patient’s own S. aureus cells, 
which were already present on the skin or mucosal membranes prior to hospital admission.8 
The nose, or rather, the anterior nares are the most consistent site from which S. aureus can be 
cultured.2 Studies, so far, have shown that eradicating S. aureus from the nose can eradicate or 
reduce the load of S. aureus from other body sites.9 Nasal carriers of S. aureus are also at 
increased risk of developing a S. aureus infection.2 Therefore, eradicating S. aureus from the 
nose may prevent these infections, as has been shown for certain patient categories, including 
dialysis-, dermatological-, and surgical patients.10-14 Mupirocin nasal ointment is currently the 
treatment of choice for eradicating S. aureus from the nose. This thesis focuses on S. aureus 
nasal carriage as a source for subsequent nosocomial S. aureus infections. 
An overview and the latest insights regarding S. aureus nasal carriage, associated risks of 
developing infections and possible preventive measures, will be given in Chapter 2. Since 
mupirocin efficacy studies in preventing nosocomial infections have only been performed in 
surgical and dialysis patients, we decided to design and perform a mupirocin efficacy study in 
non-surgical patients. These patients are also responsible for a great burden in S. aureus 
hospital infections. This randomized, placebo-controlled trial is described in Chapter 3.  
This trial lead to four new research questions:  
1. What is the risk of nosocomial S. aureus bacteremia for S. aureus carriers versus non-
carriers? 
2. Is there a difference in risk of mortality for carriers versus non-carriers once 
bacteremic with S. aureus? 
3. What is the efficacy of mupirocin on reducing S. aureus carriage at extra-nasal sites? 
4. Can invasive S. aureus strains be identified by genotyping?  
The first two research questions are addressed in Chapter 4. Chapter 5 describes a study in 
which the effect of mupirocin on nasal, pharyngeal and perineal carriage of S. aureus is 
investigated (question 3). Chapter 6 describes a nested-case control study where genotyping 
data of invasive S. aureus strains are compared to non-invasive strains (question 4). 
Development of prophylactic strategies are always based on the understanding of the 
pathogenesis of the specific disease. The mechanisms underlying S. aureus nasal carriage and 
how nasal carriage results in disease are still incompletely understood. We decided to study 
whether nose picking is a determinant of S. aureus nasal carriage. Nose picking behaviour 
seems to be an obvious determinant, but was never studied before. In collaboration with the 
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department of otolaryngology, we performed a study on nose picking behaviour and S. aureus 
nasal carriage, which we describe in Chapter 7.  
When we study S. aureus, we can extrapolate these findings to methicillin resistant S. aureus 
(MRSA). This is essentially the same micro-organism, the only difference is that the latter is 
more difficult to treat with antibiotics. The Netherlands are well known for their low 
prevalence rate of MRSA in the hospitals. In the U.S.A. more than 40% of the S. aureus 
strains cultured from hospitalized patients are methicillin-resistant, as compared to less than 
1% in the Netherlands. In the Netherlands, MRSA could usually be related to a hospital 
admission in a foreign country, indicating that most MRSA strains were imported into the 
country. But in the last few years there were reports that many MRSA strains could not be 
related to sources abroad. Therefore, we wanted to know the prevalence of MRSA carriage in 
patients admitted to the hospital with no relation to a foreign admission. We performed such a 
prevalence study with an improved detection technique, as described in Chapter 8 and 
Chapter 9.  
All studies included in this thesis are based on the assumption that the anterior nares are the 
main reservoir for S. aureus in humans. All studies, their results and conclusions are, 
therefore, ‘lead by the nose’. 
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ABSTRACT 
Staphylococcus aureus causes 25 percent of all nosocomial infections and contributes 
substantially to the complications and costs of hospitalization. Nasal carriage of S. aureus is an 
important risk factor for these nosocomial S. aureus infections. This chapter addresses the 
determinants of S. aureus nasal carriage, the risks of S. aureus nasal carriage for subsequent 
infection with this micro-organism, and strategies to prevent these infections.   
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INTRODUCTION 
Staphylococcus aureus is both a human commensal and a frequent cause of clinically important 
infections, including bacteremia, metastatic abscesses, septic arthritis, pneumonia, osteomyelitis 
and wound infections.1 S. aureus infections are frequently nosocomial and lead to increased 
hospital stay, antibiotic use, costs, and mortality.2 Though in the Netherlands the prevalence of 
methicillin resistant S. aureus (MRSA) is still very low, the worldwide increasing number of 
infections caused by MRSA, therapy has become problematic. Since 2002, the first three 
vancomycin-resistant MRSA strains have been cultured in the United States.3-5 Therefore, the 
prevention of staphylococcal infections and emergence of MRSA is essential.  
Nasal carriage of S. aureus plays a key role in the development of S. aureus infections and is a 
major reservoir for MRSA.6 Since there are already some excellent reviews on this subject 
available, this chapter will mostly focus on the latest insights on determinants of S. aureus nasal 
carriage, the risks for infection associated with S. aureus nasal carriage, and strategies for 
prevention.7-9  
 
GENERAL 
What is S. aureus nasal carriage? 
S. aureus colonizes the skin and mucosal surfaces of humans and also of several animal species. 
The mechanisms that lead to S. aureus nasal carriage are multi-factorial (Table 1). Conceptually, 
carriage is the net result of repellent and attracting forces that decide whether an individual is a 
carrier at a certain time point. Only S. aureus strains that are capable of withstanding host 
defenses and that can reach the site to which it can adhere and propagate from there, will 
establish a carrier state.  
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Table 1.  Overview of mechanisms leading to S. aureus nasal carriage. 
Mechanism Host S. aureus 
General 
 
 
 
 
 
Exposure 
 
 
Adherence 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Evading) immune response 
Age, sex, race 
Antibiotic use  
Underlying disease (IDDM*, HIV, 
liver disease, eczema, nasal 
abnormalities, and others) 
 
(heavily) colonized partner 
Hospital environment 
 
Available adhesins 
Keratin type 10 
Epithelial membrane 
 
Collagen 
Vitronectin 
Fibronectin 
Fibrinogen 
Laminin 
Mucins 
(Extracellular) matrix proteins 
Charge 
Hydrophobicity 
 
Mucosal/skin barrier 
Clearance in mucus by microvilli 
Immunoglobulins 
Lysozyme, lactoferrin, antimicrobial 
peptides 
Opsonization 
Immune status 
HLA type 
Virulence 
Antibiotic resistance 
 
 
 
 
 
 
 
Bacterial interference 
Clumping factor B  
(Lipo)teichoic acid 
Capsule 
Collagen binding protein 
Vitronectin binding protein 
Fibronectin binding protein 
Fibrinogen binding protein 
Laminin binding protein 
Capsular polysaccharides 
MSCRAMM’s# 
Charge 
Hydrophobicity 
 
Proteases, lipases 
Host cell internalization 
Protein A (binds Fc of IgG) 
Resistance to antimicrobial peptides
 
Capsule 
* insulin dependent diabetes mellitus 
# microbial surface components recognizing adhesive matrix molecules 
 
Studies, as reviewed by Kluytmans et al., have shown that the anterior nares are the most 
consistent site from which this organism can be cultured 8. In longitudinal studies, three types of 
S. aureus nasal carriers can be distinguished: persistent carriers, intermittent carriers and non-
carriers.8 Between 10 and 35 percent of healthy individuals almost always carry one strain and 
are called persistent carriers. A larger proportion (20 to 75 percent) harbors S. aureus 
intermittently, and is called intermittent carriers. Finally, between 5 and 50 percent almost never 
carry S. aureus and are called non-carriers.8  
Genotyping data reveal that persistent carriers usually carry only one identical S. aureus strain 
over time and that intermittent carriers commonly carry different strains over time.8,10,11  
The load of S. aureus is higher in persistent carriers compared to intermittent carriers, resulting in 
more dispersal and higher risk of infection.8,12,13 Persistent carriage is more common in children 
than in adults and many people shift from persistent carriage to intermittent or non-carriage 
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between the age of 10 and 20 years.8 Cross-sectional studies yield a prevalence of approximately 
35 percent in the general population, which is actually a mix of persistent and intermittent 
carriers at that time point.8,9  
The anterior nares consist of fully keratinized epidermis with hairs, sebaceous glands and sweat 
glands, squamous epithelium and ciliated mucosal membrane. S. aureus predominantly colonizes 
the moist squamous epithelium on the septum adjacent to the nasal ostium.14 This area is devoid 
of cilia and relatively absent of nasal mucous secretions, which contain antimicrobial peptides.14 
It has been suggested that S. aureus nasal carriers have deficiencies in their innate immune 
response, but recent data do not support this.15 These data show that S. aureus nasal colonization 
induces a neutrophil mediated inflammatory response, which fails to clear the colonizing 
bacteria.14  
Twin studies and family studies are not conclusive in whether there is evidence for genetic 
determinants for S. aureus nasal carriage.7 However, host determinants play an important role in 
the pathogenesis of S. aureus nasal carriage. This is illustrated in a study where persistent carriers 
and non-carriers are artificially inoculated with a mix of different S. aureus strains, after 
decolonization, including the resident strain of carriers.16 This study showed that most non-
carriers expel the S. aureus strains and that persistent carriers become carrier again and usually 
select their resident strain out of the mix.16 A contradicting study, by the same author, shows that 
the repeated exposure to S. aureus cells (e.g. a colonized partner) is probably more crucial than 
host factors.17   
S. aureus adherence may be non-specifically mediated via physicochemical forces including 
hydrophobic interactions.8 Alternatively, adherence may more specifically be accomplished 
through binding of certain bacterial cell surface moieties (adhesins) to defined structural 
receptors in the membrane of the host cell.8 Recent experiments have shown that clumping factor 
B, a S. aureus virulence factor, is capable of adhering to human cytokeratin type 10.18 Another 
study finds that cell wall teichoic acid is essential for S. aureus nasal colonization.19 Differences 
in the expression of genes coding for these factors, depending on the ecological niche, and other 
putative adhesins and receptors may provide clues to the ‘true’ determinants of carriership of S. 
aureus.   
Increased carriage rates are found in hospitalized patients. Subgroups of patients with 
significantly increased carriage rates include those with insulin dependent diabetes mellitus, those 
on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD), intravenous drug use, S. 
aureus skin infections, liver dysfunction, and human immunodeficiency virus (HIV), as reviewed 
recently.8,9 Until now it was believed that repeated punctures in drug users and diabetes patients 
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were the source for S. aureus carriage, but recent studies do not support this. Intravenous drug 
users actually had a lower prevalence of S. aureus nasal colonization when compared to drug 
users on an oral methadone program.20 However, confounding variables can not be excluded in 
this study. Additionally, an increase in fasting glucose levels was significantly associated with S. 
aureus persistent carriage in a recent study.17. Both studies indicate that repeated punctures may 
not play a crucial role in the pathogenesis to S. aureus nasal carriage.  Another novel determinant 
is smoking status. Current smoking was shown to be negatively associated with S. aureus 
carriage status.17 Unfortunately, a full understanding of the determinants of the various carriage 
states remain elusive. 
 
What are the risks of S. aureus nasal carriage? 
The nose is regarded as the ecological niche from where S. aureus can spread to other parts of the 
body. Elimination of nasal carriage by using topical mupirocin also eliminates hand carriage.21 
These observations suggest that from the nose, the skin becomes colonized with S. aureus, and 
eventually skin lesions, including surgical wounds and catheter exit sites. Whether colonization 
of a skin lesion with S. aureus leads to infection and whether the infectious process is contained 
or spreads from there, depends on a complex interplay between S. aureus virulence factors and 
host defense mechanisms.1 The risk of infection is increased by the presence of foreign material. 
This can be explained by the impaired function of host phagocytes in the presence of foreign 
material and by the coating of these materials with human serum proteins to which S. aureus can 
readily adhere and grow.1 
In 1959, several reports were published that investigated the relation between nasal carriage of S. 
aureus and the development of surgical wound infections. A clonal relation between nasal strains 
and infectious strains was often found, as determined in those days by phage typing. Further 
studies showed a significantly increased risk for development of a wound infection by nasal 
carriers. The causal relationship is emphasized by a correlation between the colonization density 
of S. aureus at the carriage site and the risk for the development of infection.8,12  
Since then, carriage of S. aureus has been identified as a risk factor for the development of 
infections in various settings. This has been studied extensively in surgical patients (general, 
orthopedic, and thoracic surgery), in patients on hemodialysis, in patients on CAPD, HIV-
infected patients, and in patients in intensive care units. Von Eiff et al. have elegantly illustrated 
in a prospective study that nasal strains and subsequent bacteremic strains have the same 
genotype in more than 80 percent of the cases, as determined by pulsed field gel 
electrophoresis.22  
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One study found that nasal carriage of S. aureus was not an independent risk factor for 
nosocomial S. aureus bacteremia, but the design of this study was not suitable to study this 
association. Nasal carriers in a sub-group of surgical patients did have a higher risk (OR: 4.0) for 
nosocomial S. aureus bacteremia compared to controls. In this study, the presence of a central 
venous catheter (OR: 6.9), anemia (OR: 3.3), and hyponatremia (OR: 3.3) were associated with 
hospital acquired S. aureus bacteremia.23 Anemia and hyponatremia may be indicators for severe 
disease and should not be considered as risk factors.  
In hemodialysis patients, S. aureus is the most frequently found pathogen in infections at the 
vascular access site and in bacteremia. The infection rate is higher in carriers on hemodialysis, 
with relative risks varying from 1.8 to 4.7.8,24-27 S. aureus isolates are usually identical to the one 
previously isolated from the patient’s nares.22,25 In patients treated with CAPD, S. aureus is the 
leading cause of exit site- and tunnel-infection, often leading to catheter loss. Only CAPD 
patients who are persistent S. aureus nasal carriers are at increased risk of acquiring S. aureus 
infections.17 Intermittent nasal carriers of S. aureus have the same risk of S. aureus infection as 
non-carriers.17 The observed relative risks for carriage are even higher than those in hemodialysis 
patients (range: 1.8 to 14.0).8,28-32 Also in CAPD patients, the nasal strain and the infectious strain 
are clonally related in most cases.8,29  
In HIV positive patients, increased rates of S. aureus bacteremia and deep soft tissue infections 
have been observed, which frequently recur. Even higher infection rates are found in patients 
with AIDS, as compared to HIV-positive asymptomatic patients. Nguyen and others found that 
nasal carriage is an important risk factor in this patient population (OR: 5.1).33 Other risk factors 
for infection in this study were presence of a vascular catheter (OR: 4.9), low CD4 cell count (< 
100 cells/mm3; odds ratio 3.5) and neutropenia. The risk for developing an S. aureus infection 
was approximately 10% for every six months in patients who were nasal carriers of S. aureus and 
had CD4 cell counts of less than 100/cells/mm3. It should be noted that nasal carriage was more 
common in patients who were not receiving cotrimoxazole prophylaxis for prevention of 
Pneumocystis jiroveci pneumonia. The latter is confirmed in another study.34 
After coagulase-negative staphylococci, S. aureus is the second most prevalent organism causing 
intravascular device-associated bacteremia.8,35,36 However, no study has been performed with the 
primary aim of establishing the role of S. aureus nasal carriage in this setting. Pujol et al looked  
at bacteremia in an intensive care unit. Most of the S. aureus bacteremias had an intravascular 
device as a source. In this study carriers of S. aureus had a relative risk of 12.4 for the 
development of S. aureus bacteremia.37 
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Methicillin-resistant S. aureus (MRSA) 
Carriage of MRSA constitutes a special problem with regard to prevention and treatment of 
infection. Studies show that nasal MRSA carriers have a higher risk of nosocomial infection with 
this micro-organism. Furthermore, patients infected with MRSA have more morbidity and 
mortality compared to patients infected with susceptible strains (Table 2).37-44 Therefore, it is 
important to keep the prevalence of MRSA low.  
 
Table 2.  Overview of studies that illustrate the increase in hospitalisation days, and the increase in mortalitity and 
costs of MRSA infections in comparison to susceptible S. aureus infections.  
Reference Increase in admission days 
 
Mortality (OR)# Increase in costs (OR) 
39 5 3.4 1.2 
40 8 - 3.0 
41 7 2.7 - 
42 17 3.2 - 
43 18 1.8 - 
77 7 1.1 - 
78 - 1.7 - 
38 - 1.4 - 
44 - 1.9 - 
# OR: odds ratio. 
- not stated. 
 
The MRSA prevalence in the Netherlands is low: less than 1% of the clinical isolates is 
methicllin resistant.45 This can be achieved by maintaining a restrictive antibiotic prescription 
policy and by screening and isolation of patients at risk for MRSA carriage (e.g. repatriated 
patients) until screening cultures prove negative. MRSA carriers need to stay in isolation and 
need to receive decolonization treatment. MRSA positive hospital personnel are relieved from 
their duties, send home, and should be treated for MRSA carriage. They can return to work after 
eradication therapy.46 
 
Decolonization strategies. 
In populations in which S. aureus nasal carriage is identified as a risk factor for infection it is 
conceivable that elimination of carriage would reduce the infection rate. Three approaches for 
elimination of carriage are available: (1) local antibiotic therapy with nasal ointments, (2) 
systemic antibiotics, (3) bacterial interference, and  combinations of these strategies (e.g. nasal 
ointment and systemic antibiotics). The available options are summarized in Table 3.  
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Table 3.  Strategies# for eliminating S. aureus from the nose (from reference 79, with permission). 
Decolonizing therapy Frequency Efficacy Remark 
Topical*: 
Mupirocin nasal ointment 2% 
Polysporin 
Bacitracin 
Chlorhexidine 
Lysostaphin nasal cream 
Povidone-iodine cream  
Tea tree oil 4% 
 
Systemic: 
Rifampicin 
Clindamycin 
 
Combinations: 
Fusidic acid 2% and oral cotrimoxazole 
Rifampicin and other oral or topical drug. 
 
 
Interference: 
S. aureus 502A 
 
Corynebacterium spp. 
 
2-3 times daily 
2-3 times daily 
3 times daily 
4 times daily 
not registered 
unclear 
unclear 
 
 
600 mg/day 
1200 mg/day 
 
 
3 times daily 
depends on  
combination 
 
 
not registered 
 
not registered 
 
Very good 
Good 
Moderate 
Poor 
Potential 
Potential 
Potential 
 
 
Good 
Potential 
 
 
Very good  
Very good 
 
 
 
Good 
 
Potential 
 
Beware of resistance. 
Use when therapy failure.  
Anaphylaxis reported. 
Anaphylaxis reported. 
Trial expected soon. 
Needs more evaluation. 
Needs more evaluation. 
 
 
Don’t use as single therapy. 
Needs more evaluation. 
 
 
As effective as mupirocin 
 
 
 
 
Prevents (re)colonization. 
Needs more evaluation. 
Eliminates S. aureus. 
Needs more evaluation. 
# most strategies are effective after 5 to 10 days. Always be aware of the possibility of resistant micro-organisms. Short-course 
therapies prevent resistance formation. 
* for MRSA decolonization, most strategies are combined with antiseptic skin scrub, which is the most effective for S. aureus 
decolonization. 
 
For the first option, mupirocin nasal ointment, has shown to be efficacious in eliminating S. 
aureus carriage. Mupirocin is active against a wide variety of gram-positive bacteria, including S. 
aureus. Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to 
bacterial isoleucyl transfer-RNA synthetase.47 Mupirocin is well tolerated and, when used 
appropriately (application to the nose twice daily for 5 days) development of resistance is 
minimal. However, mupirocin resistance does occur, by modification of isoleucyl transfer-RNA 
synthetase. Also plasmid mediated high level mupirocin resistance has been reported.48 An 
extensive review of the literature on mupirocin has been published by Hudson and Laupland.47,49  
Doebbeling et al. has found that when mupirocin was applied to the nose twice daily for 5 
consecutive days, this resulted in elimination of carriage in 91% of stable nasal carriers.50 Four 
weeks post-treatment, 87% of the subjects remained free of nasal carriage, at six months 48%, 
and at 12 months 53%. In patients on hemodialysis mupirocin is less effective. Apparently, in this 
group of patients other body sites exist were S. aureus can maintain itself.51 S. aureus is capable 
of internalization into host epithelial cells, which can be triggered by antibiotic use.52,53 The role 
of S. aureus internalization in mupirocin failure has not been established. 
Although development of resistance to mupirocin was not observed in clinical studies for 
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eradication of carriage it has been reported repeatedly in the literature.54 Generally, mupirocin 
resistance emerged in cases of prolonged and extensive use, especially for staphylococcal skin 
diseases. The resistance mechanism is transmissible and this causes concern about the future 
spread of mupirocin resistance, when it is used on a large scale. Therefore, restricted usage of this 
antimicrobial agent is recommended. Restricted means only in selected patient groups and for 
short courses.  
Polysporin ointment (containing bacitracin, polymixin B, and gramicidin) has been proven 
successful in 82 percent of  11 cases whom had previously failed a 1 week course of topical 
mupirocin.55 This ointment should be reserved for resistant organisms and/or treatment failure. 
Topical bacitracin alone is half as effective as mupirocin for nasal decolonization and is therefore 
not considered an option for the purpose of decolonization.56 A comparative study of topical 
mupirocin versus oral cotrimoxazole plus topical fusidic acid, both in conjunction with a 
chlorhexidine soap bath, yielded equal efficacy and safety for the eradication of MRSA from 
nasal and extra nasal sites.57  
Novel agents that may be helpful in the future in S. aureus decolonization, are lysostaphin, tea 
tree oil, and povidone-iodine cream. Lysostaphin is a rapidly bactericidal anti-staphylococcal 
agent that hydrolyzes the cell wall. An old study showed an elimination rate of 90 percent.58 
Recently an intranasal lysostaphin cream has been developed and clinical trials are underway. 
Tea tree oil has a wide spectrum of antimicrobial activity and is relatively non-toxic when applied 
topically.59 A controlled trial showed that tea tree oil is more effective than chlorhexidine at 
clearing superficial skin sites from MRSA, but is inferior to mupirocin in decolonizing the 
anterior nares.60 In-vitro studies with povidone-iodine cream indicate that this ointment has 
potential and is suitable for clinical trials.61   
The second approach to eliminate S. aureus nasal carriage, i.e. by administering systemic 
antibiotics, has been disappointing for most agents. Only rifampicin has proven to be an effective 
systemic agent.62 When prescribing rifampin, one must be aware of its side effects and the 
prevalence of rifampin resistant S. aureus mutants. It is advised to combine rifampin with another 
oral drug or a topical drug, like bacitracin or mupirocin. A potentially effective drug is 
clindamycin, a bacteriostatic agent that achieves high tissue concentrations. In a small study of 
seven carriers, clindamycin was able to decolonize all these carriers.62 This drug should be 
studied more extensively for the indication of nasal decolonization. Also quinolones achieve 
eradication rates of up to 70 percent and warrant further evaluation. 62 
 
The third strategy is bacterial interference. This is based upon the finding that when two 
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competing micro-organisms vie for the same ecological niche, the organism arriving first will 
usually prevail. Micro-organisms can accomplish this by blocking receptor sites and by quorum 
sensing mechanisms. However, the exact mechanism for bacterial interference has not been 
clarified. Colonization with a virulent strain of S. aureus can be prevented by active colonization 
with a non-virulent strain of S. aureus (e.g. with strain 502A) and other bacterial species. This 
strategy was used successfully in nurseries during outbreaks of S. aureus infections in the 1960’s 
and to treat patients with recurrent furunculosis.63-65 However, due to a published fatal infection 
with S. aureus 502A, this strategy has been abandoned. Apart from this incident, the benefits of 
the S. aureus 502A interference program far outweighed the hazards at that time.  
Recently S. aureus 502A has been used in a trial with CAPD patients. S. aureus 502A was able to 
colonize the nares after eliminating the resident strain and was found to colonize the exit site after 
some time 17. A Japanese study in healthy volunteers has shown successful eradication by 
application of corynebacteria in the nose.66 More studies are needed to see if these strategies are 
practical for daily clinical practice and beneficial for patient’s outcome. 
For all strategies, recolonization or colonization with new S. aureus strains have been described. 
Therefore, follow-up of individual patients by nasal culturing is warranted and treated when these 
cultures are positive. Staying ahead of antibiotic resistance by developing alternative effective 
eradication strategies, stresses the point that the exact mechanisms of S. aureus nasal carriage 
need to be elucidated.  
 
Does decolonization prevent infection in surgical patients? 
To prevent S. aureus infection, elimination of S. aureus nasal carriage seems to be the most 
straightforward strategy. The introduction of mupirocin ointment for this indication, in the late 
1980s, lead to several intervention studies. In this section we will discuss the different clinical 
trials with mupirocin nasal ointment, which are summarized in Table 4.  
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Table 4.  Summary of randomized controlled intervention studies (from reference 79, with permission). 
Ref Intervention Population Outcome 
68 
 
67 
 
 
74 
 
 
70 
 
73 
Mupirocin 
 
Mupirocin 
 
 
Vaccine 
 
 
Mupirocin 
 
Mupirocin 
 
Surgical 
 
Orthopedic 
 
 
Hemodialysis 
 
 
Hemodialysis 
 
CAPD$  
Two-fold reduction in nosocomial S. aureus infections.  
 
Non-significant 1.7 fold reduction in surgical site infection rate. 
Five-fold reduction in endogenous S. aureus infection. 
 
Two-fold reduction for approximately 40 weeks in 
Development of S. aureus bacteremia. 
. 
Four-fold reduction in S. aureus infection. 
 
Three-fold decrease in exit-site S. aureus infection. 
Not cost effective. 
$: chronic ambulatory peritoneal dialysis 
 
One study compared cardio-thoracic surgery patients who received mupirocin prophylaxis 
(n=868) with a historical control group (n=928).8 The surgical wound infection rate in the control 
group was 7.3% and was 2.8% in the treated group (p<0.001).8 Two randomized controlled trials 
have been published, studying the efficacy of mupirocin in a general surgical and an orthopedic 
patient population.67,68  Perl and co-workers included 3,864 patients in her study, both carriers 
and non-carriers, who were randomized to either mupirocin or placebo. Overall, 2.3% of 
mupirocin recipients and 2.4% of placebo recipients had S. aureus infections at the surgical site. 
Nasal carriage of S. aureus was eliminated in 83.4% of patients who received mupirocin, versus 
27.4% of those who received placebo. Among the S. aureus nasal carriers (n=891), 4.0% of those 
who received mupirocin had overall nosocomial S. aureus infections, as compared with 7.7% of 
those who received placebo (odds ratio for infection, 0.49 [0.25-0.92]).  
Kalmeijer et al. also included carriers and non-carriers, before an orthopedic surgical 
intervention.67 A total of 315 and 299 patients were randomized to receive mupirocin and 
placebo, respectively. The preoperative nasal carriage rate was approximately 30%. Eradication 
of nasal carriage was significantly more effective in the mupirocin group (eradication rate, 83.5% 
versus 27.8%). In this study, mupirocin nasal ointment did not reduce the S. aureus surgical site 
infections rate significantly (3.8% in the mupirocin group and 4.7% in the placebo group), nor the 
duration of hospital admission. In the mupirocin group, the rate of endogenous S. aureus 
infections (i.e. the strain that causes the infection has the same genotype as the strain previously 
cultured from the nose) was 5 times lower than in the placebo group (not significant).  
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Does decolonization prevent infection in dialysis patients? 
Several oral and topical antibiotics have been studied for eradication of S. aureus nasal carriage 
in hemodialysis patients and are summarized by Chow and Yu.62 Rifampicin in conjunction with 
nasal bacitracin can result in a significant reduction of the S. aureus infection rate in 
hemodialysis patients. However, emergence of rifampicin-resistant strains has been observed. 
Short course therapies and combination therapies may prevent the emergence of resistant isolates  
Mupirocin has also been evaluated extensively in hemodialysis patients, and has been reviewed 
by Boelaert. 69 In a randomized, double-blind placebo controlled trial, stable nasal carriers were 
treated with mupirocin for two weeks three times daily, and then thrice weekly for a total of 9 
months.70 A significant reduction in the S. aureus infection rate (1/104 patient-months among 
treated and 6/147 patient-months among non-treated) was observed. The administration of 
mupirocin to nasal carriers was later adjusted to an initial course of 5 days, 3 times per day, and 
thereafter once a week during the remaining period on hemodialysis. Using this schedule a highly 
effective elimination of carriage was achieved and this was accompanied by a four to six-fold 
reduction in the S. aureus-bacteremia rate.70  
The effect of decolonizing the nares from S. aureus has also been studied in peritoneal dialysis 
patients. The effects of intermittent administration of rifampicin in patients on CAPD was studied 
in a randomized controlled trial.71 No significant difference in the S. aureus peritonitis rates was 
found. Until now two reports have been published studying the effects of mupirocin on the 
infection rate in CAPD patients. A case-control study in a CAPD patient population found that 
the S. aureus peritonitis rate was significantly reduced in S. aureus nasal carriers who were given 
mupirocin.72 There was a significant lower catheter loss due to exit-site infections in the treated 
group. The overall peritonitis rate was not reduced, mainly due to a significantly higher rate of 
peritonitis caused by gram-negative bacteria in the treated group compared to the not-treated 
group. Recolonization occurred frequently, especially after three months.  
Also a randomized controlled study was performed in this patient population.73 Nasal carriers 
were treated with mupirocin or placebo ointment twice daily for five days and was repeated every 
four weeks. In 1,144 patients screened, 267 carriers were identified (23.3%). No overall 
differences in the rates of catheter tunnel or exit site infections or peritonitis were found. The S. 
aureus exit-site infection rate was significantly lower in the treated group (1 in 99.3 patient 
months versus 1 in 28.1 patient months, p=0.006).73 There was no significant increase in gram-
negative infections and development of resistance to mupirocin was not observed. The possibility 
of development of resistance should be accounted for when using mupirocin for prolonged 
periods such as in CAPD patients. It can be concluded that elimination of S. aureus nasal carriage 
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in patients on CAPD decreases the exit site infection rate. The effect on the peritonitis rates 
remains unclear. Researchers and clinicians should be cautious for organism replacement. 
Prevention of S. aureus infections is meaningless if other, potentially more serious, infections 
come in place. 
 
Vaccination 
The past 100 years many attempts have been made to develop a vaccine to control 
Staphylococcal disease in humans and cattle. The fact that an infection with S. aureus does not 
protect against a new infection with S. aureus, illustrates that vaccine development is not easy. 
Some recent advances in vaccine development do show some protective action. A double-blind 
trial in patients receiving hemodialysis, has evaluated the use of a conjugate vaccine with S. 
aureus type 5 and 8 capsular polysaccharides.74  
These two capsular types account for approximately 85 percent of all clinical isolates and can 
induce a type-specific opsonophagocytic killing by neutrophils in vitro and confer protection in 
animals. The study has shown that this vaccine can confer partial immunity against S. aureus 
bacteremia for approximately 40 weeks, after which protection wanes as antibody levels 
decrease. Nearly 90 percent of the patients had a response to the vaccine and the decrease in 
vaccine efficacy paralleled the decrease in levels of specific antibodies. It would be interesting to 
study the efficacy of this vaccine or an improved version of this vaccine in other patient 
populations at risk for S. aureus infection.  
 
Is prophylaxis cost-effective? 
Cost-effectiveness studies have been performed for mupirocin prophylaxis in hemodialysis 
patients, peritoneal dialysis patients, and thoracic surgery patients.2,75,76 Bloom et al evaluated 
three management strategies: (1) all patients are screened by a nasal culture every three months 
and those carrying S. aureus are treated with mupirocin, twice daily for five days, (2) all patients 
are treated, irrespective of their carrier state, with mupirocin weekly for 3 days, twice daily, (3) 
no preventive measures are taken, only infections are treated.  It was assumed that 75% of S. 
aureus infections are attributable to nasal carriage in hemodialysis patients and eliminating nasal 
carriage of S. aureus reduces the number of infections with 45 percent to 55 percent. The annual 
savings of the first strategy were $784,000 per thousand dialysis patients and of the second 
strategy the savings were $1,117,000 per thousand dialysis patients. Both strategies prevented 
death and improved the quality of life. Since the risk of development of resistance with 
widespread use of mupirocin is increased, the first strategy would be preferred. 
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Davey et al also performed a cost-effectiveness study in peritoneal dialysis patients, on basis of a 
randomized placebo controlled trial, described earlier.73,76 Patients in the mupirocin group had 
lower antibiotic and hospitalization costs. However, overall antibiotic costs, including mupirocin, 
were significantly higher in the mupirocin group. Mupirocin prophylaxis would have been cost 
neutral if the exit site infection rate in the placebo group increases to 75 percent, or if the costs of 
screening was reduced from 15 English pounds to 3 pounds, or if the costs of mupirocin treatment 
was reduced from 93 pounds to 40 pounds per patient-year. This study did not include the 
patient’s quality of life and the long-term effects of S. aureus infection into consideration. One 
may conclude that short-term savings of mupirocin prophylaxis in dialysis patients in health care 
costs are unlikely to be sufficiently great to offset the cost of mupirocin. 
Vandenbergh et al assessed the cost-effectiveness of perioperative intranasal application of 
mupirocin calcium ointment in cardiothoracic surgery, based on results of an intervention study 
with historical controls.2 Postoperative costs were increased significantly in patients with a 
surgical-site infection, in comparison with uninfected patients.  The mean attributable costs of 
these surgical site infections were estimated at $16,878. The incidence of surgical site infections 
was 7.3% in the control group and 2.8% in the mupirocin group. A sensitivity analysis showed 
that of the four variables, which could influence the resulting cost-effectiveness, being the cost of 
mupirocin, the effectiveness of the intervention, the cost of a surgical site infection and the 
incidence of surgical site infection without using mupirocin, only the costs of a surgical site 
infection had a major influence on the model. Therefore, they conclude that, provided that 
perioperative mupirocin reduces the surgical site infection rate, mupirocin prophylaxis in patients 
undergoing cardiothoracic surgery is cost-effective.  
 
CONCLUSION 
This review has summarized the clinical impact of S. aureus nasal carriage and the effect of 
several prophylactic measures on these infections. S. aureus nasal carriers are at increased risk of 
acquiring invasive S. aureus infections. So far, there is only evidence that mupirocin prophylaxis 
is efficacious in hemo- and peritoneal dialysis patients, and patients undergoing surgery. In 
CAPD patients, mupirocin is only effective in preventing exit-site infections and not deeper 
infections like peritonitis and tunnel infections. For surgical patients, the profile of patients that 
are most at risk should be identified to make this strategy more effective. More studies should be 
performed to identify other patient categories that may benefit from prophylaxis. Since infections 
with multi-resistant S. aureus strains rising, more effort should be put in elucidating the 
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mechanisms leading to S. aureus carriage and infection, to be able to develop new and better 
effective prophylactic strategies.  
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ABSTRACT 
Background: Staphylococcus aureus nasal carriage is a major risk factor for nosocomial S. 
aureus infection. Studies show that intranasal mupirocin can prevent nosocomial surgical site 
infections. No data are available on the efficacy of mupirocin in non-surgical patients.  
Objective: To assess the efficacy of mupirocin prophylaxis in preventing nosocomial S. 
aureus infections in nonsurgical patients.  
Design: Randomized, double-blind, placebo-controlled trial. 
Setting: 3 tertiary care academic hospitals and 1 nonacademic hospital. 
Patients: 1602 culture-proven S. aureus carriers hospitalized in nonsurgical departments. 
Intervention: Therapy with mupirocin 2% nasal ointment (n = 793) or placebo ointment (n = 
809), twice daily for 5 days, started 1 to 3 days after admission. 
Measurements: Nosocomial S. aureus infections according to defined criteria, in-hospital 
mortality, duration of hospitalization, and time to nosocomial S. aureus infection. S. aureus 
isolates were genotyped to assess whether infection was caused by endogenous strains. 
Results: The mupirocin and placebo groups did not statistically differ in the rates of 
nosocomial S. aureus infections (mupirocin, 2.6%; placebo, 2.8%; risk difference, 0.2% [95% 
CI, –1.5% to 1.9%]), mortality (mupirocin, 3.0%; placebo, 2.8%; risk difference, –0.2% [CI, –
1.9% to 1.5%]), or duration of hospitalization (median for both, 8 days). However, time to 
nosocomial S. aureus infection was decreased in the mupirocin group from 12 to 25 days (P > 
0.05). A total of 77% of S. aureus nosocomial infections were endogenous. 
Conclusion: Routine culture for S. aureus nasal carriage at admission and subsequent 
mupirocin application, does not provide an effective prophylaxis for nosocomial S. aureus 
infections in nonsurgical patients. 
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INTRODUCTION 
Staphylococcus aureus is a frequent cause of nosocomial infections, including bacteremia and 
wound infections.1,2 Approximately 25% of all nosocomial infections are caused by S. aureus, 
affecting both surgical and nonsurgical patients and leading to increased hospital stay, 
antibiotic use, costs, and mortality.3-5 Nasal carriers of S. aureus have an increased risk for 
these infections.6-9 Recent data show that 80% of nosocomial bacteremic S. aureus strains are 
endogenous and originate from the nose of S. aureus carriers.7 Since 20% of the population 
carry this pathogen persistently and 60% carries it intermittently, a substantial number of 
these nosocomial infections may be prevented by eliminating S. aureus from the nose.10 
Intranasal application of mupirocin twice daily for 5 days successfully eradicates S. aureus in 
83% to 88% of carriers and reduces S. aureus hand carriage.8,11-13 Several studies have shown 
that patients undergoing surgery or dialysis (peritoneal and hemodialysis) benefit from S. 
aureus eradication from the nose because of the reduction in nosocomial S. aureus 
infections.10 Mupirocin prophylaxis has been proven to be effective in preventing nosocomial 
S. aureus infections in randomized, placebo-controlled trials among dialysis and surgical 
patients and patients with recurrent skin infections.8,14-17 Although the efficacy of mupirocin 
prophylaxis use has been confirmed only in these patients, mupirocin has many extralabel 
indications. The resulting widespread use has lead to mupirocin resistance.18 Since mupirocin 
is a major weapon to control methicillin-resistant S. aureus outbreaks, it should be used in a 
prudent and restrictive manner. Prudent use implies that it be used only for patients in whom 
it has proven efficacy. 
The efficacy of mupirocin prophylaxis in a general nonsurgical patient population is not yet 
known. Therefore, we decided to study whether mupirocin prophylaxis in nasal S. aureus 
carriers hospitalized in nonsurgical wards decreases the incidence of nosocomial S. aureus 
infections. We assessed whether these nosocomial S. aureus infections were caused by 
endogenous strains, and we measured the effect of this intervention on mortality and duration 
of hospital stay. 
  
METHODS 
Design and Patients 
This is a multicenter, randomized, double-blind, placebo-controlled trial. The 4 participating 
hospitals were Erasmus University Medical Center (Rotterdam, 1300 beds), University 
Medical Center St. Radboud (Nijmegen, 950 beds), VU University Medical Center 
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(Amsterdam, 730 beds), and Amphia Hospital, Langendijk (Breda, 500 beds). The first 3 
hospitals are tertiary care hospitals, and all are teaching hospitals in the Netherlands. The 
institutional review board of each hospital approved the study. 
Between 1 February 1999 and 1 February 2001, adult patients hospitalized in nonsurgical 
departments were screened for nasal S. aureus carriage at the time of admission. All patients 
whose screening cultures grew S. aureus within 72 hours after admission were eligible for the 
study. Additional inclusion criteria were age 18 years or older, not discharged or expected to 
be discharged within 1 day, not being transferred to a nonparticipating department, and 
provision of written informed consent. Exclusion criteria were known allergy to mupirocin or 
glycerin ester, presence of a nasal tube, recent or current mupirocin use (mostly patients 
undergoing hemodialysis or peritoneal dialysis), and any culture-proven S. aureus infection at 
the time of inclusion. 
Trial participants were randomly assigned to receive mupirocin 2% nasal ointment or placebo 
ointment (both were obtained from GlaxoSmithKline, Harlow, United Kingdom) twice daily 
for 5 days. Mupirocin and placebo ointments were similar in appearance and odor and were 
supplied in identical tubes. Randomization was performed by a computer-generated allocation 
list and stratified for each hospital. The allocation list and study medication were stored by the 
departments of medical microbiology and infectious diseases at the participating centers. 
Study personnel and patients were blinded throughout the study. Study medication was 
dispensed by trained study personnel, who performed the first application according to the 
manufacturer's instructions. Subsequent applications were done by the patient or nursing 
personnel according to oral and written instructions. Patients and nurses were informed about 
possible adverse events (mainly local irritation, itching or burning, rhinorrhoea, and rarely 
hypersensitivity reactions). They were instructed to report any adverse event related to the 
treatment, and medication was withdrawn if necessary. Patients did not receive follow-up 
cultures to check for clearance of S. aureus nasal carriage. 
 
Follow-up and Definitions 
At randomization, the following patient data were collected: demographics, main diagnosis, 
underlying illnesses, immunosuppressive and antibiotic medication, and presence of 
indwelling devices or prosthetic material. The main diagnosis was coded according to the 
International Classification of Diseases, Ninth Revision (ICD-9). 
Nosocomial S. aureus infections were followed up by checking the microbiological culture 
data from any site of all included patients on a weekly basis until 6 weeks after discharge. In 
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case of a positive culture result, hospital records were checked and, if necessary, the treating 
physician was interviewed. Nosocomial infections were defined according to criteria of the 
Centers for Disease Control and Prevention.19 A nosocomial infection was caused by S. 
aureus when this pathogen was cultured from the site of infection. Patients with nosocomial 
S. aureus infection were considered to have sepsis if 2 or more of the following conditions 
were present: temperature greater than 38° C or less than 36° C; heart rate greater than 90 
beats/min; respiratory rate greater than 20 breaths/min or PaCO2 level less than 4.3 kPa; and 
leukocyte count greater than 12 × 109 cells/L or less than 4 × 109 cells/L; or greater than 10% 
immature (band) forms, according to standard criteria.20 Infections that were not clearly 
nosocomial were classified by an expert panel of 2 infectious disease specialists not related to 
the trial. 
 
Microbiology 
Nasal swabs were collected by nursing personnel at admission. The swabs were streaked onto 
5% sheep blood agar plates (Becton Dickinson, Le Pont de Claix, France), incubated for 48 
hours at 35° C, and checked each day for bacterial growth. Suspected colonies were identified 
as S. aureus with the Staphaurex Plus agglutination test (Abbott Murex, Chatillon, France). 
Patients with positive culture test results were eligible for randomization. The identity of all 
positive isolates was later confirmed by an automated system (MicroScan Walk-a-Way, 
Dade-Behring Inc., West Sacramento, California). Strains yielding negative results on 
confirmation were retested with the AccuProbe hybridization test (Gen-Probe Inc., San Diego, 
California), according to the manufacturer's guidelines. Patients were incorrectly categorized 
as nasal carriers of S. aureus if the agglutination screening test result was positive but both the 
subsequent determination with the automated system and the hybridization test result were 
negative. Susceptibility to mupirocin was only tested in strains causing infections and was 
performed by disk diffusion.21 
Infections were treated by the patients' physician, and treatment was not influenced by the 
trial team members. Cultures were processed according to standard microbiologic methods. 
All S. aureus strains were stored in glycerol medium at –80° C. Nasal and clinical S. aureus 
isolates from the same patient were genotyped by pulsed-field gel electrophoresis and 
considered to be clonally related if their genotype patterns did not differ by more than 3 
bands, according to standard criteria.22 
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Sample Size and Statistical Analysis 
On the basis of a literature review and pre-study data from the participating centers, we 
estimated a priori the incidence of nosocomial S. aureus infections among S. aureus nasal 
carriers to be 6%.9,23 Thus, about 800 patients in each treatment group would demonstrate a 
statistically significant 50% reduction in nosocomial S. aureus infections in patients treated 
with mupirocin (with a power of 80% and an alpha level of 0.05). 
The primary end point was the incidence of nosocomial S. aureus infections. Secondary 
outcome measures were time to nosocomial S. aureus infections, duration of hospitalization, 
and in-hospital mortality. 
Data were analyzed by using SPSS 10.0 for Windows (SPSS Inc., Chicago, Illinois). The 
risks for nosocomial S. aureus infection and mortality in the 2 treatment groups were 
compared by estimating odds ratios, risk differences, and their 95% CIs per type of infection. 
Odds ratios with CIs not containing unity and risk differences with CIs not containing 0 were 
considered statistically significant. Differences per treatment group in duration of 
hospitalization and time to infection were tested for significance by the Mann-Whitney test. 
Other categorical variables were compared by Pearson chi-square or Fisher exact test where 
appropriate. Variables that differed between the 2 treatment groups by univariate analysis (P < 
0.1) were included in a logistic regression model. A P value less than 0.05 was considered 
statistically significant. 
Data were analyzed on an intention-to-treat and per-protocol basis. The intention-to-treat 
analysis contained all randomized patients fulfilling the inclusion criteria. The per-protocol 
analysis excluded the following patients: those with false-positive diagnoses of S. aureus 
carriership, those who did not complete the treatment course, and those who developed 
nosocomial S. aureus infection before the end of their prophylactic course. 
 
Role of the Funding Source 
This study was financed by Zon-Mw, The Netherlands Organization for Health Research and 
Development. This organization had no involvement in the study design, data collection, data 
analysis, data interpretation, or writing of this report. 
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RESULTS 
Enrollment 
A total of 17 529 nonsurgical patients were screened for nasal carriage of S. aureus. Of these 
patients, 4479 (25.6%) patients were found to have S. aureus nasal carriage and 1627 were 
initially randomly assigned (Figure 1). There were 627 patients randomly assigned at Erasmus 
Medical Center, 462 patients randomly assigned at the University Medical Center St. 
Radboud, 126 patients randomly assigned at the VU University Medical Center, and 412 
patients randomly assigned at the Amphia Hospital.  
 
Figure 1. Study profile 
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The demographic characteristics of excluded patients did not differ from those of included 
patients (data not shown). In 25 patients hospitalized with a S. aureus infection, the culture 
results became known after randomization and these patients were excluded from analyses 
(Figure 1). Mupirocin was administered to 793 patients and placebo to 809 patients. 
Application commenced at a mean of 1.8 days (range, 1 to 3 days) after admission. 
The demographic and clinical characteristics of the 2 treatment groups were similar (Table 1). 
In 24 patients (14 receiving placebo and 10 receiving mupirocin), obstacles to ointment 
application occurred. Eleven of these patients stopped the prophylaxis prematurely. Four of 
the 24 patients (2 of which used mupirocin ointment) reported side effects (itching or burning 
sensation of the nose). No serious adverse events were observed or reported. 
  
Intention-to-Treat Analysis 
The overall cumulative incidence of nosocomial S. aureus infections was 21 of 793 (2.6%) in 
the mupirocin group and 23 of 809 (2.8%) in the placebo group (risk difference, 0.2% [CI, –
1.5 to 1.9]) (Table 2). In addition, in-hospital mortality (risk difference, –0.2% [CI, –1.9 to 
1.5]) and duration of hospitalization did not differ between treatment groups. In each group, 1 
death could directly be related to a nosocomial S. aureus infection. In patients developing a 
nosocomial S. aureus infection, the median time to infection was 25 days for the mupirocin 
group and 12 days for the placebo group (P = 0.28). The multiple logistic regression showed 
that the following variables were independent risk factors for nosocomial S. aureus infections: 
male sex, being immunocompromised, and the presence of an indwelling device (Table 3). 
Sepsis was diagnosed in 94% of the patients with nosocomial S. aureus bacteremia and in 
83% of patients with S. aureus pneumonia. 
All strains causing nosocomial S. aureus infections were mupirocin sensitive. Another 1039 
S. aureus nasal strains from this study sample were tested, and none was found to be 
mupirocin resistant. Only 1 nasal strain was methicillin resistant (prevalence, 0.06%). 
Genotyping of nasal and subsequent infection strains revealed that 34 of 44 (77.3%) of these 
strains were clonally related to the nasal strain (Table 2). 
 
Per-Protocol Analysis 
In the per-protocol cohort, the overall cumulative incidence of nosocomial S. aureus 
infections was 14 of 716 (1.9%) in the mupirocin group and 18 of 742 (2.4%) in the placebo 
group (risk difference, 0.5% [CI, –1.1 to 2.1]). There were no statistically significant 
differences in mortality (risk difference, –0.2% [CI, –2.1 to 1.6]) or duration of hospitalization 
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(Table 2). In patients developing nosocomial S. aureus infections, the median time to 
infection was 32 days in the mupirocin group and 13 days in the placebo group (P = 0.02). 
The same variables in the intention-to-treat analysis were used for logistic regression analysis. 
In this analysis, an indwelling device was the only independent risk factor (Table 3). 
 
Table 1. Patient Characteristics* 
Characteristic Mupirocin Group 
(n = 793) 
Placebo Group 
(n = 809) 
Mean (±SD) age, y           57.6 ± 16.5 57.4 ± 17.3 
Men, n (%)           456    (57.5)           453    (56.0) 
Hospitalized in intensive care unit, n (%)             34      (4.3)             53      (6.6) 
Underlying illness, n (%)   
   Diabetes           126    (15.9)           137    (16.9) 
   Autoimmune disorder             46      (5.8)             56      (6.9) 
   Neoplasms           136    (17.2)           123    (15.2) 
   Obstructive pulmonary disease             85    (10.7)             99    (12.3) 
   Skin disease             99    (12.5)           117    (14.5) 
   HIV positive             10      (1.3)               8      (1.0) 
   Post-transplantation             28      (3.5)             14      (1.7) 
   Renal insufficiency             35      (4.4)             28      (3.5) 
   Liver function disorder             80    (10.1)             68      (8.4) 
Medication, n (%)    
   Chemotherapy             55      (7.0)             65      (8.0) 
   Corticosteroids           123    (15.6)           126    (15.6) 
   Immunosuppressive therapy             44      (5.6)             32      (4.0) 
   Antibiotics           107    (13.5)           107    (13.3) 
Foreign bodies or indwelling devices, n (%)   
   Central venous access             15       (1.9)             14      (1.7) 
   Implant             98     (12.4)             95    (11.8) 
   Urine catheter             29       (3.7)             29      (3.6) 
   Other indwelling device             24       (3.0)             26      (3.2) 
* HIV = human immunodeficiency virus.
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Table 2. Study Outcomes and Corresponding Risk Differences. 
Outcome Intention to Treat 
 Mupirocin 
(n=793) 
Placebo 
(n=809) 
Risk Difference* 
(95% CI) 
Nosocomial S. aureus infections, n (%)    
     All† 21 (2.6) 23 (2.8)  0.2  (-1.5 to 1.9) 
     Bacteremia     7 (0.9) ‡ 10 (1.2)  0.3  (-0.7 to 1.5) 
     Pneumonia  5 (0.6)   1 (0.1) -0.5  (-1.4 to 0.2) 
Surgical site infection, n (%)  5 (0.6)   8 (1.0)  0.4  (-0.6 to 1.4) 
Skin or soft tissue infection, n (%)  2 (0.3)  4 (0.5)  0.2  (-0.5 to 1.0) 
Urinary tract infection, n (%)  2 (0.3) 0 -0.3  (-0.9 to 0.3) 
In-hospital mortality, n (%) 24 (3.0) 23 (2.8) -0.2  (-1.9 to 1.5) 
Median Hospitalization (interquartile 
range), d§ 
8 (5.0 to 14.0) 8 (5.0 to 15.5)  
* CIs not containing unity were considered significant. For skin or soft-tissue and urinary tract infections, no estimates are 
given in case these infections did not occur in 1 of the treatment groups. 
† Identical nasal and clinical isolates as determined by pulsed-field gel electrophoresis: overall, 34 of 44 (77.3%); bacteremia, 
14 of 17 (82.4%); pneumonia, 6 of 6 (100%); surgical site infection, 9 of 13 (69.2%); skin or soft-tissue infection, 4 of 6 
(66.7%); and urinary tract infection, 1of 2 (50.0%). 
‡ 1 patient had endocarditis. 
§ Mann-Whitney test: P > 0.2. 
 
 
Table 2. (Continued) 
Outcome Per Protocol 
 Mupirocin 
(n=793) 
Placebo 
(n=809) 
Risk Difference* 
(95% CI) 
Nosocomial S. aureus infections, n (%)    
     All† 14 (1.9) 18 (2.4)  0.5  (-1.1 to 2.1) 
     Bacteremia   4 (0.6)   8 (1.1)  0.5  (-0.5 to 1.6) 
     Pneumonia   4 (0.6)   1 (0.1) -0.5  (-1.3 to 0.3) 
Surgical site infection, n (%)   4 (0.6)   5 (0.7)  0.1  (-0.8 to 1.1) 
Skin or soft tissue infection, n (%) 0   4 (0.5)  0.5  (-0.1 to 1.4) 
Urinary tract infection, n (%)   2 (0.3) 0 -0.3  (-1.0 to 0.3) 
In-hospital mortality, n (%) 23 (3.2) 22 (3.0) -0.2  (-2.1 to 1.6) 
Median Hospitalization (interquartile 
range), d§ 
8 (4.0 to 14.0) 8 (5.0 to 16.0)  
§ P = 0.19 
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Table 3. Independent Relationship of Possible Risk Factors for Nosocomial Staphylococcus aureus Infection* 
Variable Odds Ratio (95% CI)† 
 Intention to Treat Per Protocol 
Sex   
   Men 2.25 (1.12--4.53) 1.9 (0.90--4.39) 
   Women 1  
Renal insufficiency   
   Present 2.71 (0.97--7.57) 2.93 (0.92--9.37) 
   Absent 1  
Solid tumor   
   Present 1.65 (0.79--3.39) 1.89 (0.82--4.39) 
   Absent 1  
Liver dysfunction   
   Present 1.76 (0.77--3.99) 1.84 (0.72--4.68) 
   Absent 1  
Immunocompromised   
   Present 2.15 (1.13--4.09) 1.61 (0.75--3.47) 
   Absent 1  
Indwelling device   
   Present 3.41 (1.29--8.98) 3.35 (1.04--10.81) 
   Absent 1  
Study medication   
   Mupirocin 0.92 (0.50--1.70) 0.77 (0.38--1.57) 
   Placebo 1  
* Obtained by multiple logistic regression. Along with mupirocin prophylaxis vs. placebo, we included variables in the 
regression model that were significant (P < 0.1) in the univariate analysis and included skin disease as a confounder. 
† CIs not containing unity were considered statistically significant. 
 
 
DISCUSSION 
This study showed that screening for S. aureus nasal carriage on admission by routine culture 
and applying mupirocin in S. aureus carriers to prevent nosocomial S. aureus infections in 
nonsurgical patients is not an efficacious strategy. None of the odd ratios and risk differences 
for the different types of nosocomial infections and mortality indicated sufficient mupirocin 
effectiveness to merit treatment (risk difference for overall infection, 0.2% [CI, –1.5 to 1.9]; 
risk difference for mortality, –0.2% [CI, –1.9 to 1.5]; P > 0.05). We found that 82.4% of the 
bacteremic strains were clonally related to the nasal strain at admission, which confirms the 
results found by Von Eiff and colleagues.7 
Although the rate of S. aureus nasal carriage found in this study (25.6%) is within the range 
described in the literature (19% to 55%), the incidence of nosocomial S. aureus infections was 
far lower than that estimated à priori.10 
The observed low incidence can be explained by the relatively small proportion of patients in 
intensive care in our study sample. Also, the national trend for shorter hospitalizations 
reduces the period at risk for nosocomial infections and increases the chance of missing 
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nosocomial S. aureus infections.24 Furthermore, the few risks described in the literature are 
mainly based on patients in the intensive care unit who are at a greater risk for infection.9,23 
We detected nosocomial infections by checking the microbiology reports. This may not be 
optimal, although 1 study found this method to have a sensitivity of approximately 90%.25 We 
believe that we detected most of these infections, since S. aureus infections usually lead to 
clinically evident disease. Since the study was blinded, missed infections would be evenly 
distributed between the treatment groups. A nonsurgical patient population in general 
probably has a relatively low risk for nosocomial S. aureus infections. This is illustrated by 
the 1.2% incidence of nosocomial S. aureus bacteremia in a similar patient sample, which was 
found by Von Eiff and colleagues.7 We found a similar incidence in our placebo group and 
thus conclude that our study did not have exclusion bias. 
Two other randomized, controlled trials that studied the efficacy of mupirocin in a general 
surgical and an orthopaedic patient sample have recently been published.8,26 These studies 
also showed little to no efficacy of mupirocin prophylaxis. The general surgery study included 
both carriers and non-carriers who were randomly assigned to either mupirocin or placebo. 
Overall, 2.3% of mupirocin recipients and 2.4% of placebo recipients had S. aureus infections 
at surgical sites. Among the S. aureus nasal carriers, mupirocin-treated patients had 
significantly fewer nosocomial S. aureus infections at any site (4.0%) than placebo-treated 
patients (7.7%; odds ratio, 0.49 [CI, 0.25 – 0.92]). However, prophylactic mupirocin did not 
significantly reduce the rate of S. aureus infection at surgical sites.8 The orthopaedic trial also 
included carriers and non-carriers receiving a surgical intervention.26 In this study, mupirocin 
did not reduce the rate of S. aureus infection at surgical sites (mupirocin, 3.8%; placebo, 
4.7%) or the duration of hospital stay. In the mupirocin group, the rate of endogenous S. 
aureus infections was 5 times lower than that in the placebo group (P > 0.05). 
In our study, the time to infection shifted by almost 2 weeks in the subgroup of patients with 
nosocomial S. aureus infection. Patients in the mupirocin group, who had a prolonged 
hospital stay, seemed to catch up in infection probability after this delay. This may be due to 
recolonization with S. aureus from extra-nasal sites several weeks after mupirocin 
prophylaxis was stopped. Several studies show recolonization with S. aureus occurs in 38% to 
43% of patients after 4 to 6 weeks after mupirocin application.11,12,27 The role of S. aureus 
carriage at extra-nasal sites (for example, throat, skin, and perineum) in recolonization after 
mupirocin treatment and in developing infections needs further study. S. aureus present in a 
lesion (for example, exit site of an indwelling device) may not be eradicated by solely 
applying mupirocin to the nose. Topical mupirocin application to such sites may be needed to 
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reduce nosocomial S. aureus infections, such as line-related sepsis in patients with tunnelled, 
cuffed hemodialysis catheters.28 
To prevent recolonization, repetitive mupirocin application to patients with prolonged 
hospital stay may have resulted in more efficacy of this prophylactic regimen, which is the 
case for dialysis patients.10 However, this would affect a small proportion of all patients, since 
90% of the patients in this study were already discharged within 25 days. Also, many 
nosocomial S. aureus infections occur early after admission. These infections may not be 
preventable by nasal application of mupirocin given a few days after admission. Future 
studies should consider screening high-risk patients and starting prophylaxis before admission 
or using a rapid molecular-based screening method and treating carriers the same day. 
Although we did not find mupirocin-resistant strains in our study, large-scale use might 
induce more mupirocin-resistant organisms in the sample.18 Therefore, future intervention 
trials should preferably focus on patients who are known S. aureus carriers and at high risk 
for S. aureus infections, including immunocompromised patients and patients requiring 
indwelling devices, as shown by the regression analysis in this study. This analysis also 
suggests that S. aureus carriers with chronic renal insufficiency, without dialysis indication, 
have an increased risk for S. aureus infection. 
This study does not support the strategy of routine culture at admission and subsequent 
mupirocin application in S. aureus nasal carriers to prevent S. aureus nosocomial infection in 
a general nonsurgical population. Because more than 80% of nosocomial cases of S. aureus 
bacteremia are endogenous, strategies that can effectively and safely eliminate S. aureus 
carriage from relevant sites may still play an important role in preventing infections with this 
pathogen. We recommend continued effort in elucidating the mechanisms leading to S. aureus 
carriage and subsequent infection and ongoing development and testing of prophylactic 
strategies. 
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ABSTRACT 
Staphylococcus aureus is the second most frequent cause of nosocomial blood infections. We 
screened 14,008 non-bacteremic, non-surgical patients for S. aureus nasal carriage at 
admission, and monitored them for the development of bacteremia. Nosocomial S. aureus 
bacteremia was three times more frequent in S. aureus carriers (40/3420: 1.2%) than in non-
carriers (41/10588: 0.4%; relative risk 3.0; 95% CI: 2.0 to 4.7). However, in bacteremic 
patients, all cause mortality was significantly higher in non-carriers (19/41: 46%) than in 
carriers (7/40: 18%; p=0.005). Additionally, S. aureus bacteremia-related death was 
significantly higher in non-carriers than in carriers (13/41 [32%] versus 3/40 [8%]; p=0.006).  
S. aureus nasal carriers and non-carriers differ significantly in risk and outcome of 
nosocomial S. aureus bacteremia. Genotyping revealed that 80% of the strains causing 
bacteremia in carriers were endogenous. 
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INTRODUCTION 
Staphylococcus aureus accounts for about 13% of all nosocomial blood stream infections, and 
is the second most common cause of these infections after coagulase-negative staphylococci.1 
S. aureus bacteremia increases length of hospital stay, antibiotic use, costs, and mortality.1 S. 
aureus nasal carriage is a risk factor for acquiring nosocomial infections.2 Von Eiff and 
colleagues have shown that 80% of nosocomial S. aureus bacteremia episodes in S. aureus 
carriers are attributable to an endogenous source.3 However, the risk is known only for 
selected patient groups and not for the general patient population in hospitals.2 Risk estimates 
are mostly based on case-control studies or on studies in which carriership was assessed after 
patients had a positive blood culture. The latter studies do not rule out the possibility that S. 
aureus nasal colonisation developed secondary to infection. A valid risk estimate is important 
in cost-benefit assessment of regimens aimed at preventing S. aureus infections. We estimated 
the al risk of S. aureus carriers versus non-carriers of acquiring nosocomial S. aureus 
bacteremia in a general, non-surgical hospital population.  
 
METHODS 
This study was performed in four hospitals in The Netherlands: Erasmus MC in Rotterdam 
(1300 beds), UMC St. Radboud in Nijmegen (950 beds), VU University Medical Centre in 
Amsterdam (730 beds), and Amphia Hospital in Breda (500 beds). The first three are tertiary 
care hospitals and all four are teaching hospitals. Institutional Review Board approval was 
obtained.  
Between February 1st, 1999 and February 1st, 2001, nurses took nasal swabs from the 
anterior nares of all adult patients at admission to participating non-surgical departments, 
were collected at admission by nursing personnel, after oral informed consent was obtained 
(some patients declined participation). One-fourth of S. aureus nasal carriers were included in 
a clinical randomised trial that evaluated the efficacy of mupirocin versus placebo nasal 
ointment in preventing nosocomial S. aureus infections. Mupirocin was not efficacious in this 
trial and mupirocin-treated patients were therefore not excluded from the present study.4 
Identification and susceptibility testing of S. aureus was performed with conventional 
methods. In case of uncertainty, identification was confirmed with the AccuProbe® 
hybridisation test (Gen-Probe Inc., San Diego, California, USA). Methicillin resistance was 
rare: 0.03% of isolates tested. Patients screened at more than one admission were included 
only once, and only the first bacteremic episode with S. aureus counted. Blood specimens 
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were routinely obtained for culture in case of fever (body temperatures of ≥38.5° C), or when 
bacteremia was suspected for other reasons. For patients with blood cultures positive with S. 
aureus, taken 2-120 days after a nasal swab specimen, hospital records were checked, blinded 
to carrier status, and if necessary, the attending physician was interviewed. Infections were 
classified as nosocomial using standard criteria, and those that could not be classified as such, 
were deemed to be community-acquired.5 We judged in-hospital mortality to be linked to S. 
aureus bacteremia if there was clinical or microbiological evidence of infection at time of 
death. 
Nasal and blood S. aureus isolates from the same patient were genotyped by pulsed-field gel 
electrophoresis (PFGE), and were interpreted according to criteria by Tenover and 
collaegues.6 Statistical analysis included calculation of the relative risk with 95% confidence 
intervals, Chi-square test for dichotomous variables, and Mann-Whitney test for non-
parametric comparisons, using statistical software (SPSS version 10.0, SPSS Inc., USA). 
Logistic regression was performed to identify risk factors for mortality in patients with S. 
aureus bacteremia. P-values below 0.05 were regarded as significant.  
 
RESULTS 
A total of 14,014 patients were initially screened. Of these, six seemed to have community-
acquired S. aureus bacteremia and were excluded, leaving a total of 14,008 who were 
included in the study. Of these 3,420 (24.4%) carried S. aureus in the nose. During follow-up 
81 developed S. aureus bacteremia. Carriers had a threefold higher risk than non-carriers of 
acquiring nosocomial S. aureus bacteremia (Table 1). All S. aureus isolates causing infection 
were meticillin sensitive. Genotyping by PFGE, revealed that 32/40 (80%) of invasive S. 
aureus strains of carriers were identical to the nasal strain detected at admission, and were 
thus considered to be of endogenous origin. In 44/81 (54%) of the cases, the probable source 
of nosocomial S. aureus bacteremia was an intravascular catheter (Table 2). Follow-up of 
patients with S. aureus bacteremia revealed that non-carriers had significantly higher in-
hospital mortality compared to carriers (Table 2). Logistic regression including all possible 
risk factors (Table 2) as covariates and all-cause mortality as the outcome variable showed 
that only carrier status (OR 0.2, p=0.016) and having a central venous catheter (OR 4.7, 
p=0.016) were independent risk factors. With S. aureus bacteremia-related mortality as the 
outcome variable, only carrier status proved a significant (protective) covariate (0.1, 
p=0.013). Although bacteremic non-carriers were older than carriers, age was not identified as 
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a confounder (p=0.85), probably because the age distribution in of those who died was similar 
to that of those who survived. 
 
Table 1. Relative risk of nosocomial S. aureus bacteremia by S. aureus nasal carriership.  
    Nosocomial S. aureus bacteremia 
       Yes         No       Relative risk 
        n (%)         n (%)  (95% confidence interval) 
S. aureus carrier   40*   (1.2)      3,380   (98.8)      3.0 (2.0 – 4.7) 
Non-carrier   41     (0.4)    10,547   (99.6)      1.0 
* Nasal and subsequent bacteremic S. aureus isolates were clonally related in 80% of the cases, as determined by pulsed field 
gel electrophoresis. Excluding carriers with exogenous bacteremia resulted in a relative risk of 2.4 (95% CI: 1.5 to 3.8). 
 
Table 2. Comparison of patients with nosocomial S. aureus bacteremia by nasal carriage status. 
            S. aureus carrier  Non-carrier  P-value  
            (n=40)   (n=41)   Univariate 
Age, mean (±SD)*         53.7 ± 18.6  64.6 ± 16.3  0.007  
Male sex, n (%)#          23    (58.5)  28    (68.3)  0.32   
Reason for admission, n (%): 
-Cardiac             9    (22.5)  21    (51.2)  0.001 
-Malignancy            9    (22.5)    4      (9.8)  0.12 
-Infection             5    (12.5)    3      (7.3)  0.43 
-Other           15    (37.5)    8    (19.5)  0.07 
Underlying disease or risk factor, n (%): 
-Diabetes           10    (25.0)    9    (22.0)  0.75 
-Immunocompromised         14    (35.0)    5    (12.2)  0.02 
-Central venous access         18    (45.0)  19    (46.3)  0.90 
-Other indwelling device        13    (32.5)  22    (53.7)  0.05 
Outcome 
Hospitalisation days, median (± SD)       25 ± 72   50 ± 64  0.01 
Days to bacteremia, median (± SD)       11 ± 21   16 ± 25  0.22 
In-hospital mortality (all causes)§         7$   (17.5)  19    (46.3)  0.005 
In-hospital mortality (S. aureus related)        3    (7.5)   13    (31.7)  0.006 
Source of bacteremia, n(%): 
-Intravascular device-related        21    (52.5)  23    (56.1)  0.75 
-Wound             9    (22.5)    3      (7.3)  0.05 
-Other             6    (15.0)    8    (19.5)  0.59 
-Unknown            4    (10.0)    7    (17.1)  0.36 
* Mean age of all carriers was 57.0 ± 18.4 and of non-carriers 59.8 ± 17.4 years.  
# 56% of all carriers and 53% of all non-carriers were male.  
$ All bacteremic strains of carriers who died were from an endogenous origin. 
 
DISCUSSION AND CONCLUSION 
The current prospective study demonstrates that S. aureus nasal carriers have a heightened 
risk of developing nosocomial S. aureus bacteremia. However, non-carriers with S. aureus 
bacteremia had higher mortality risk than did carriers, which could not be accounted for by 
differences in underlying disease and age. As a result, in-hospital mortality (all causes) after 
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S. aureus bacteremia occurred in both groups, was similar (0.2%). Only having a central 
venous catheter or being a non-carrier were correlated with increased mortality, possibly 
indicating more severe disease.  
Duration of hospital stay, both until bacteremia and discharge, was longer for bacteremic non-
carriers than for carriers. Extended hospital stay in non-carriers with S. aureus bacteremia 
could be the result of more severe underlying disease of bacteremic non-carriers compared to 
carriers. Longer hospital stays increases the time at risk of colonisation with an exogenous S. 
aureus strain, which may lead to subsequent infection. On the other hand, more severe 
bacteremia in non-carriers than in carriers might have resulted in prolonged length of stay. 
Since most strains causing nosocomial S. aureus bacteremia in carriers were of endogenous 
origin, carriers could be immunologically adapted to their S. aureus strain. They could, 
therefore have a more adequate immune response than non-carriers, or, alternatively, 
exogenous strains might be more virulent than endogenous strains. 
We conclude that S. aureus nasal carriers and non-carriers differ significantly in risk and 
outcome of nosocomial S. aureus bacteremia. Carriers suffer a threefold higher risk of 
nosocomial S. aureus bacteremia, but if they get bacteremic they have a lower mortality risk 
compared to non-carriers. Possibly, differential strategies to prevent S. aureus bacteremia are 
needed in both carriers and non-carriers. In understanding S. aureus disease and related 
mortality, we now need to know whether nasal carriers of S. aureus really have a reduced risk 
of mortality from invasive S. aureus infection and what the underlying immunological 
mechanisms are. 
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ABSTRACT 
Nasal carriage with Staphylococcus aureus is an important risk factor for S. aureus infections. 
Mupirocin nasal ointment is currently the treatment of choice for decolonizing the anterior 
nares. However, recent clinical trials show limited benefit from mupirocin prophylaxis in 
preventing nosocomial S. aureus infections, probably due to (re)colonization from extra-nasal 
carriage sites. Therefore, we studied the effectiveness of mupirocin nasal ointment treatment 
on the dynamics of S. aureus nasal and extra-nasal carriage. Twenty non-carriers, 26 
intermittent carriers, and 16 persistent carriers had nasal, throat and perineum taken one day 
before and five weeks after mupirocin treatment (twice daily for five days) and assessed for 
growth of S. aureus. Identity of cultured strains was assessed by restriction fragment length 
polymorphisms of the coagulase and protein A genes. The overall carriage rate (either nasal-, 
pharyngeal-, perineal carrier, or a combination of those) was significantly reduced after 
mupirocin treatment from 30 to 17 carriers (P=0.003). Of those 17 carriers, 10 (60%) were 
still colonized with their old strain, 6 (35%) with an exogenous strain, and one with both 
(5%). Two non-carriers became carriers after treatment. The acquisition of exogenous strains 
after mupirocin treatment is a common phenomenon. The finding warrants that mupirocin 
should only be used in proven carriers for decolonization purposes. Mupirocin is overall 
effective in decolonizing nasal carriers, but less effective in decolonizing extra-nasal sites.  
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INTRODUCTION 
In humans, the nose is the primary reservoir of S. aureus 1,2. Approximately 30% of the 
healthy population carry S. aureus in the nose, which is an important risk factor for S. aureus 
infections 1. S. aureus nasal carriers have a threefold increased risk for nosocomial S. aureus 
bacteremia compared to non-carriers3. Approximately 80% of invasive nosocomial S. aureus 
infections is of endogenous origin in nasal carriers 3,4. 
Mupirocin nasal ointment is effective in temporarily eradicating S. aureus from the nose. 
When mupirocin is applied to the nose twice daily for five consecutive days, it has been 
reported that this results in elimination rates of 91% directly after therapy, 87% after 4 weeks, 
and 48% after six months 5. However, despite these high elimination rates, three recent 
clinical studies found little to no efficacy of mupirocin in preventing nosocomial S. aureus 
infections 6-8. 
In order to determine the effect of mupirocin treatment on S. aureus carriage at  extra-nasal 
sites re, we studied the effect of mupirocin treatment on different carrier types: persistent-, 
intermittent-, and non-nasal carriers of S. aureus. Pharyngeal carriage of S. aureus was 
assessed as well, since nasal application of mupirocin results in low concentrations of this 
drug in the pharynx 9,10. Furthermore, perineal carriage was assessed, since perineal carriers 
are known to disperse more S. aureus into the environment 11. Non-carriers were included as 
well, to be able to identify whether mupirocin application in non-carriers may lead to carriage 
due to loss of colonization resistance 12. To assess the role of extra nasal carriage sites in 
recolonization of the nose after mupirocin treatment, all strains were genotyped. 
 
MATERIALS AND METHODS 
Study-population and general study design 
Healthy, adult volunteers (n=165) were screened for nasal carriage of S. aureus on at least 
five separate occasions, one week apart. A participant was labeled as a persistent carrier if at 
least 80% of the cultures were S. aureus positive, as a non-carrier if all nasal cultures were S. 
aureus negative, and as an intermittent carrier in all other cases. Only participants who 
attended all culture occasions were included in the study. 
 
Treatment and follow-up 
Participants, who gave informed consent, self-administered mupirocin 2% nasal ointment 
(SmithKline Beecham, Rijswijk, The Netherlands) twice daily, for five days, according to 
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manufacturer's guidelines. Nasal, pharyngeal and perineal samples, were taken just before 
mupirocin treatment, and once five weeks after treatment. Therapy failure was defined as 
having a positive nasal culture with S. aureus five weeks after the end of treatment. A nasal 
culture was taken by rotating a sterile swab four times in the anterior nares (Transwab; 
Medical wire & equipment Co. Ltd., Corsham, Wilts, England). All swabs were processed on 
the same day. The swab was plated on a Columbia blood agar plate-medium (Becton-
Dickinson, Etten-Leur, the Netherlands) and submerged in phenol red mannitol broth 
(PHMB). Plates were read after one and two days of incubation and broths after three days of 
incubation 35 °C. Broths with color change from red to orange-yellow were subcultured on 
blood-agar plates. Identification of S. aureus was based on colony morphology, gram stain, 
catalase test and latex-agglutination test (Staphaurex Plus, Murex, Dartford, UK). 
 
Genotyping 
Genotyping was performed on the last cultured S. aureus strain before mupirocin treatment 
and on those strains cultured after mupirocin treatment. S. aureus DNA was obtained 
according to Boom method 13. Restriction fragment length polymorphisms (RFLP) of the 
coagulase and protein A genes were determined for typing of all cultured S. aureus strains, as 
described previously 14,15. Pulsed-field gel electrophoresis (PFGE) was performed to confirm 
the results obtained by RFLP, when appropriate, according to described methods 16. Strains 
were considered to be unrelated in case the RFLP pattern of either the coagulase gene or 
protein A gene differed from the other strain. PFGE patterns were compared using the criteria 
by Tenover 17. 
 
Statistical analysis 
Volunteers were classified, as described above, as persistent-, intermittent- and non-nasal 
carriers using the results of at least five screening cultures. Per carriage type, the efficacy of 
mupirocin was assessed by comparing the culture results of the samples taken just before 
mupirocin treatment, with the culture results of the samples taken five weeks after mupirocin 
treatment. Mupirocin therapy was considered to have failed if an individual carried S. aureus 
in the nose five weeks after treatment, irrespective of extra-nasal carriage. Non-parametric 
paired tests were used where appropriate. P-values, two-sided, below 0.05 were considered 
significant. 
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RESULTS 
At least five serial cultures were obtained from 62 individuals from the initial cohort of 165 
volunteers. Twenty volunteers were non-carrier (NC; 32%), 26 were intermittent carrier (IC; 
42%) and 16 were persistent carrier (PC; 26%; Table 1) and all participated in the mupirocin 
intervention. No serious side effects were observed and all volunteers completed the 
treatment. The overall carriage rate (either nasal-, pharyngeal-, perineal carrier, or a 
combination of those) was significantly reduced after treatment from 30 to 16 carriers (Table 
1; P=0.003). 
 
Table 1. Change in carriage sites, just before and 5 weeks after mupirocin treatment. 
Carriage site 
 
Persistent Carrier  
(n=16) 
Intermittent carrier  
(n=26) 
Non Carrier  
(n=20) 
  
Before 
treatment * 
After 
treatment 
Before 
treatment ^ 
After 
treatment 
Before 
treatment 
After 
treatment 
nose alone 6 3 5 1 0 1 
nose-throat 6 1 5 3 0 1 
nose-throat-perineum 0 1 1 1 0 0 
nose-perineum 3 0 0 0 0 0 
throat alone 0 2 2 0 1 1 
throat-perineum 0 0 1 0 0 0 
perineum alone 0 0 0 1 0 0 
All 15 7 14 6 1 3 
* one persistent carrier had a negative nasal culture just before mupirocin treatment 
^ 15 intermittent carriers had negative culture results just before mupirocin treatment. 
 
Mupirocin significantly reduces nasal carriage in persistent carriers (n=16) 
Of the sixteen persistent carriers, one carrier had a negative nasal culture just before 
mupirocin treatment. Five (31%) carriers had therapy failure five weeks after mupirocin 
treatment (Table 1). Four remained colonized with the same strain of which all had at least 
one extra nasal carriage site (3 throat, 1 perineum). One volunteer acquired a new strain and 
never carried S. aureus on extra-nasal sites. In persistent carriers, mupirocin was effective in 
decolonizing S. aureus from the nose five weeks after treatment (P=0.002), but not effective 
in decolonizing throat and perineal carriage (P=0.69 and P=0.5 respectively). 
 
No significant reduction of nasal carriage in intermittent nasal carriers after mupirocin 
treatment (n=26) 
From the 26 intermittent carriers, 11 (42%) carried S. aureus just before treatment. Three of 
these (27%) had therapy failure. Two remained colonized with the same strain of which one 
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was a perineal carrier before treatment. From those who did not carry S. aureus just before 
treatment, two became colonized after treatment, of which one was a combined pharyngeal 
and perineal carrier just before treatment. Overall, mupirocin treatment did not significantly 
reduce nasal (P=0.11), throat (P=0.29), and perineal (P=1.0) carriage, in this subgroup of 
intermittent carriers. 
 
Rare acquisition of exogenous S. aureus after mupirocin treatment in non nasal carriers 
(n=20) 
Within the non-carrier group there was one apparent throat carrier before mupirocin 
treatment. After treatment two non-carriers became colonized with S. aureus (10%), of which 
none carried S. aureus on extra nasal sites before treatment. The pharyngeal carrier remained 
pharyngeal  carrier with the same strain. 
 
Special emphasis on pharyngeal carriage (n=16) and perineal carriage (n=5). 
In general there were 16 pharyngeal carriers before treatment, irrespective of carriage at other 
sites (12 were also nasal carrier). In 5/12 (42%) cases the throat strain was different from the 
nasal strain. After treatment six (38%) remained throat carriers, of which one acquired a new 
strain, a significant reduction in throat carriage after mupirocin treatment (P=0.002). 
Interestingly, of those who were non-throat carrier before treatment (n=46), 5 (11%) became 
colonized in the throat with S. aureus. Four of these new throat carriers were nasal carriers 
before treatment and one was a non-carrier.  
There were five perineal carriers (four were also nasal carrier) before treatment and three after 
treatment (non significant reduction). Only one perineal carrier remained carrier after 
mupirocin treatment with an identical strain. Two non perineal carriers became perineal 
carrier after treatment, of which one with an endogenous strain.  
 
DISCUSSION 
Our results showed similar mupirocin effectivity on nasal decolonization at five weeks post 
treatment as reported in previous studies 5. We found a S. aureus nasal carriage elimination 
rate of 69% in persistent carriers and 58% in intermittent carriers. Therapy failure is not likely 
to be due to mupirocin resistance, since the prevalence of mupirocin resistant strains is very 
low in the Netherlands: none found in more than 1000 strains 6. Only one strain was found to 
be mupirocin resistant after therapy in our study (data not shown). Though the MRSA 
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prevalence is very low in the Netherlands, the findings of this study may be extrapolated to an 
endemic MRSA setting, as long as these strains are mupirocin sensitive 18. 
Mupirocin nasal ointment also had a significant effect on pharyngeal S. aureus carriage 
decolonization, but not on perineal carriage. The effectiveness of mupirocin in reducing the 
occurrence of perineum carriage in this cohort was low, due to new acquisition of S. aureus at 
this site. Unlike in nasal carriage, where the effectiveness is much higher, mupirocin does not 
seem to have a preventive effect in S. aureus perineum carriage. Though the nose is the 
primary reservoir for S. aureus, the perineum itself is not directly affected by local application 
of mupirocin to the nose, as we saw in our study. Application of a local antibiotic or 
disinfectant on the perineum could be an option for optimal decolonization.  
Interestingly, ten volunteers became colonized at new sites, five weeks after mupirocin 
treatment, of which five were exogenous strains (two were non-carriers). Furthermore, two 
carriers became colonized with exogenous strains at their old sites after treatment. Overall we 
can state that of those 17 carriers at any site after treatment, ten (60%) were colonized with 
their old strain, six (35%) with an exogenous strain, and one (5%) with both old and 
exogenous strain. Therefore the acquisition of exogenous strains after mupirocin treatment is 
a common phenomenon. The finding that two non-carriers became carriers after treatment  
(17% of all therapy failures) warrants that mupirocin should only be used in proven carriers 
for decolonization purposes. Mupirocin also eradicates coagulase negative staphylococci and 
corynebacteria, which may be present in non-carriers, and this change in nasal flora may 
facilitate colonization with S. aureus, by eliminating the bacterial intereference 12. 
We conclude that mupirocin is overall effective in decolonizing nasal carriers, but less 
effective in decolonizing extra-nasal sites. These extra-nasal sites may be a source for S. 
aureus infections. The majority of the S. aureus strains of those who remain colonized five 
weeks after treatment are endogenous. But acquisition of exogenous S. aureus strains occurs 
and warrants that decolonization should only be performed in proven carriers. Furthermore, 
patients treated with mupirocin should receive follow-up cultures to determine treatment 
failure, which is already introduced for dialysis patients. 
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ABSTRACT 
We screened 14,008 non-surgical patients for S. aureus nasal carriage at admission and 
assessed them for invasive S. aureus disease and in-hospital mortality. Multi locus sequence 
typing was performed for endogenous invasive strains and nasal strains of matched 
asymptomatic carriers to investigate whether virulent clones could be identified in nasal 
carriers. Clonal complex (CC45) was significantly underrepresented (OR: 0.16; 95% CI: 0.04-
0.59), and CC30 was overrepresented (not significant) among invasive strains (OR 1.91; 95% 
CI: 0.91-4.0). There was no clonality among invasive S. aureus strains in non-carriers. 
Patients infected with S. aureus strains belonging to a clonal complex had a higher mortality 
rate (OR 3.03; 95%CI: 1.09-8.43), indicating co-evolution of S. aureus virulence and spread 
among humans.  
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INTRODUCTION 
Staphylococcus aureus is one of the leading causes of nosocomial infections, varying from 
superficial wound infections to more invasive infections, like deep abcesses, osteomyelitis 
and bacteremia.1 These infections lead to prolonged hospital stay, increased antibiotic use, 
and increased costs.2 S. aureus nasal carriers have a threefold increased risk of acquiring 
nosocomial S. aureus bacteremia compared to non-carriers, but have a lower mortality rate 
when infection occurs.3 This higher survival rate of carriers may be due to partial immunity. 
Alternatively, S. aureus strains of asymptomatic nasal carriers of S. aureus, may belong to a 
less virulent genotype compared to strains from nasal carriers with proven invasive disease. 
We, therefore, wanted to investigate whether certain S. aureus clones found in S. aureus nasal 
carriers are more or less likely to cause invasive disease, and whether invasive nosocomial S. 
aureus disease in non-carriers is due to a special clone. We analyzed a collection of S. aureus 
strains isolated from a previously described cohort of patients admitted to the hospital using a 
microarray based method for multilocus sequence typing (MLST).3-5  
 
METHODS 
Study design 
We performed a nested case control study in a cohort of 14,008 adult non-surgical patients, 
who were screened for S. aureus nasal carriage at hospital admission.5,6 All patients were 
monitored for the development of invasive S. aureus disease by checking microbiology data 
on a weekly basis, as described earlier.3,5  The study was performed in four teaching hospitals 
from separate regions of the Netherlands. Medical ethical approval was obtained from all 
participating centers.  
Nasal and invasive strains were genotyped by PFGE, of which the resulting data were 
interpreted according to standard criteria.7. MLST was performed for invasive strains, that 
were genetically similar as determined by PFGE, and for nasal strains of matched carriers, 
who did not develop invasive S. aureus infection (asymptomatic carriers). For each case of 
invasive nosocomial infection, two matched controls were included, who were matched for: S. 
aureus nasal carriage, the hospital of admission, date of admission (range one month), sex, 
age class (allowed difference: up to 5 years), and absence of S. aureus infections during 
follow-up. If more matched controls were possible, those with the age closest to the index 
were selected. Moreover, invasive S. aureus strains from non-carriers, cultured from blood or 
deep foci of infection, were analysed by MLST. 
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Multi Locus Sequence Typing.  
For this study we used an oligonucleotide array for MLST of S. aureus, as described earlier 4. 
Briefly, DNA was extracted using lysostaphine and the QIAamp DNA Minikit (Qiagen, 
Westburg, Leusden, The Netherlands). DNA was used in a multiplex PCR with specific 
primers targeting the seven housekeeping genes as defined by Enright et al. 8 PCR products 
were fragmented and labeled with a new DNA-amplicon labeling technique (bioMérieux, 
Marcy l’Etoile, France), purified with the QIAquick Nucleotide Removal kit (Qiagen) and 
hybridized with the oligoprobe arrays in the GeneChip Fluidics Station (Affymetrix, St.Clara, 
Calif.).4 Each probe array was stained with streptavidine-RPE (phycoerythrin; Dako, France) 
and signal was measured with the GeneArray scanner (Agilent, Palo Alto, Calif.). Probe array 
cell intensities, base call, sequence determination, and reports were generated by functions 
available in the GeneChip software (Affymetrix). A candidate allele selection index was 
determined by the percentage homology between the experimentally derived sequence and the 
distinct reference sequence tiled on the array. 
For some house keeping genes the oligo-mediated MLST procedure can generate ambiguous 
results, because polymorphisms can be present in the 5’ and 3’ proximal ten nucleotides of the 
amplicons.8 These are not recognized by the oligoprobes. In such cases the entire 
housekeeping gene was reamplified and both strands of the amplicons were sequenced to 
identify possible polymorphisms.4 
 
Statistical analysis. 
Comparison of MLST results was based upon related sequence types (BURST) software, as 
described before.9 Data were analysed with the help of SPSS software. Frequencies were 
compared by Chi-square test and continuous variables by T-test. P-values below 0.05 were 
considered significant. Odds ratio’s with 95% confidence intervals were calculated for the 
case-control study. 
 
Association between S. aureus genotype,  
S. aureus invasive disease and in-hospital mortality 
 
 73
RESULTS 
General 
Demographic data of patients (60 cases, 118 controls) are summarized in Table 1. Most 
invasive strains originated from blood cultures (92%). Two controls were excluded since 
these were found to have an S. aureus infection at a later stage, and were not replaced by new 
controls. Additionally, 34 invasive S. aureus strains originating from blood cultures of 
hospitalised non-nasal carriers of S. aureus, as described earlier, were selected for MLST 
analysis 3. Five strains of the original cohort were lost and were therefore not analysed.  
 
Table 1.  Patient characteristics.  
Cases are carriers who acquired invasive S. aureus disease during hospitalization with their own strain, and 
controls are carriers who did not acquire S. aureus invasive disease. Non-carriers are those who were not 
colonized by S. aureus in the nose at admission but did develop invasive S. aureus disease during 
hospitalization. 
     Cases  Controls Non-carriers 
     (n=60)  (n=118)* (n=34)         . 
Sex (n, % male)    33  (55.0%) 65  (55.1%) 24   (66.7) 
Mean age (years ± SD)   53  (±17) 53  (±17) 64   (±17)# 
Hospital (n, %) located in 
 Nijmegen   17  (28.3%) 33  (28.0%) 12   (35.3%) 
 Amsterdam     8  (13.4%) 16  (13.5%)   5   (14.7%) 
 Breda      5  (8.3%) 10  (8.5%) ND** 
 Rotterdam   30  (50.0%) 59  (50.0%) 17   (50.0%) 
 
Strains obtained by: 
Blood culture (n, %)  55  (91.7%)   0 (0.0%) 34   (100%)   
Other sterile site (n, %)   5     (8.3%)   0 (0.0%)   0   (0.0%) 
* 2 controls were found to have a S. aureus infection at a later stage and were excluded from further analysis. 
# Non-carriers were significantly older than cases (P=0.005) 
** ND: not done. Breda did not store invasive S. aureus strains from non-carriers. 
 
Sequence types, invasive disease and mortality 
Overall, 32 different sequence types (STs) were identified (Figure 1). Nine STs accounted for 
80% of all tested strains, of which three STs (30, 15 and 45), were the most prevalent (20%, 
15%, and 12%, respectively). There were no significant differences in the distribution of STs 
per hospital (data not shown). STs were grouped by BURST analysis in clonal clusters (CC) 
as shown in Table 2. Singletons also included STs 5, 9, 12, and 22, which were identified as a 
clonal complex in earlier studies.9 Only CC45 was significantly more prevalent among non-
invasive strains (OR: 0.16; 95% CI: 0.04 - 0.59). Most invasive strains belonged to CC30 and 
many were different singletons. Invasive strains of non-carriers did not differ markedly in 
their distribution of STs as compared to invasive strains of carriers (Table 2). 
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Figure 1. Dendrogram showing the relatedness of  the found S. aureus sequence types.  
 
\ 
 
 
 
 
 
 
 
 
Table 2. Distribution of identified clonal complexes in cases (S. aureus nasal carriers with invasive S. aureus 
infection) and their controls (asymptomatic S. aureus carriers). Corresponding odds ratios are given. The 
distribution of clonal complexes belonging to invasive S. aureus isolates from non-carriers is given. 
Clonal Complex (CC) Cases  Controls OR (95% CI)  Non-carriers  
1      1 (1.7%) 4 (3.4%) 0.48 (0.02-4.75)     3 (8.8%)   
25   1 (1.7%) 6 (5.1%) 0.32 (0.01-2.75)  3 (8.8%)   
30   21 (35.0%) 26 (22.0%) 1.91 (0.91-4.00)  6 (17.6%)  
45   3 (5.0%) 29 (24.6%) 0.16 (0.04-0.59)  5 (14.7%)  
Singletons  34 (56.7%) 53 (44.9%) 1.60 (0.82-3.15)  15 (44.1%)  
New ST   0  0  -   2 (5.9%) 
Total   60  118  -   34   
CC 1 includes sequence types: 1, 3, 81, and 188 
CC 25 includes sequence types: 25 and 26. 
CC 30 includes sequence types: 30, 34, and 39. 
CC 45 includes sequence types: 45, 46, 47, and 53 
Singletons include sequence types: 5, 7, 8, 9, 12, 15, 22, 50, 97, 120, 182, 500, 501, and 502. 
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Table 3.  Mortality data of patients with invasive S. aureus infection, by carriage status. 
    In-hospital mortality n/total (%) 
Clonal cluster  Carrier*   Non-carrier  Total    
1   1/1     (100%)  2/3    (67%)  3/4     (75%) 
25   1/1     (100%)  1/3    (33%)  2/4     (50%) 
30   2/21   (10%)  4/6    (67%)  6/27   (22%) 
45   0/3     (0%)  3/5    (60%)  3/8     (38%) 
singleton  2/34   (6%)  5/15  (33%)  7/49   (14%)** 
new   0/0     (-)  0/2      (0%)  0/2     (0%)** 
total   6/60  (10%)  15/34 (44%)  21/94 (22%) 
* Significant higher mortality in non-carriers as compared to carriers (Chi square: P=0.00015). No specific clonal cluster 
could be identified that was associated with the higher mortality rate in non-carriers.  
**  Significant higher mortality in those infected with S. aureus strains belonging to a clonal cluster versus those infected 
with singletons or new sequence types (P=0.029). 
 
The overall mortality rate in non-carriers with invasive S. aureus infection was higher than in 
carriers, as described earlier (Table 3; P=0.00015) 3. By the present MLST analysis we could 
not identify a specific clone in non-carriers with invasive S. aureus infection that could 
explain the higher in-hospital mortality in this group. However, there was a significant higher 
mortality rate in those infected with S. aureus strains belonging to a clonal cluster (14/43 
[33%]) compared to those infected with strains classified as singletons or new sequence types 
(7/51 [14%]; P=0.029). 
 
DISCUSSION 
In a previous study, patients were screened for S. aureus nasal carriage at admission in 4 
distinct teaching hospitals and followed for the development of nosocomial invasive S. aureus 
disease. In the present study, invasive S. aureus strains from S. aureus carriers were compared 
by MLST with carriage strains isolated from matched controls, who did not develop invasive 
S. aureus infections. The STs of invasive S. aureus strains from non-carriers were defined as 
well. The distribution of the  STs was comparable with that found in other studies.9 
Overall, no major clonal cluster could be identified that was responsible for invasive S. aureus 
disease. However, invasive strains belonged in 35% of the cases to ST 30 (not significant). 
Interestingly, we did identify a clonal complex (CC45) that was significantly more prevalent 
among non-invasive strains. We could not identify a clonal cluster that was significantly more 
prevalent in invasive strains of non-carriers compared to the other groups.  
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Earlier we reported a considerable higher mortality rate in S. aureus non-carriers with 
invasive S. aureus as compared to carriers with invasive S. aureus disease in the same cohort.3 
No single clonal cluster could be identified that could explain the higher mortality rate in this 
patient category. But this analysis is not definite since some clonal clusters had small 
numbers.  
However, mortality rates were significantly higher among patients infected with a S. aureus 
strain belonging to a MLST clonal complex, compared to patients infected with a strain not 
belonging to a clonal complex. This finding indicates that staphylococcal clones that have 
successfully spread among humans, i.e. evolved into prevalent clonal complexes or lineages, 
are those that have more virulence factors associated with lethality of S. aureus disease. 
Further screening of the staphylococcal genome for virulence factors could aid in identifying 
the putative factor(s) responsible for the higher mortality rate of strains belonging to clonal 
complexes. 
Feil et al also identified CC30 as a major clone in invasive nosocomial disease.9 They 
attributed this observation to widespread presence of EMRSA-16 within this CC.8,9 However, 
in our study no MRSA was identified, so this does not explain this finding. The prevalence of 
MRSA is very low in The Netherlands.10 Clearly CC30 is a successful S. aureus lineage, 
irrespective of methicillin resistance. Due to the abundance of strains belonging to CC30, as 
found in our study and by Melles et al, the chances of this lineage to acquire a SCCmec are 
likely higher.11 Once SCCmec is acquired, these ST 30 MRSA strains can replace ST 30 
MSSA strains easily in settings with high antibiotic use, including hospitals.  
Peacock and co-workers compared 155 S. aureus isolates from invasive disease with carriage 
isolates from healthy individuals, in the same cohort as Feil did.12 They proposed that allelic 
variants of a polymorphic locus can make different contributions to the disease process. It 
remains unclear how. They also found evidence for considerable horizontal transfer of genes 
against a clonal background. It is now well established that within and between S. aureus 
clones there is a significant high level of exchange of mobile DNA coding for virulence and 
resistance.13-15 Melles et al showed that all clones can cause life-threatening infections, but 
certain clones are more virulent than others.11 It would be interesting to investigate whether 
there is a difference in competence for the uptake of (mobile) DNA between clones.  
 
Association between S. aureus genotype,  
S. aureus invasive disease and in-hospital mortality 
 
 77
CONCLUSION 
By multi locus sequence typing we could not identify a S. aureus clonal cluster that was more 
likely to cause invasive S. aureus infections. We did find that clonal cluster 45 was more 
prevalent in asymptomatic carriers. Clonal cluster 30 is in general a prevalent clone, 
independent of methicillin resistance. There were no prevalent clones of invasive S. aureus 
strains in non-carriers and no specific clone that could explain the higher in-hospital mortality 
rate. However, overall mortality, irrespective of carriage status, was significantly higher for 
those patients infected with strains belonging to a clonal complex, indicating co-evolution of 
S. aureus virulence and spread among humans.  
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ABSTRACT 
 
Nasal carriage of Staphylococcus aureus is an important risk factor for subsequent S. aureus 
infections. We studied whether nose picking was associated with S. aureus nasal carriage in 
238 Ear, Nose- and Throat disease (ENT) patients and 109 healthy employees by nasal 
culture, questionnaire (5 point scale answers) and nasal examination by an ENT-doctor (ENT 
patients only). Nose pickers are significantly more likely to carry S. aureus than non-pickers: 
37/69 (53.6%) versus 60/169 (35.5%) respectively (RR: 1.51; CI: 1.03 - 2.19). There is a 
significant positive correlation between self-perceived frequency of nose picking and 
frequency of positive cultures (R: 0.31; P=0.004), and load of S. aureus in the nose (R: 0.32; 
P=0.003), suggestive for a causal relationship. 
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INTRODUCTION 
Staphylococcus aureus, irrespective of resistance to methicillin, is a frequent cause of both 
community and hospital acquired infections, with substantial morbidity and mortality as a 
result.1,2 About one-third of all persons is found to carry S. aureus in the nose.3 Nasal carriage 
of S. aureus is a well-known risk factor for acquiring S. aureus infections and eradication of 
this micro-organism from the nose can be an effective preventive measure, mostly in surgical 
and dialysis patients.3-6 The same prophylactic strategy is used for eradicating carriage of 
methicillin resistant S. aureus (MRSA), as an infection control policy.  
Although numerous studies have been performed, a valid explanation for the S. aureus 
carriership has yet to be given. Since hand and nasal carriage of S. aureus are associated and 
S. aureus resides in the anterior part of the nose, we considered the habit of nose picking as a 
potential determinant of S. aureus nasal carriage.7 In a pilot study, we demonstrated a positive 
trend between nose picking and S. aureus nasal carriage (Wertheim et al. Presentation at 9th 
International Symposium on Staphylococci and Staphylococcal Infections. Denmark 2000). 
We, therefore, studied this determinant in a larger cohort with predefined criteria for nose 
picking.  
 
METHODS 
Participants 
Participants were patients who visited the Ear, Nose, and Throat (ENT) outpatient clinic and 
healthy volunteers, including personnel and medical students, of the Erasmus University 
Medical Centre Rotterdam, the Netherlands. Ethical review board approval was obtained. All 
participants gave written informed consent. 
 
ENT-patients 
Patients (≥ 18 years) who visited the ENT outpatient clinic between June 2001 and July 2002, 
and did not come primarily for nose complaints, were screened for nasal carriage of S. aureus 
and assessed for nose picking behaviour. The following exclusion criteria were used: signs of 
rhinitis, use of antibiotics at the time of inclusion, and inability to understand the Dutch 
language. The following data were obtained: demographics, medical history, and medication. 
Patients were given a standardized questionnaire on behaviour and symptoms related to the 
nose on which they could give answers on a five-point scale (Table 1). Patients were not 
informed that the primary determinant of this investigation was their nose picking behaviour.  
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Table 1. Topics addressed in the questionnaire. 
                             Complaints Behaviour   
                             -Epistaxis -Smoking   
                             -Nasal dryness -Exhaling smoke through the nose 
                             -Nasal itchiness -Blowing the nose 
                             -Nasal crusts -Turning up the nose 
                             -Nasal wounds -Picking the nose 
                             -Runny nose -Rubbing the nose externally 
                             -Rhinitis 
 
A nasal examination was performed by an ENT specialist, who was blinded for S. aureus 
carriage status of the patient and the patient’s answers to the questionnaire. The following 
symptoms and signs were scored: vestibulitis, recurrent epistaxis, septal hyperkeratosis, 
scratch effects in the vestibulum nasi, wounds and erosions in the vestibulum nasi, septum 
perforation and any nasal injury that was considered by the ENT doctor to be potentially due 
to nose picking. Only if these signs could not be explained otherwise they were scored as a 
sign of nose picking. In conclusion, the ENT specialist had to state whether the examined 
patient was considered a nose picker according to his/her clinical expertise. The anterior nares 
were cultured once, just prior to the ENT examination.  
Patients were identified as nose pickers if they answered to pick at least sometimes and had at 
least one nose picking sign found by nasal examination.  
 
Healthy volunteers 
Between January 2002 and May 2003, nasal swabs were obtained from the healthy volunteers 
(≥18 years). At least 5 nasal swabs were obtained with one-week intervals to differentiate 
between the different carrier types of S. aureus. Volunteers were excluded if they used 
antibiotics. 
Frequent carriers were defined as having at least two-third of their cultures positive for S. 
aureus, moderate carriers had one- to two-third of the cultures positive, occasional carriers 
had fewer than one-third of the cultures positive, and non-carriers had none of the cultures 
positive for S. aureus. These persons filled in the same questionnaire as described above, but 
were not examined by an ENT specialist.  
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Microbiology 
Nasal specimens were obtained using sterile cotton-wool swabs and transport medium 
(Transwab, Medical Wire & Equipment Co. Ltd., Corsham, United Kingdom). Both the left 
and right anterior nares were swabbed by rubbing the swab four times in each nostril. The 
swabs were immediately placed in Stuart’s medium and were cultured within 24 hours.  
Nasal swabs from ENT patients were cultured quantitatively on selective media: phenol-red 
mannitol salt agar (PHMA) and phenol red mannitol salt broth (PHMB), as described earlier.8 
Colonies morphological suspect of S. aureus were subcultured overnight on Columbia blood 
agar (BA) plates (Becton-Dickinson B.V., Etten-Leur, The Netherlands) and a catalase- and 
latex-agglutination test (Staphaurex PlusR, Murex, Dartford, UK) were performed.  
Nasal swabs from healthy volunteers were cultured on BA plates and suspended in PHMB. 
The media were incubated for 48 hrs at 35 °C and checked each day for bacterial growth. 
Suspected S. aureus colonies were identified with catalase- and latex-agglutination test. The 
degree of growth was ascertained in a semi-quantitative manner. 
  
Statistics 
For data analysis we used SPSS version 10.0 statistical software. The five point-scale answers 
to the questionnaire (never, rarely, sometimes, regular, frequent) and the different degrees of 
carriage were coded from 0 to 4. The number of S. aureus CFU’s were recorded 
quantitatively and then 10Log-transformed (10Log[CFU+1]) to obtain a normal distribution. 
Correlations were measured with the Spearman method. For 2 by 2 tables, the Fisher’s exact 
test was used. Means were compared by unpaired t-tests and one-way ANOVA, where 
appropriate. P-values < 0.05 were considered significant. 
 
RESULTS 
ENT-patients 
A total of 375 patients were asked to participate in this study of which 137 patients were 
excluded (Figure 1). The 238 included patients (58% male; mean age 47 years) had as most 
common primary complaint ear and hearing problems (71%). In this study population 97/238 
(41%) patients were S. aureus nasal carriers and we found 69/238 (29%) to meet the criteria 
for nose picking. Nose pickers, as identified by questionnaire and nasal examination, were 
more often S. aureus carrier than non-pickers, 37/69 (54%) versus 60/169 (36%) respectively, 
resulting in a relative risk of 1.51 (95% CI: 1.03-2.19; Figure 2). This result was confirmed 
when only using the ENT-specialist classification of nose picking by physical examination: 
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59% of the patients classified as nose picker were S. aureus nasal carrier versus 35% of those 
considered non-picker (P=0.019).  
In this patient population there was no correlation between the answers given to the 
questionnaire and number of S. aureus CFU’s (R: 0.10; P = 0.18). However, significantly 
more CFU’s were detected in patients who mentioned to pick at least sometimes (geometric 
mean CFU’s: 1.9), versus those who mentioned not to pick their nose at all (geometric mean 
CFU’s: 0.9; P=0.02).  
Self-reported nose picking was significantly correlated with self-reported nasal itchiness (R: 
0.25; P<0.001), nasal crusts (R: 0.423; P<0.001), nasal dryness (R: 0.21; P=0.001), nasal 
wounds (R: 0.20; P=0.001), turning up once nose (R: 0.19; P=0.004) and nose rubbing (R: 
0.31; P<0.001). Self-reported nose picking frequency was only significantly correlated with 
nasal crusts found during nasal examination (R: 0.16; P=0.013). There were no significant 
associations between the separate signs of nose picking and S. aureus carriage. If we take the 
number of S. aureus CFU’s into account, there was a significant correlation with S. aureus 
load and nasal wounds (R: 0.14; P=0.032), nasal crusts (R: 0.13; P=0.048), and vestibulitis 
(R: 0.14; P=0.035). 
 
Figure 1. Study profile 
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*ENT: Ear-, Nose-, Throat disease. 
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Figure 2. Frequency of S. aureus nasal carriers in ENT-patients per nose-picking category. 
 
 
 
Categories: N-N: rarely to never picks and no signs of nose picking; P-N: picks at least 
sometimes, but no signs of nose picking; N-S: rarely to never picks, but signs of nose picking 
present; P-S: picks at least sometimes and signs of nose picking present. 
* Category P-S included significantly more S. aureus carriers compared to all other categories  
(P=0.013), and compared to category N-S (P=0.024) and N-N (P=0.036), but not category P-N 
(P=0.072). 
 
Healthy volunteers 
Eighty-six volunteers (33.3% male; mean age: 23 years; Figure 1), who filled in the 
questionnaire and had at least 5 nasal cultures taken, were included in the study. On average 7 
cultures were obtained per volunteer (range: 5-10 cultures). Carrier types detected were: 33 
non-carriers (38.5%), 22 occasional carriers (25.5%), 9 moderate carriers (10.5%), and 22 
frequent carriers (25.5%). There was a significant positive correlation between self perceived 
frequency of nose picking and frequency of positive cultures (R: 0.31; P=0.004; figure 3), and 
the semi-quantitative count of S. aureus CFU’s (R: 0.33; P=0.002; figure 4). The reported 
frequency of nose picking was significantly correlated with the self-reporting on having nasal 
crusts (R: 0.45; P<0.001), nasal rubbing (R: 0.23; P=0.033), and turning up once nose (R: 
0.29; P=0.007). 
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Figure 3. Correlation between self reported frequency of nose picking and the proportion of positive nasal 
cultures in healthy volunteers. 
 
 
 
 
Figure 4. Density of nasal S. aureus and nose picking frequency in healthy volunteers 
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DISCUSSION 
The findings of this study support the hypothesis that nose picking is associated with nasal 
carriage of S. aureus. The habit of nose picking is probably initiated by having nasal crusts. In 
the first study sample of ENT-patients, significantly more carriers were found in those 
classified as nose picker by predefined criteria. Also those patients classified as nose picker 
by the ENT-specialist, based on his clinical expertise, had a significant higher S. aureus 
carriage rate. Furthermore, there exists a significant correlation of proportion of positive 
cultures and the load of S. aureus present in the nose with self-graded frequency of nose 
picking. This positive dose-response suggests a causal relation between nose picking and 
nasal carriage of S. aureus.  
We realize that the used questionnaire is a subjective measurement. It was unfeasible for us to 
observe participants secretly for their nose picking behaviour, which led us to the used study 
design. This disadvantage is partly compensated by blinding the participant for his/her 
carriage status and not telling the objective of the study. The questionnaire was also 
anonymous, which probably improved the sincerity of the given answers. We also included 
the nasal examination by an ENT specialist to score objective signs of nose picking.  
Jefferson et al. studied the habit of nose picking and found that 90% of his study population 
picked their nose with various frequencies and degrees of severity, leading even to a 
perforated septum in two cases.9 To be classified as a nose picker in our study, one needed at 
least to have one objective clinical sign assumed to be due to nose picking. Therefore patients 
classified as nose pickers all had some form of traumatic lesions, probably due to nose 
picking. Interestingly, nose picking signs with a negative answer to the questionnaire, was not 
predictive for S. aureus nasal carriage. Patients with rhinitis were excluded, since the 
associated inflammation impeded determination of nose picking signs.  
We classified patients as nose pickers in case of observed damages to the nasal mucosa and 
dermis. This surface acts as a first line defence to microbial colonization and invasion. 
Lesions therein will expose extra-cellular matrix molecules, including fibronectin and 
collagen, to which S. aureus can adhere.2,10,11 However, recent in-vitro studies found that S. 
aureus cell wall teichoic acid, clumping factor B and other cell-wall associated adhesins may 
be involved in adhering to nasal epithelial cells, suggesting that exposure of extra-cellular 
matrix molecules may not be essential for colonization.12-15 However, S. aureus is well known 
to heavily colonize skin lesions, including eczematous lesions, indicating that, in-vivo, S. 
aureus exhibits high affinity to extra-cellular matrix molecules.11 
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Alternatively, carriage of S. aureus in the nose may elicit an immune response with irritation 
and itchiness as a result, that may elicit more frequently or rigorously nose picking. A recent 
study suggests that S. aureus colonization induces a local inflammatory response.16 
Eradicating S. aureus from the nose may result in reduced inflammation and itchiness. It still 
needs to be resolved whether nose picking is a cause or consequence of S. aureus nasal 
carriage.  
Hand carriage is known to be associated with nasal carriage of S. aureus. The number of 
staphylococci on the fingers rises with increasing nasal counts.17 Furthermore, nasal S. aureus 
carriers are more likely to be hand carriers of S. aureus and nasal eradication of S. aureus 
often leads to disappearance of the micro-organism from the hands as well.18 A study by Hare 
et al., elegantly demonstrated that nine students, observed during a one hour lecture, touched 
their mouth or nose on 6 to 23 separate occasions.19 Another study showed that nasal S. 
aureus carriers carry different loads of S. aureus on their left and right fingers.17 Clearly, 
hands are the major vector for transmitting S. aureus from the environment into the nose, and 
vice versa. It is likely that staphylococci are introduced into the nose by the hand and that 
persistence of carriage may in part be determined by the frequency, duration and intensity of 
nose picking. The data as presented in figure 2 suggest that nose picking or nasal trauma 
alone do not lead to a higher carriage rate. It is probably a combination of both the 
introduction of S. aureus by the finger and having nasal trauma (either by nose picking or 
other causes) that facilitates S. aureus nasal carriage. Future S. aureus eradication studies 
could incorporate an advice to shed the habit of picking one’s nose, reducing the probability 
of recolonization. Understanding the pathogenesis of S. aureus nasal carriage helps 
optimising prophylactic strategies to prevent S. aureus disease and spread of MRSA. 
We conclude that nose picking is associated with nasal carriage of S. aureus, and may well be 
causal.  
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... Vloeibare media verhogen de detectiekans en maken het afnemen van meerdere sets kweken 
overbodig. Derhalve wordt het gebruik hiervan aangeraden ... Een benadering is het toevoegen 
van antibiotica. In een studie werd hiermee een significant betere detectie gevonden in 
vergelijking met vaste media bij een aanmerkelijke vereenvoudiging van de laboratorium 
werkzaamheden. Dit medium bestaat uit een phenyl-mannitol bouillon met aztreonam en 
ceftizoxim. Ceftizoxim is gekozen omdat hierdoor de expressie van meticillineresistentie wordt 
verbeterd. Men kan de bouillon, ongeacht de kleur, na 48 uur afenten op een bloedagar, waarne 
de bloedagar verder wordt bewerkt. Echter men kan ook afenten nadat een kleuromslag van 
rood naar oranje-geel is opgetreden. De kleuromslag wordt beoordeeld na 48 en na 72 uur. 
Indien de laatste werkwijze wordt gekozen, wordt een gelijktijdig ingezette bloedagar 
beoordeeld op groei van niet-fermentatieve gram-negatieve staven. Bij aanwezigheid hiervan 
wordt de bouillon altijd afgeënt, ongeacht de kleur. Non-fermenters maken het milieu alkalisch 
waardoor de kleuromslag mogelijk niet meer optreedt. Uit de eerder genoemde studie blijkt dat 
bij deze werkwijze bij ongeveer 75% van alle bouillons geen afenting nodig is ... 
 
     NVMM richtlijn detectie van MRSA  in Nederland 2002 
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ABSTRACT 
 
We tested a phenyl mannitol broth containing ceftizoxim and aztreonam (PHMB+) for detection 
of methicillin-resistant Staphylococcus aureus (MRSA) with reference MRSA strains and, 
subsequently, with clinical samples (n=1,098). All reference MRSA strains induced color change 
in PHMB+ after 24–72 hours incubation. In a clinical setting, 40 MRSA strains were detected 
with PHMB+ versus only 23 with a routine method. Thus, this selective broth significantly 
(p<0.001) improved the rate of MRSA detection. 
 
 
Improved detection of MRSA  using phenyl mannitol broth 
 containing aztreonam and ceftizoxime 
 
 
 
97
 
INTRODUCTION 
Detection of methicillin-resistant Staphylococcus aureus (MRSA) in clinical samples continues 
to be important, since infections due to MRSA have a high morbidity and mortality. Moreover, 
some MRSA strains have the potential to spread rapidly and colonize other patients. In The 
Netherlands, therefore, patients who are suspected for MRSA carriage are isolated until screening 
cultures are repetitively negative for MRSA. Methods to detect MRSA in clinical samples should 
ideally have a high sensitivity and a short time to reporting. To increase the sensitivity one can 
simply take more screening samples on the same day or on consecutive days, but this is more 
cumbersome and increases the time to reporting. Another way to increase the sensitivity is to use 
a broth in addition to agar plates as was demonstrated previously. 1-5 To increase the sensitivity of 
the detection of MRSA from a single sample and to improve laboratory efficiency, we developed 
a new selective broth containing phenol red, mannitol, aztreonam and ceftizoxim. First, we tested 
the broth with laboratory reference strains. Subsequently, we compared our routine method of 
direct plating of specimens onto blood agar plates and mannitol salt agars with the new selective 
broth combined with a blood agar plate.  
 
METHODS 
The selective broth (PHMB+) was made by adding 5 µg/ml ceftizoxim (Yamanouchi) and 75 
µg/ml aztreonam (Bristol-Myers Squibb) to phenyl mannitol broth with 0.05% salt (Becton 
Dickinson, Le Pont de Claix, France). See table 1 for a recipe of the broth. We tested PHMB+ 
with 5 different MRSA and 5 different methicillin sensitive S. aureus (MSSA) strains isolated 
from patients. Methicillin resistance was confirmed by MecA PCR, according to the method 
described by Murakami.6 At first, all 10 strains were subcultured onto Brucella blood agar and 
incubated for 18 hours at 37° C. From each strain a suspension was made in 0.9% NaCl with a 
density of 0.5 McFarland (108 cfu/ml) and dilution series of 108 cfu/ml to 100 cfu/ml were made. 
Five-hundred microliters of each dilution were pipetted in 5 PHMB+ broths (4.5 ml) of different 
production dates, each 1 week apart. Every batch of PHMB+ was prepared by the same person 
and stored at 4° C until use. One hundred microliters of the original solution of 0.5 McFarland 
was streaked on a Brucella blood agar plate as a control for the density of cfu’s. The broths were 
incubated for 14 days at 37° C, and were inspected on a daily basis for color change from red to 
orange/yellow.  
From June 1997 to December 1997 the Department of Medical Microbiology and Infectious 
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Diseases received 1,098 consecutive specimens for the detection of MRSA. These specimens 
originated from patients and employees and were either screening samples or samples taken 
during a putative MRSA outbreak. From employees, only the anterior nares were cultured. From 
patients, specimens were taken from rectum, nose, throat, wounds, insertion sites of venous and 
arterial lines, and urine if a urine catheter was present. Samples were collected and transported 
with commercial swabs (Transwab®, Medical Wire & Equipment Co. Ltd., Wiltshire, United 
Kingdom) to the laboratory and then stored for a maximum of 16 hours at 4° C until inoculation.  
Only one swab was available per collection site. 
 For the routine culture of MRSA the swabs were streaked on 5% sheep blood agar plates (BA, 
Becton Dickinson, Le Pont de Claix, France) and phenyl mannitol salt (7%) agar plates (PHMA, 
Becton Dickinson, France). Subsequently, the swabs were submerged in PHMB+. All media were 
incubated for 3 days at 37° C and checked for growth of Staphylococci each day. The broth was 
examined daily for color change from red to orange/yellow for three days. When the color of the 
broth had changed to orange/yellow, a loop of broth was subcultured on BA. If growth of a non-
fermenter was observed on the primary BA, the broth was subcultured on BA irrespective of the 
color of the broth. This subculture was examined for suspect colonies after incubating 18- 24 hrs 
at 37° C. Colonies suspected for S. aureus were identified with a Staphaurex Plus® agglutination 
test (Abbott Murex, Chatillon, France) and tested with methicillin disk diffusion performed 
according to the NCCLS guidelines.7 All morphologically different strains were tested. 
Staphaurex Plus® positive strains were confirmed with the AccuProbe® hybridization test (Gen-
Probe Inc., San Diego, USA), according to guidelines of the manufacturer. Methicillin resistance 
was confirmed with MecA PCR.6 MecA positive strains were send to the laboratory of the 
National Institute of Public Health and the Environment (RIVM, Bilthoven, The Netherlands) for 
MRSA phage typing (unpublished method). The difference in proportion of detected MRSA 
strains between the two methods was statistically tested with the Sign test for paired samples 
using SPSS software, p<0.05 was considered significant. 
 
RESULTS 
In the experimental setting the MSSA strains did not produce any color change in the PHMB+ 
broth, irrespective of the concentration of cfu’s, of the incubation time, or the storage time of the 
broth. All MRSA strains gave a distinct color change at the dilution step corresponding to 
approximately 100 cfu/ml after incubating for 72 hours. At densities of 105 cfu/ml  and higher, the 
color change was observed within 24 hours. The storage life of the broth was at least 4 weeks at 
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4° C in the dark (data not shown). 
 In the clinical setting a total of 1,098 cultures were performed. The cultures were taken from 
nares (n=466), perineum (n=220), throat (n=215), wounds (n=101), exit sites catheters (n=43), 
urine (n=22), and other sites (n=31). One-hundred-thirty-six (12 %) of these cultures were 
positive for S. aureus of which 40 (29 %) were methicillin resistant (MecA PCR positive). The 
MRSA strains were cultured from eight different patients. Phage typing of the MRSA strains 
showed 5 distinct phage types and one was untypable. Twenty-three (57%) of the MRSA strains 
grew on both  BA, PHMA and in PHMB+. Seventeen additional strains only grew in PHMB+, and 
not on BA or PHMA (Sign test: p<0.001). The PHMB+ showed 263/1,098 (24%) color changes 
(Table 2). The most prevalent organisms in positive PHMB+, apart from MRSA, were coagulase-
negative Staphylococci (n=107) and Enterococcus spp. (n=33). 
 
DISCUSSION AND CONCLUSION 
The results show that by using the selective broth we detected almost twice as many MRSA 
strains compared with the routine technique. Furthermore, only a small fraction of the PHMB+ 
broths need to be subcultured due to the presence of selective antibiotics. At the time of this study 
our laboratory used methicillin agar diffusion instead of oxacillin to test for methicillin 
resistance. Since this test was used for both culture techniques we do not believe this will have a 
great effect on our results. This is the only study that presents a selective broth with antibiotics 
inhibiting growth of both gram-positive and gram-negative bacteria for the selection of MRSA 
strains. Previous studies have used high concentrations of salt for selectivity, with or without 
aztreonam or oxacillin.1-5,8-12 By using only salt one selects MRSA as well as MSSA strains and 
salt has the disadvantage that some MRSA strains will not grow when concentrations exceed 
2.5%.10 The rationale for using ceftizoxim and aztreonam in the selective broth instead of 
oxacillin and colistin was that earlier studies had shown that both oxacillin and colistin resulted 
in inhibited or slower growth of MRSA strains (data not shown). Furthermore, ceftizoxim is 
known to increase the phenotypic level of resistance to methicillin.13-15  
This study was designed to improve the efficiency and sensitivity of detecting MRSA, and in this 
respect "the need for speed" remains important. The use of the BA plate is still necessary to 
detect non-fermenters that produce an alkaline environment in the broth, thereby prohibiting the 
phenol red to turn yellow. Therefore, broths should always be subcultured when a non-fermenter 
grows on BA. When there is an outbreak with a new MRSA strain we suggest to immediately 
determine it’s growth characteristics in the PHMB+.  Do this by making a dilution series of the 
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cultured strain, incubate and check the time required until color change. From the results one can 
choose the optimal incubation time for specimens from contact patients and health care workers. 
The present study clearly shows that MRSA screening with a selective phenyl mannitol broth 
including aztreonam and ceftizoxim is efficient and sensitive. This method is now implemented 
in the routine MRSA screening of our and other Dutch hospitals.  
 
Table 1. Recipe of the selective broth PHMB+. 
Step 1 
Mix 21 mg of dehydrated Phenol Red Mannitol Broth (PHMB, Becton Dickinson) with 1000 ml destilled 
water. Sterilize for 15 minutes at 121°C. Let it cool down to room temperature. 
 
Step 2 
Mix 5 mg Ceftizoxim (Yamanouchi) with 5 ml destilled water. Add to PHMB and mix. 
 
Step 3 
Mix 75 mg Aztreonam (Bristol-Myers Squibb) with 5 ml destilled water. Filter through FP 030/2 filter 
(Schleicher & Schuell). Add to PHMB and mix. 
 
Step 4 
Fill sterile tubes with 8 ml PHMB+. Store at 4° C in the dark. Shelf-life is at least 4 weeks.  
 
 
 
Table 2. MRSA detected with the routine method versus PHMB+.  
Species Routine PHMB+ 
Coagulase-negative Staphylococcia NR 111 
Methicillin resistant S. aureus (MRSA)b 23 40 
Enterococcus spp.c NR 37 
Coagulase-negative Staphylococci + Enterococcus spp. NR 35 
Otherd NR 40 
Note: most frequent microorganisms causing color change in the PHMB+ are mentioned (n=263). 
a In combination with other species (n=4). 
b Sign test: p < 0.001 
c In combination with other species (n=4). 
d Gram positive rods, yeasts and methicillin sensitive S. aureus (n=3). 
NR: not registered. 
 
Improved detection of MRSA  using phenyl mannitol broth 
 containing aztreonam and ceftizoxime 
 
 
 
101
 
REFERENCES 
1.  Cookson BD, Webster M, Phillips I. Control of epidemic methicillin-resistant Staphylococcus aureus. 
Lancet 1987;1(8534):696. 
2.  Ford M, Perry JD, Robson I, et al. Evaluation of tube coagulase and a fluorogenic substrate for rapid 
detection of methicillin-resistant Staphylococcus aureus from selective enrichment broth in an outbreak of 
EMRSA 15. J Hosp Infect 1999;41(2):133-5. 
3.  Sautter RL, Brown WJ, Mattman LH. The use of a selective staphylococcal broth v direct plating for the 
recovery of Staphylococcus aureus. Infect Control Hosp Epidemiol 1988;9(5):204-5. 
4.  Sautter RL, Wells LW. Selective staphylococcal broth. J Clin Microbiol 1990;28(10):2380-1. 
5. Van Ogtrop ML. Effect of broth enrichment cultures on ability to detect carriage of Staphylococcus aureus. 
Antimicrob Agents Chemother 1995;39(9):2169. 
6.  Murakami K, Minamide W, Wada K, Nakamura E, Teraoka H, Watanabe S. Identification of methicillin-
resistant strains of staphylococci by polymerase chain reaction. J Clin Microbiol 1991;29(10):2240-4. 
7.  National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk 
susceptibility tests, 5th ed. Approved standard. National Committee for Clinical Laboratory Standards, 
Villanova, Pa. 1993. 
8.  Davies S, Zadik PM. Comparison of methods for the isolation of methicillin resistant Staphylococcus 
aureus. J Clin Pathol 1997;50(3):257-8. 
9.  Hansen SL, Pope WA. Screening method for rapid detection of methicillin-resistant (heteroresistant) 
Staphylococcus aureus. J Clin Microbiol 1985;22(5):886-7. 
10. Jones EM, Bowker KE, Cooke R, Marshall RJ, Reeves DS, MacGowan AP. Salt tolerance of EMRSA-16 
and its effect on the sensitivity of screening cultures. J Hosp Infect 1997;35(1):59-62. 
11.  Kampf G, Weist K, Swidsinski S, Kegel M, Ruden H. Comparison of screening methods to identify 
methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1997;16(4):301-7. 
12.  Mir N, Sanchez M, Baquero F, Lopez B, Calderon C, Canton R. Soft salt-mannitol agar-cloxacillin test: a 
highly specific bedside screening test for detection of colonization with methicillin-resistant Staphylococcus 
aureus. J Clin Microbiol 1998;36(4):986-9. 
13.  Moriyasu I, Igari J, Yamane N, et al. [Multi-center evaluation of Showa ceftizoxime disk susceptibility test 
to discriminate between the strains of methicillin-resistant Staphylococcus aureus (MRSA) and those 
susceptible (MSSA)]. Rinsho Byori 1994;42(3):271-7. 
14.  Taguchi F, Saito-Taki T, Okuda S, Kikuno R. [Newly developed MRSA medium]. Nippon Saikingaku 
Zasshi 1992;47(6):759-65. 
15.  Tokue Y, Shoji S, Satoh K, Watanabe A, Motomiya M. Comparison of a polymerase chain reaction assay 
and a conventional microbiologic method for detection of methicillin-resistant Staphylococcus aureus. 
Antimicrob Agents Chemother 1992;36(1):6-9. 
 
Part IV – Chapter 8 
 102 
 
CHAPTER 9 
 
LOW PREVALENCE OF METHICILLIN-RESISTANT STAPHYLOCOCCUS 
AUREUS (MRSA) AT HOSPITAL ADMISSION IN THE NETHERLANDS 
 
Heiman F.L. Wertheim, Margreet C. Vos, Hélène A.M. Boelens, Andreas Voss, Christina 
M.J.E. Vandenbroucke-Grauls, Marlene H.M. Meester, Jan A.J.W. Kluytmans, Peter H.J. van 
Keulen, Henri A. Verbrugh 
Journal of Hospital Infection 2004; 56: 321-325 
Ned Tijdschr Geneeskd 2004; 148: 1044-1048 
 
 
 
NRC Handelsblad, 9 april 2005
Part IV – Chapter 9 
 104
ABSTRACT 
In the Netherlands, less than 1% of clinical isolates of Staphylococcus aureus is methicillin-
resistant (MRSA). A national Search and Destroy policy prevents MRSA from becoming 
endemic. Some MRSA outbreaks cannot be related to patients at risk for MRSA carriage. 
This study was designed to measure the prevalence of MRSA among patients without risk 
factors for MRSA carriage at the time of admission to the hospital.  
In 4 Dutch hospitals, patients admitted to non-surgical departments in the period 1999-2000 
were screened for MRSA nasal carriage. Nasal swabs were streaked on 5% sheep blood agar 
(BA), submerged in a selective broth, and incubated for 2-3 days at 35°C. Colonies suspected 
for S. aureus were identified with an agglutination test. Susceptibility testing was performed 
by an automated system and additional oxacillin disk diffusion. Methicillin resistance was 
confirmed by a DNA hybridisation test and MecA PCR. MRSA strains were genotyped by 
pulsed field gel electrophoresis (PFGE). 
Twenty-four percent (2,332/9,859) of the patients were S. aureus nasal carriers. Only 3 
(0.03%) patients were MRSA carriers. These patients were not repatriated, nor known to be 
MRSA carrier prior to screening. Genotyping revealed that the strains were not clonally 
related and were not related to MRSA outbreaks in the hospital where the patients were 
admitted. 
We conclude that at routine admission to a Dutch hospital (excluding high-risk foreign 
admissions) the MRSA prevalence is low (0.03%), due to the Dutch Search and Destroy 
policy and restrictive antibiotic prescribing. 
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INTRODUCTION 
The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in the Netherlands is 
among the lowest in the world. The European Antimicrobial Resistance Surveillance System 
(EARSS), a European resistance surveillance network, shows that the prevalence of MRSA 
among clinical S. aureus isolates is below 1% in the Netherlands.1 Prevalences in other 
countries are much higher: Belgium 28%, France 33%, Germany 19%, and the United States 
50%.1,2 A great threat is the emergence of vancomycin-resistant S. aureus isolates, of which 
the first has been isolated in the United States in 2002.3 A low MRSA prevalence may prevent 
the emergence of such highly resistant isolates. 
The low prevalence in The Netherlands can largely be explained by our national Search and 
Destroy policy, in combination with restrictive antibiotic use.4 The Search and Destroy policy 
implies that patients that are repatriated from countries outside the Netherlands and contacts 
of MRSA patients are strictly isolated at hospital admission until screening cultures for 
MRSA prove negative (‘search’; Table 1). In case of MRSA carriage, individuals are kept in 
isolation and treated to eradicate MRSA (‘destroy’). This policy is according to a guideline, 
established by the Dutch Working Group Infection Prevention (WIP guideline 35a; available 
at http://www.wip.nl). This guideline has recently been updated after this study was 
performed. Also, the use of antibiotics in the Netherlands is very low due to a restrictive 
prescribing policy: the defined daily doses of antibiotics used per 1000 people per day (DDD) 
in primary health care is 8.9, compared to 36.5 DDD in France.5 This low antibiotic pressure 
in the Netherlands, probably limits the selection of resistant micro-organisms, including S. 
aureus.5,6 
Since 1995, the Netherlands were confronted with a few MRSA outbreaks that could not be 
related to patients with known risk factors for MRSA carriage as mentioned in Table I.7 If 
MRSA strains are circulating in the community outside the hospitals, the risk factors as 
described in Table 1 would not be sufficient for a successful Search and Destroy policy, and 
further outbreaks could be the consequence. This study measured the prevalence of MRSA 
nasal carriage in non-risk patients at admission. 
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Table 1. Risk factors for MRSA carriage in the Netherlands, according to the national guidelines of the Working 
Group Infection Prevention (WIP-guideline 35a; available at: http://www.wip.nl). We do not refer to the new 
guideline because it was developed after this study. 
1. All patients transferred from a foreign hospital or nursing home, who 
 
 - have been admitted there for at least 24 hours 
or 
  - have been operated there 
or 
  - have a drain or catheter in place at the time of transfer 
or 
  - are intubated 
or 
- have open wounds or infections like abscesses or furuncles 
 
2.  All patients that are known positive for MRSA. 
 
3.  Contacts of a MRSA carrier. 
 
METHODS 
Between April 1999 and April 2000, 9,859  patients of non-surgical departments were 
screened for MRSA nasal carriage at admission. The participating hospitals were: Erasmus 
MC in Rotterdam (1300 beds), UMC St. Radboud in Nijmegen (950 beds), VU Medical 
Center in Amsterdam (730 beds), and Amphia hospital in Breda (500 beds). Medical Review 
Board approval was obtained. 
Nose swabs were obtained by nursing personnel at admission. Swabs were inoculated on 
blood agar plates (Becton Dickinson, France) and in a selective phenyl mannitol broth 
containing aztreonam and ceftizoxime (PHMB+), as described previously.8 The selective 
broth was examined daily for color change from red to orange/yellow for 3 days. When the 
color of the broth had changed to orange/yellow, a loop of broth was subcultured onto a blood 
agar plate. Growth suspect for S. aureus was tested with an agglutination test 
(StaphaurexPlus, Abbott Murex, France). All StaphaurexPlus positive strains were send to 
Erasmus MC, where the identification of S. aureus was confirmed and susceptibility testing 
performed by an automated system (Microscan-Walk-Away, Gram positive panel, Dade-
Behring, USA). Susceptibility for oxacillin was performed by disk diffusion according to the 
criteria of the National Committee for Clinical Laboratory Standards (NCCLS).9 The minimal 
inhibiting concentration (MIC) for oxacillin was measured by E test® (AB biodisk, Solna, 
Sweden). Breakpoints of all MIC results were according to NCCLS criteria.9 StaphaurexPlus 
positive strains with an antibiotic susceptibility profile suspect for methicillin resistance were 
confirmed by a S. aureus specific DNA hybridisation test (AccuProbe, Gen-Probe Inc., USA) 
and a PCR to identify the MecA gene. MRSA strains were genotyped by pulsed field gel 
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electrophoresis (PFGE) and compared with other circulating MRSA strains of the hospitals 
involved. MRSA isolates were considered to be identical if their PFGE patterns did not differ 
by more than three bands, according to standard PFGE interpretation criteria.10 Detection of a 
MRSA strain from a patient in this study would not lead to the standard practice of isolation 
measures, because the susceptibility testing was performed at a later stage (after discharge). 
 
RESULTS 
During the study period 9,859 patients were screened for MRSA nasal carriage. Patients were 
screened on average 1.8 days after admission (range: 0-3 days). Twenty-four percent 
(2,332/9,859) of the patients were S. aureus nasal carrier. Thirty-three strains were lost for 
susceptibility testing (random error). Only 3 (0.03%) patients were MRSA carriers and all 3 
patients originated from the same hospital (Hospital D). These patients had no known risk 
factors for MRSA carriage. Two of the three patients were hospitalised previously in hospital 
D, the other patient (patient 1) was hospitalised previously elsewhere (Table 2). 
To investigate whether these MRSA strains were isolated earlier in hospital D, PFGE patterns 
were compared to patterns of other MRSA strains isolated in hospital D from 1993 to 2002. 
Genotyping showed that all three MRSA strains were unique, indicating  that they were not 
related to any MRSA outbreak in hospital D. This indicates that these strains were neither 
acquired nor disseminated in that hospital. 
The three “new” strains were send to the National Institute of Public Health and Environment 
(RIVM, Bilthoven, The Netherlands) for genotyping (PFGE) and compared with the PFGE 
genotypes of national MRSA strains, isolated since 2002. Only one of the three MRSA strains 
belonged to a known PFGE cluster (cluster 153), the other two MRSA strains were unknown.  
 
Table 2. Characteristics of the colonised patients and their MRSA strains. 
Patient characteristics MRSA characteristics 
Patient Age 
Years 
Disease Isolated MRSA 
risk 
Admitted 
Before 
Days 
admitted
RIVM
a 
Oxa 
b 
Cli Cip Gen Rif 
1, male 52 ischemic 
heart 
disease 
Noc No Yes 14 153 4 S S S S 
2, male 26 ulcerative 
colitis 
No No Yes 3 250 256 S R R S 
3, male 79 arrhythmia No No Yes 1d 251 32 S S S S 
 
Oxa: oxacillin; Cli: clindamycin; Cip: ciprofloxacin; Gen: gentamicine; Rif: rifampicin; S: susceptible; R: resistant. 
a PFGE genotyping result RIVM: PFGE cluster 153 is a known cluster. Clusters 250 and 251 are new.   
b Minimal inhibiting concentration for oxacillin (mg/L). 
cThis patient was admitted to a single room. 
d This patient was readmitted 3 weeks later, again for a single day. 
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DISCUSSION 
This study illustrates that the MRSA prevalence at hospital admission in the Netherlands, 
among patients without risk factors for MRSA carriage, is very low (0,03%). This prevalence 
is much lower than the 10% prevalence of MRSA carriage among patients repatriated from 
foreign countries and admitted to Hospital D in the year 2000. Extending the screening 
procedure to patients without risk factors as mentioned in Table I seems therefore not 
indicated.  
This low prevalence level illustrates that the Dutch Search and Destroy policy in combination 
with restrictive antibiotic prescription policy, is still effective. A less stringent MRSA policy 
would probably lead to an increase of MRSA carriage in the community, as observed in 
France where the prevalence of MRSA at admission to the hospital is 1,3%.11 Once MRSA is 
endemic in the hospitals, the prevalence in the community will be higher than in the 
Netherlands, as shown in an American meta-analysis: 1.3%.2 Furthermore, it is known that 
patients who have ever been hospitalised, have more risk to be MRSA carrier (RR: 2,35), than 
persons without a history of hospitalization.2  
Any MRSA outbreak in a Dutch hospital, results in unpopular hygienic measures, not always 
fully appreciated by clinicians and hospital administrators. The study clearly indicates that 
Search and Destroy in the present Dutch situation is still effective.  Dropping this policy 
would certainly lead to endemic MRSA in due time, with all consequences for our current 
antibiotic prescription policy and for patients with MRSA infections. Being forced to replace 
our current first choice antibiotic (flucloxacillin) by glycopeptides or oxazolidinones will 
increase health-care costs. A recent Dutch study showed the Search and Destroy policy to be 
cheaper than the presence of endemic MRSA.12 A recent meta-analysis illustrated that the 
mortality of patients with an invasive MRSA infection is double the mortality of patients with 
an invasive methicillin-susceptible S. aureus infection13. Furthermore, the replacement of 
penicillins by glycopeptides increases the risk that vancomycin resistant microorganisms, 
including S. aureus, may appear in the Netherlands. 
Since 2002 more MRSA outbreaks are observed in the Netherlands. In addition to the Search 
and Destroy policy and restrictive antibiotic use, we need a national registration system of 
MRSA patients and of hospitals experiencing a MRSA outbreak. This could ensure that 
patients, colonised with MRSA and those who are transferred from a hospital with a MRSA 
outbreak, can be tagged and traced and control measures can be initiated. It is expected that in 
the near future, molecular techniques will allow to significantly reduce the time of the MRSA 
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screening to a few hours. Rapid MRSA testing will be of great benefit for both the patient and 
nursing personnel.14 
It is striking that none of the three MRSA isolates in this study caused an outbreak, since none 
of these three patients was isolated. For patient 1 this can be explained by the fact that he 
received mupirocin nasal ointment soon after admission, as a consequence of enrolment in a 
clinical trial. Follow-up nasal cultures of this patient were negative. This patient was also 
admitted to a single room, which would further contribute to the prevention of MRSA 
transmission to other patients. The duration of hospitalisation of the other two patients was 
short (1 and 3 days), possibly too short for transmission to other patients or hospital 
personnel. 
We conclude that the MRSA prevalence at admission to the hospital in the Netherlands in the 
years 1999 and 2000 was very low (0.03%). This low prevalence is due to our national Search 
and Destroy policy and due to restrictive antibiotic use. We need to make sure that we can 
maintain this low MRSA prevalence, since this is beneficial for patients (less morbidity and 
mortality) as well as for the healthcare system (less costs). Therefore, we believe that a 
national registry of MRSA positive patients and hospitals with MRSA outbreaks is necessary.  
 
REFERENCES 
1.  EARSS. (European Antimicrobial Resistance Surveillance System). Annual Report EARSS-2000. 
Bilthoven, The Netherlands. Available at: www.earss.rivm.nl. 
2.  Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a 
meta- analysis of prevalence and risk factors. Clin Infect Dis 2003;36(2):131-9. 
3.  From the Centers for Disease Control. Staphylococcus aureus resistant to vancomycin--United States, 
2002. JAMA 2002;288(7):824-5. 
4.  Vandenbroucke-Grauls CM. Methicillin-resistant Staphylococcus aureus control in hospitals: the Dutch 
experience. Infect Control Hosp Epidemiol 1996;17(8):512-3. 
5.  Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 
2001;357(9271):1851-3. 
6.  McGowan JE, Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev 
Infect Dis 1983;5(6):1033-48. 
7.  Wannet WJB, Heck MEOC, Pluister GN, Van Kesteren JH, de Neeling AJ, Geubbels ELPE. MRSA in 
de Nederlandse ziekenhuizen. Inf Bull 2001;12(9):310-313. 
8.  Wertheim H, Verbrugh HA, van Pelt C, de Man P, van Belkum A, Vos MC. Improved detection of 
methicillin-resistant Staphylococcus aureus using phenyl mannitol broth containing aztreonam and 
ceftizoxime. J Clin Microbiol 2001;39(7):2660-2. 
9.  NCCLS Standards. Performance standards for antimicrobial disk susceptibility tests. National 
Committee for Clinical Laboratory Standards 1993;5th ed(Approved standard). 
Part IV – Chapter 9 
 110
10.  Tenover FC, Arbeit, R.,  Archer, G., et al. Comparison of traditional and molecular methods of typing 
isolates of Staphylococcus aureus. J Clin Microbiol 1994;32:407-415. 
11.  Papia G, Louie M, Tralla A, Johnson C, Collins V, Simor AE. Screening high-risk patients for 
methicillin-resistant Staphylococcus aureus on admission to the hospital: is it cost effective? Infect 
Control Hosp Epidemiol 1999;20(7):473-7. 
12.  Vriens M, Blok H, Fluit A, Troelstra A, Van Der Werken C, Verhoef J. Costs associated with a strict 
policy to eradicate methicillin- resistant Staphylococcus aureus in a Dutch University Medical Center: a 
10-year survey. Eur J Clin Microbiol Infect Dis 2002;21(11):782-6. 
13.  Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of 
mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus 
bacteremia: a meta- analysis. Clin Infect Dis 2003;36(1):53-9. 
14.  Francois P, Pittet D, Bento M, et al. Rapid Detection of Methicillin-Resistant Staphylococcus aureus 
 Directly from Sterile or Nonsterile Clinical Samples by a New Molecular Assay. J Clin Microbiol 
 2003;41(1):254-60. 
PART  V 
 
DISCUSSION 
 
CHAPTER 10 
 
SUMMARY 
 
 
 
 
 
 
 
 
 
 
 
Part V – Chapter 10 
 114
SUMMARY 
General  
At its introduction in the 80’s, mupirocin was reported to be highly effective in eliminating S. 
aureus nasal carriage, thus raising hopes that S. aureus nosocomial infections could be better 
prevented than in the past. Unfortunately, these hopes are not fulfilled. S. aureus remains high 
upon the list of causative organisms of nosocomial infections. Furthermore, S. aureus has 
become more resistant than ever.1 Prevalence rates of MRSA strains in blood cultures have 
skyrocketed in most countries (the Netherlands are among the few countries with low MRSA 
prevalence rates), to prevalence rates of more than 40 percent.2-4 Three vancomycin- and 
methicillin-resistant S. aureus strains have been cultured from three different patients in the 
United States since 2002.5-7 These observations would predict that S. aureus infections will 
become more difficult to treat. Preventing S. aureus infections is, therefore, now more 
important than ever. 
 
Preventing nosocomial S. aureus infection 
Earlier studies, have shown that eradication of S. aureus from the nose of patients with 
mupirocin nasal ointment may prevent subsequent S. aureus infection.8 We studied the 
efficacy of mupirocin nasal ointment in preventing nosocomial S. aureus infections in a non-
surgical patient population with a randomised controlled trial (chapter 3). The findings of our 
study do not support the strategy of routine culture at admission and subsequent mupirocin 
application in S. aureus nasal carriers to prevent S. aureus nosocomial infection in a general 
non-surgical population. However, we did find that more than 80% of nosocomial cases of S. 
aureus bacteremia are of endogenous origin, which confirms the data of Von Eiff et al.9 This 
illustrates that strategies that can effectively and safely eliminate S. aureus carriage from 
relevant sites may still play an important role in preventing infections with this pathogen. 
 
Several explanations can be given for the observed lack of efficacy of mupirocin prophylaxis 
in this study.  
1. First, in our study, there was an overall low rate of acquiring a nosocomial S. aureus 
infection, rates being lower than the a priori risk estimate. The sample size, therefore, 
was too small to detect potentially significant (albeit small) differences in rate of 
nosocomial infections.  
2. Secondly, mupirocin prophylaxis was started 2-3 days after admission. Within this 
period, the risk of nosocomial infections is already present, which was observed in our 
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population. However, excluding these patients with such early-onset nosocomial S. 
aureus infections from our analysis did not lead to a significant risk reduction. 
Therefore, it is recommended to investigate the efficacy of screening and starting 
mupirocin treatment of patients earlier, preferably on the day of admission. Molecular 
and other novel diagnostic techniques that allow rapid and accurate detection of S. 
aureus carriage, have recently become available and make this feasible.10 
3. Thirdly, most nosocomial S. aureus infections developed in patients with a relatively 
long hospital stay. We observed that in the placebo group infections occurred on day 
12 (median) after admission, while the median number of admission days of all 
included patients was eight, in both the placebo and mupirocin group. Most 
nosocomial S. aureus bloodstream infections occur late during hospitalization, which 
is confirmed by a U.S. study.1 Therefore, future interventions should be focused on 
patients at risk for a prolonged hospital stay.  
4. Fourth and last, mupirocin treatment alone may not be sufficient for S. aureus 
decolonization. Several studies show recolonization with S. aureus occurs in 38% to 
43% of patients after 4 to 6 weeks after mupirocin application.11-13 Extra-nasal body 
reservoirs of S. aureus probably play an important role in nasal recolonization.  
 
The fourth point described above made us study the role of S. aureus carriage at extra-nasal 
sites (throat and perineum) in recolonization after mupirocin treatment in a group of healthy 
volunteers (chapter 5). We found that mupirocin was overall effective in decolonizing the 
anterior nares, but less effective in decolonizing extra-nasal sites. The majority (60%) of the 
S. aureus strains of those volunteers who remained colonized five weeks after treatment were 
of endogenous origin (i.e. the same strain as before treatment present in the nose). However, 
acquisition of exogenous S. aureus strains is also common (40%), suggesting that 
decolonization should only be performed in proven carriers. This is even more stressed by the 
fact that we found one mupirocin resistant strain after treatment in this study and that two 
non-carriers became carriers after treatment. Decolonization may be improved by adding 
washing with disinfectant soap to the regimen. Also new promising compounds for nasal 
decolonization are being developed, including lysostaphin and fatty acid (lauric esthers) 
compounds, that may aid in improving decolonization strategies.14,15  
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The risk of S. aureus nasal carriage 
Chapter 4 provides solid evidence that nasal carriers of S. aureus are indeed at increased risk 
of S. aureus bloodstream infections once they become admitted to the hospital. Nasal carriers 
have a threefold increased risk of acquiring nosocomial bloodstream infections as compared 
to non-carriers. In contrast, there was a fourfold decreased risk of in-hospital mortality in 
nasal carriers who acquired nosocomial S. aureus bloodstream infections, as compared to 
patients who were non-carrier at admission, but developed a similar infection anyway. 
Although, the two patient groups differed in age and clinical background, correcting for 
underlying disease and demographic characteristics did not significantly alter these findings. 
Previous studies identifying risk factors for fatal outcome of S. aureus bacteremia never 
included S. aureus nasal carriage. These studies did identify older age, infection with a 
methicillin-resistant strain, central venous access, disease severity, and underlying illness as 
risk factors for fatal outcome.3,16-19 The higher mortality rate observed among non-carriers 
with infection needs confirmation. Novel strategies need to be developed to prevent S. aureus 
infection in non-carriers, who presumably acquire this micro-organism through cross-
transmission.20 
 
Several explanations can be given for the found higher mortality in non-carriers versus 
carriers with a S. aureus infection: 
1. Non-carriers maybe infected with a more virulent hospital S. aureus clone, compared 
to carriers, acquired during hospital admission. We, therefore, compared the genotypes 
(sequence types) of invasive S. aureus strains of both carriers and non-carriers, as 
determined by multilocus sequence typing (MLST).21 The sequence types of S. aureus 
strains causing invasive disease in non-carriers did not differ from carriers (see 
Chapter 6).  This suggests that there probably is not a prevalent virulent ‘hospital’ S. 
aureus clone causing disease in non-carriers through cross-transmission. However, 
one study showed that staphylokinase production, a virulence factor, was lower in 
patients with lethal outcome of S. aureus bacteremia.22 Although, a bacterial 
explanation for the higher mortality in this patient category is less likely, a detailed 
screen for potential virulence genes associated with fatal outcome still needs to be 
performed.  
2. Host-related immunological mechanisms may provide an alternative explanation for 
the lower mortality rate observed in S. aureus nasal carriers with invasive disease. One 
study shows that S. aureus nasal carriers have neutralizing antibodies against S. aureus 
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superantigens, whereas non-carriers have no antibodies or very low titers.23 A mouse 
model illustrates that intranasal application of S. aureus superantigens protects against 
subsequent death due to S. aureus infection.24 Furthermore, certain viral and bacterial 
vaccines can effectively be applied intranasally and result in protective immunity in 
both humans and animals.25-27 Clearly, S. aureus cells in the nares of carriers may 
likewise lead to some sort of immune response. Research in this field is lacking. One 
study showed that S. aureus nasal colonization induces a neutrophil mediated 
inflammatory response, but this response fails to clear the colonizing bacteria.28 Since 
in more than eighty percent of the cases, S. aureus cells causing invasive disease in 
carriers are identical to the same strain found á priori in the nose, some level of 
cellular and/or humoral immunity to this endogenous strain may already be present, 
which may help reduce the risk of fatal outcome. 
 
In Chapter 6, we compared the genotypes (sequence types) of invasive S. aureus strains of 
both carriers and non-carriers, as determined by MLST (see above).21 The sequence types of 
S. aureus strains causing invasive disease in non-carriers did not differ significantly from 
carriers. We did identify a clonal complex (CC45) that was significantly more prevalent 
among non-invasive strains. No major clonal cluster could be identified that was responsible 
for invasive S. aureus disease in S. aureus carriers. Though, fifty percent of the invasive 
strains belonged to CC30, this was not statistically significant. Patients infected with a S. 
aureus strain belonging to a clonal cluster had a significant higher risk of dying, than those 
infected with a singleton or new sequence type. At this moment we cannot explain the higher 
mortality rate in those infected with S. aureus strains belonging to a clonal cluster. Strains 
belonging to a clonal cluster are in general more prevalent and, therefore, seem to be better 
adapted to the human host. It could be that specific virulence factors are needed for this 
adaptation, which can result in a higher mortality rate in those infected. These findings 
warrant further analysis of the S. aureus genomic structure and expression of virulence genes 
in relation to disease.  
 
Nose picking behaviour and S. aureus nasal carriage 
Since S. aureus nasal carriers are at increased risk for invasive disease, it is important to 
elucidate the mechanisms leading to S. aureus nasal carriage, to be able to develop new 
eradication strategies. We decided to investigate nose picking as a possible determinant, since 
hand carriage is known to be associated with nasal carriage of S. aureus (Chapter 7). 
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Previous studies show that the number of staphylococci on the fingers rises with increasing 
nasal counts.29 Furthermore, nasal S. aureus carriers are more likely to be hand carriers of S. 
aureus and nasal eradication of S. aureus often leads to disappearance of the micro-organism 
from the hands as well.12 A study by Hare et al., demonstrated that nine students, observed 
during a one hour lecture, touched their mouth or nose on 6 to 23 separate occasions.30 
 
In our nose picking study, significantly more S. aureus carriers were found among those 
classified as nose picker by predefined criteria. Also those patients classified as nose picker 
by the Ear-, Nose-, Throat specialist, had a significant higher S. aureus carriage rate. 
Furthermore, we found a significant correlation between the number of positive cultures, the 
load of S. aureus present in the nose, and the self-graded frequency of nose picking. This 
‘dose-response’ relationship suggests a causal relation between frequency of nose picking 
behaviour and S. aureus nasal carriage. Nose picking or nasal traumas alone do not lead to a 
higher carriage rate. Possibly a combination of both the introduction of S. aureus by the finger 
and having nasal trauma may suffice in establishing S. aureus nasal carriage.  
 
The nasal mucosa and dermis is a first line defence to microbial colonization and invasion. 
Lesions therein will expose extra-cellular matrix molecules, including fibronectin and 
collagen, to which S. aureus can adhere.2,31,32 However, recent in-vitro studies found that S. 
aureus cell wall teichoic acid, clumping factor B and other cell-wall associated adhesins may 
be involved in adhering to nasal epithelial cells, suggesting that exposure of extra-cellular 
matrix molecules may not be essential for colonization.33-36 However, S. aureus is well known 
to heavily colonize skin lesions, including eczematous lesions, indicating that, in-vivo, S. 
aureus exhibits high affinity to extra-cellular matrix molecules.32 It still needs to be resolved 
whether nose picking is a cause or consequence of S. aureus nasal carriage.  
 
Methicillin-resistant S. aureus (MRSA) 
In preventing S. aureus infections, it is essential to keep the prevalence of methicillin-resistant 
S. aureus (MRSA) strains low. Infections with MRSA can only be treated with usually less 
effective and generally more expensive antibiotics. Furthermore, MRSA infections have a 
worse prognosis than infections with susceptible strains. In the Netherlands, patients at risk 
for MRSA carriage are, according to national guidelines, screened and isolated until MRSA 
screening cultures are proven negative.37 Identified MRSA carriers will remain in isolation 
and are offered an eradication treatment. This strategy is also known as a ‘search and destroy’ 
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policy. Due to this policy, the MRSA prevalence within clinical S. aureus isolates is still 
below one percent.4 Since the prevalence is low it is essential to have a very sensitive and 
specific test to screen for MRSA.  
 
In Chapter 8 we describe the development of a novel sensitive diagnostic method to screen 
for MRSA. At the time of the study (1997), screening a patient for MRSA was usually 
performed by direct plating patient samples solely on solid culture media, e.g. plating on 
Columbia blood agar. The results of our study show that by using a selective broth with 
antibiotics inhibiting growth of both gram-positive (ceftizoxim) and gram-negative bacteria 
(aztreonam), twice as many MRSA strains were detected as compared with the routine 
technique. We used ceftizoxim, since this agent is known to increase the phenotypic level of 
resistance to methicillin.38 This method is now implemented in the routine MRSA screening 
of our and many other Dutch hospitals.  
 
Since 1995, MRSA outbreaks were reported in the Netherlands that could not be related to 
risk factors as defined by our national guideline.39,40 We, therefore, decided to screen patients 
not at risk for MRSA carriage, to assess whether our guideline was still sufficient (Chapter 
9). We found that the MRSA prevalence at hospital admission in the Netherlands, among 
patients without risk factors for MRSA carriage, is still very low (0.03%). Changing the risk 
factors for MRSA carriage in our national guideline is, therefore, not indicated. The low 
prevalence level illustrates that the Dutch ‘search and destroy’ policy in combination with 
restrictive antibiotic prescription policy, remains effective. Adherence to this policy may be 
improved by implementing rapid molecular techniques for the detection of MRSA, which will 
be of great benefit for both the patient (shorter isolation) and hospital (lower costs).41  
 
Conclusions and recommendations for the clinician 
 S. aureus screening of patients at admission by routine nasal culture at and subsequent 
application of mupirocin ointment to the anterior nares for five days in S. aureus nasal carriers 
is not effective in preventing S. aureus nosocomial infections in a general non-surgical 
population, and, therefore, can not be recommended. 
 When an attempt is made to eradicate S. aureus nasal carriage in an individual, follow-
up nasal cultures are needed to monitor recolonization with S. aureus is a common 
phenomenon. 
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 As compared to patients that do not carry S. aureus in the nose at admission, nasal 
carriers of S. aureus have a threefold increased risk of acquiring nosocomial S. aureus 
bloodstream infections.  
 The outcome of nosocomial S. aureus bacteremia is, in part, dependent on the 
premorbid S. aureus nasal carriage status: when non-nasal carriers of S. aureus acquire a 
nosocomial S. aureus bloodstream infection, they have a fourfold increased risk of dying, as 
compared to S. aureus nasal carriers with nosocomial S. aureus bloodstream infections. 
Premorbid nasal carriage with S. aureus may, thus, confer paradoxical effects in patients 
admitted to the hospital: it increases the risk of invasive disease, but simultaneously provides 
them with partial protection against a fatal outcome in case such infections develop.  
 Nose picking and nasal carriage of S. aureus are associated. This association may well 
be causal since there exists a positive correlation between frequency of nose picking, and both 
the number of positive cultures and S. aureus load. 
 Clinicians should continue to support and follow the Dutch national policy of ‘search 
and destroy’, with regards to MRSA, as outlined by the Working Party on Infection 
Prevention (WIP). The Netherlands has, so far, been spared from the burden of endemic 
MRSA, and that should stay so. 
  
Conclusions and recommendations for the investigator 
 In future studies aimed at preventing nosocomial S. aureus infections, it is 
recommended to test for S. aureus nasal carriage and treat carriers as soon as possible, i.e. on 
the day of admission. The recent development of accurate and rapid diagnostic techniques to 
screen for S. aureus carriage makes this approach possible. 
 Future studies aimed at preventing nosocomial S. aureus bloodstream infections 
should be focused on patient categories likely to have a prolonged hospital stay (e.g. 5 days).  
 Since nasal application of mupirocin ointment alone was found to be insufficient to 
prevent S. aureus infection during hospital admission, other body sites should be considered 
as potential sources of S. aureus infection. Total body washing with a disinfecting soap may, 
therefore, be a necessary augmentation of the intervention strategy. 
 The role of S. aureus carriage at extra-nasal sites in the development of S. aureus 
infections needs further study. 
 The higher mortality rate in non-carriers versus carriers of S. aureus associated with S. 
aureus bloodstream infections should be confirmed and the underlying mechanism(s) 
unravelled. 
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 The type of host immune response to S. aureus nasal colonization needs to be re-
investigated. So far, the immunological consequences of S. aureus nasal carriage have not 
been studied in much detail. 
 Future S. aureus eradication studies may incorporate an intervention aimed at 
shedding the habit of picking one’s nose, since nose picking is associated with a higher S. 
aureus nasal carriage rate. 
 Further analysis of the S. aureus genomic structure and expression of specific genes in 
relation to clinically well-defined types of S. aureus diseases should be performed. A cost-
effective, high throughput screening method for a complete S. aureus virulence profile, is a 
prerequisite for this kind of research. 
 A screening-test for MRSA should continue to include an enrichment broth culture, 
until another technique is proven to be more sensitive and specific than this current gold 
standard. 
 A rapid sensitive and specific test should be developed to screen patients for both 
methicillin-sensitive and methicillin-resistant S. aureus carriage (i.e. with a turn-around-time 
of two hours). 
 
Recommendations for the policymaker 
 Spend more money on studies aimed at preventing S. aureus infections, since this is 
likely to be highly cost-effective. In the Netherlands there are 1.6 million hospital admissions 
per year. Approximately 0.1 percent of these patients (n=1600) will acquire a nosocomial S. 
aureus bloodstream infection during their hospital stay.1 A S. aureus bloodstream infection 
costs 10.000 euros on average, and carries an associated mortality of 25% (400 
deaths/year).1,42 In the Netherlands, therefore, nosocomial S. aureus bloodstream infections 
alone, will cost society 16 million euros every year. To this sum should also be added the 
costs of other types of nosocomial S. aureus infections, including surgical wound infections, 
urinary tract infections, osteomyelitis, and pulmonary infections. 
 More continuing effort should be given to promoting, on both a national and 
international level, the Dutch national ‘search and destroy’ policy for controlling MRSA. This 
policy has been very effective for almost two decades, whereas less stringent policies adopted 
by other countries have miserably failed to contain the spread of MRSA within their borders. 
 
Part V – Chapter 10 
 122
REFERENCES 
1.  Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream 
infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. 
Clin Infect Dis 2004;39(3):309-17. 
2.  Lowy F. Staphylococcus aureus infections. N Engl J Med 1998;339:520-532. 
3.  Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of 
mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus 
bacteremia: a meta- analysis. Clin Infect Dis 2003;36(1):53-9. 
4.  European Antimicrobial Resistance Surveillance System (EARSS). Annual Report 2002; available at 
www.earss.rivm.nl. 2002. 
5.  From the Centers for Disease Control. Staphylococcus aureus resistant to vancomycin--United States, 
2002. Jama 2002;288(7):824-5. 
6. From the Centers for Disease Control and Prevention. Vancomycin resistant Staphylococcus aureus--
Pennsylvania, 2002. Jama 2002;288(17):2116. 
7.  Vancomycin-resistant Staphylococcus aureus--New York, 2004. MMWR Morb Mortal Wkly Rep 
2004;53(15):322-3. 
8.  Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, 
underlying mechanisms, and associated risks. Clin Microbiol Rev 1997;10(3):505-20. 
9.  Von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus 
aureus bacteremia. Study Group. N Engl J Med 2001;344(1):11-6. 
10.  Paule SM, Pasquariello AC, Hacek DM, et al. Direct detection of Staphylococcus aureus from adult and 
neonate nasal swab specimens using real-time polymerase chain reaction. J MolDiagn 2004;6(3):191-6. 
11.  Martin JN, Perdreau-Remington F, Kartalija M, et al. A randomized clinical trial of mupirocin in the 
eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. J Infect 
Dis 1999;180(3):896-9. 
12.  Reagan DR, Doebbeling BN, Pfaller MA, et al. Elimination of coincident Staphylococcus aureus nasal 
and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med 
1991;114(2):101-6. 
13.  Fernandez C, Gaspar C, Torrellas A, et al. A double-blind, randomized, placebo-controlled clinical trial 
to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of 
Staphylococcus aureus among hospital personnel. J Antimicrob Chemother 1995;35(3):399-408. 
14.  Kokai-Kun JF, Walsh SM, Chanturiya T, Mond JJ. Lysostaphin cream eradicates Staphylococcus 
aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother 2003;47(5):1589-97. 
15.  Kitahara T, Koyama N, Matsuda J, et al. Antimicrobial activity of saturated fatty acids and fatty amines 
against methicillin-resistant Staphylococcus aureus. Biol Pharm Bull 2004;27(9):1321-6. 
16.  Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically Ill 
patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus 
aureus. Arch Intern Med 2002;162(19):2229-35. 
Summary 
 123
17.  Chang FY, MacDonald BB, Peacock JE, Jr., et al. A prospective multicenter study of Staphylococcus 
aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of 
methicillin resistance. Medicine (Baltimore) 2003;82(5):322-32. 
18.  Topeli A, Unal S, Akalin HE. Risk factors influencing clinical outcome in Staphylococcus aureus 
bacteraemia in a Turkish University Hospital. Int J Antimicrob Agents 2000;14(1):57-63. 
19.  McClelland RS, Fowler VG, Jr., Sanders LL, et al. Staphylococcus aureus bacteremia among elderly vs 
younger adult patients: comparison of clinical features and mortality. Arch Intern Med 
1999;159(11):1244-7. 
20.  Solberg CO. Spread of Staphylococcus aureus in hospitals: causes and prevention. Scand J Infect Dis 
2000;32(6):587-95. 
21.  Van Leeuwen WB, Jay C, Snijders S, et al. Multilocus sequence typing of Staphylococcus aureus with 
DNA array technology. J Clin Microbiol 2003;41(7):3323-6. 
22.  Jin T, Bokarewa M, McIntyre L, et al. Fatal outcome of bacteraemic patients caused by infection with 
staphylokinase-deficient Staphylococcus aureus strains. J Med Microbiol 2003;52(Pt 10):919-23. 
23.  Ritz HL, Kirkland JJ, Bond GG, Warner EK, Petty GP. Association of high levels of serum antibody to 
staphylococcal toxic shock antigen with nasal carriage of toxic shock antigen-producing strains of 
Staphylococcus aureus. Infect Immun 1984;43(3):954-8. 
24.  Collins LV, Eriksson K, Ulrich RG, Tarkowski A. Mucosal tolerance to a bacterial superantigen 
indicates a novel pathway to prevent toxic shock. Infect Immun 2002;70(5):2282-7. 
25.  Olszewska W,  Steward MW. Nasal  delivery of epitope based vaccines. Adv Drug Deliv Rev 2001; 51 
 (1-3):161-71. 
26.  Stiles BG, Garza AR, Ulrich RG, Boles JW. Mucosal vaccination with recombinantly attenuated 
staphylococcal enterotoxin B and protection in a murine model. Infect Immun 2001;69(4):2031-6. 
27.  Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal 
administration of conjugate vaccine plus interleukin-12. Infect Immun 2003;71(8):4780-8. 
28.  Cole AM, Tahk S, Oren A, et al. Determinants of Staphylococcus aureus nasal carriage. Clin Diagn Lab 
Immunol 2001;8(6):1064-9. 
29.  Solberg CO. A study of carriers of Staphylococcus aureus with special regard to quantitative bacterial 
estimations. Acta Med Scand Suppl 1965;436:1-96. 
30.  Hare R, Thomas CG. The transmission of Staphylococcus aureus. Br Med J 1956;12(4997):840-4. 
31.  Patti JM, Allen BL, McGavin MJ, Hook M. MSCRAMM-mediated adherence of microorganisms to 
host tissues. Annu Rev Microbiol 1994;48:585-617. 
32.  Cho SH, Strickland I, Boguniewicz M, Leung DY. Fibronectin and fibrinogen contribute to the 
enhanced binding of Staphylococcus aureus to atopic skin. J Allergy Clin Immunol 2001;108(2):269-74. 
33.  Weidenmaier C, Kokai-Kun JF, Kristian SA, et al. Role of teichoic acids in Staphylococcus aureus 
nasal colonization, a major risk factor in nosocomial infections. Nat Med 2004;10(3):243-5. 
34.  Weidenmaier C, Kokai-Kun JF, Peschel A. Reply to "Nasal colonization by Staphylococcus aureus". 
Nat Med 2004;10(5):447. 
35.  Foster TJ. Nasal colonization by Staphylococcus aureus. Nat Med 2004;10(5):447. 
Part V – Chapter 10 
 124
36.  O'Brien LM, Walsh EJ, Massey RC, Peacock SJ, Foster TJ. Staphylococcus aureus clumping factor B 
(ClfB) promotes adherence to human type I cytokeratin 10: implications for nasal colonization. Cell 
Microbiol 2002;4(11):759-70. 
37.  Werkgroep Infectie Preventie. Beleid bij Meticilline-resistente Staphylococcus aureus. Available at: 
www.wip.nl. 2003. 
38.  Wertheim H, Verbrugh HA, van Pelt C, de Man P, van Belkum A, Vos MC. Improved detection of 
methicillin-resistant Staphylococcus aureus using phenyl mannitol broth containing aztreonam and 
ceftizoxime. J Clin Microbiol 2001;39(7):2660-2. 
39.  Wannet WJB, Heck MEOC, Pluister GN, Van Kesteren JH, de Neeling AJ, Geubbels ELPE. MRSA in 
de Nederlandse ziekenhuizen. Inf Bull 2001;12(9):310-313. 
40.  Wagenvoort J. Nederlandse MRSA isolaten zonder buitenlandse oorsprong. Inf Bull 2002;13(1):17-19. 
41.  Francois P, Pittet D, Bento M, et al. Rapid Detection of Methicillin-Resistant Staphylococcus aureus 
Directly from Sterile or Nonsterile Clinical Samples by a New Molecular Assay. J Clin Microbiol 
2003;41(1):254-60. 
42.  Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and -
resistant Staphylococcus aureus infections. Ann Pharmacother 2004;38(9):1377-82. 
 
CHAPTER 11 
 
SAMENVATTING 
 
 
 
 
 
 
 
  
Part V – Chapter 11 
 126
SAMENVATTING 
Algemeen 
Sinds medio vorige eeuw is men op de hoogte dat dragers van S. aureus in de neus een 
verhoogd risico hebben op S. aureus infecties. Met de introductie van mupirocine neuszalf 
(antibioticum) in de jaren tachtig, ter eradicatie van S. aureus uit de neus, leidde tot de 
hypothese dat S. aureus infecties voor een groot deel konden worden voorkomen. Helaas is 
deze hypothese niet uitgekomen. S. aureus staat nog steeds hoog op de ranglijst van micro-
organismen die ziekenhuisinfecties veroorzaken. Verder wordt S. aureus meer resistent tegen 
antibiotica.1 De frequentie van meticilline-resistente S. aureus (MRSA) stammen die uit 
bloedkweken worden geïsoleerd, is fors gestegen in veel landen. Van de gekweekte S. aureus 
stammen zijn in sommige landen zelfs meer dan 40 procent meticilline-resistent.2-4 Tevens 
zijn sinds 2002 drie vancomycine- en meticilline-resistente S. aureus stammen gekweekt uit 
verschillende patiënten in de Verenigde Staten.5-7 Dit betekent dat de behandeling van 
infecties met resistente S. aureus stammen nog moeilijker zal gaan worden met minder 
effectieve antibiotica. Daarom is het voorkomen van S. aureus infecties nu belangrijker dan 
ooit. 
 
Preventie van nosocomiale S. aureus infecties 
Eerder onderzoek, in voornamelijk chirurgische patiënten, laat zien dat eradicatie van S. 
aureus uit de neus met mupirocine neuszalf, S. aureus infecties kan voorkomen.8 Wij hebben 
de effectiviteit van mupirocine neuszalf in het voorkomen van S. aureus infecties onderzocht 
in een niet-chirurgische ziekenhuispopulatie middels een gerandomiseerde placebo 
gecontroleerde studie (hoofdstuk 3). De resultaten van dit onderzoek ondersteunen niet het 
routinematig aantonen van S. aureus neusdragerschap middels kweek en het vervolgens 
behandelen van dragers met mupirocine neuszalf om S. aureus infecties te voorkomen in niet-
chirurgische patiënten. Dit onderzoek laat zien dat meer dan 80% van nosocomiale S. aureus 
bacteriëmieën van endogene oorsprong zijn. Deze bevinding is een aanmoediging om 
strategieën te blijven ontwikkelen die effectief en veilig S. aureus kunnen decolonizeren van 
het lichaam, om infecties met dit pathogeen te voorkomen. 
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Er zijn meerdere verklaringen mogelijk voor de gevonden gebrek aan effectiviteit van 
mupirocine profylaxe in deze studie.  
1. Allereerst was de incidentie van S. aureus ziekenhuisinfecties lager dan tevoren 
ingeschat. De onderzoeksgrootte is daarom achteraf gezien te klein om potentiële 
(echter kleine) statistisch significante verschillen in het voorkomen van 
ziekenhuisinfecties te kunnen aantonen.  
2. Een andere mogelijke verklaring is dat mupirocine pas werd toegediend twee tot drie 
dagen na opname, omdat dan pas de kweekresultaten bekend waren. In deze periode 
kan een patiënt al een ziekenhuisinfectie oplopen, zoals waargenomen in deze studie. 
Echter, uitsluiten van de analyse van patiënten met deze vroeg ontstane infecties, 
veranderde niet onze eerdere conclusies. Het is aanbevolen om het screenen op S. 
aureus dragerschap en vervolgens S. aureus eradicatie in dragers op dezelfde dag van 
opname te doen. Snelle en betrouwbare moleculaire methoden zijn nu beschikbaar om 
dit mogelijk te maken.9 
3. De meeste S. aureus ziekenhuis infecties ontstaan in patiënten die relatief lang in het 
ziekenhuis liggen. In de placebo groep ontstonden de infecties pas na een mediane 
opnameduur van 12 dagen, terwijl de mediane opnameduur van alle geïncludeerde 
patiënten acht dagen was. Het gevonden tijdstip van ontstaan van S. aureus 
bacteriëmieën wordt bevestigd door ander onderzoek.1 Hieruit kan worden 
geconcludeerd dat een potentiële interventie strategie zich voortaan moet richten op 
patiënten met een verlengde opnameduur om zo effectief mogelijk zijn.  
4. De gevonden vertraging van 13 dagen in de tijd tot ontstaan van S. aureus 
ziekenhuisinfecties in de mupirocine groep suggereert dat na verloop van tijd met 
mupirocine behandelde patiënten weer worden gerekoloniseerd met S. aureus. Na 
rekolonisatie met S. aureus hebben deze dragers weer een verhoogd risico op het 
verkrijgen van infecties met dit micro-organisme. Dit betekent dat vervolgen op 
rekolonisatie is aanbevolen en dat, indien nodig, dit moet leiden tot een nieuwe 
eradicatiekuur.  
 
De vraag resteert of mupirocine behandeling op zich zelf niet voldoende is voor effectieve S. 
aureus dekolonisatie. Verschillende studies laten rekolonisatie met S. aureus zien in de neus 
na 4 tot 6 weken in 38% tot 43% van de gevallen na mupirocine applicatie.10-12 Deze 
bevindingen impliceren dat mupirocine alleen niet afdoende is. Andere reservoirs van het 
lichaam dan de neus spelen waarschijnlijk een rol in rekolonisatie van de neus. Daarom 
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hebben wij de rol van S. aureus dragerschap van de keel en perineum onderzocht in 
rekolonisatie in zowel dragers als niet dragers van S. aureus, die zijn behandeld met 
mupirocine (hoofdstuk 5). In dit onderzoek was mupirocine effectief in het dekolonizeren van 
het vestibulum nasi, maar minder effectief in het dekolonizeren van keel en perineum. 
Bij falen van eradicatie met mupirocine, is onderzocht of de S. aureus stammen na 
mupirocine behandeling gelijk waren aan de stam voor behandeling middels genotypering. In 
60 procent van de gevallen was dit het geval. Echter, de acquisitie van exogene (nieuwe) S. 
aureus stammen werd tevens gezien in 35 procent van de gevallen. In de resterende 5 procent 
was sprake van rekolonisatie met zowel endogene als exogene stammen. Twee niet-dragers 
zijn na mupirocine behandeling drager geworden. Mogelijk door het verstoren van de 
aanwezige nasale flora en expositie aan S. aureus heeft S. aureus dragerschap kunnen 
ontstaan. Mupirocine neuszalf dient te worden voorbehouden aan bewezen S. aureus dragers 
om te voorkomen dat niet dragers alsnog drager worden.  
Eradicatie van S. aureus uit de neus kan mogelijk worden verbeterd door naast mupirocine 
applicatie in de neus, ook te wassen met desinfecterende zeep. Hierdoor wordt S. aureus 
dragerschap buiten de neus nog harder aangepakt. Verder worden nieuwe veelbelovende 
producten ontwikkeld voor neus dekolonizatie, zoals lysostaphine en vetzuren, die mogelijk 
een verbetering kunnen bewerkstelligen in het elimineren van S. aureus.13,14 Toekomstige 
studies dienen uit te wijzen of dit inderdaad het geval is. 
 
Risico van S. aureus neusdragerschap 
Het onderzoek beschreven in hoofdstuk 4, laat zien dat S. aureus neusdragers een drievoudig 
verhoogd risico hebben ten op zichte van niet-dragers op het krijgen van een nosocomiale 
bloedbaan infectie met S. aureus. Wanneer men echter de mortaliteit berekent in de twee 
groepen, ziet men dat niet-dragers met een S. aureus bloedbaaninfectie een significant 
verhoogd risico hebben op overlijden dan dragers. Hoewel de twee onderzochte groepen zeer 
verschillend zijn in leeftijd en onderliggend lijden, veranderen de bevindingen niet na 
statistische correcties.  Eerdere studies die determinanten van overlijden door invasieve S. 
aureus infecties hebben onderzocht laten zien dat leeftijd, meticilline-resistentie, en ernst van 
ziek zijn, belangrijke risico factoren zijn voor overlijden.3,15-18 In deze studies is nooit S. 
aureus neusdragerschap meegenomen als variabele. De in onze studie gevonden hogere 
mortaliteit onder niet-dragers met een S. aureus bloedbaaninfectie dient wel te worden 
bevestigd in een volgende studie. Nieuwe methoden dienen te worden ontwikkeld om S. 
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aureus infecties te voorkomen in niet-dragers, die deze bacterie waarschijnlijk via 
kruisbesmetting oplopen.19 
Meerdere verklaringen zijn mogelijk voor de hogere mortaliteit onder niet dragers met een S. 
aureus bloedbaaninfectie, te weten: 
1. Niet-dragers raken geïnfecteerd met een meer virulente ‘ziekenhuis’ kloon. Om dit aan 
te tonen dan wel uit sluiten, hebben wij de genotypen (multi locus sequence typing, 
MLST) van invasieve S. aureus stammen van zowel dragers als niet dragers 
vergeleken met behulp van een DNA micro-array techniek (hoofdstuk 6).20 De 
frequentie van de verschillende MLST typen van invasieve S. aureus stammen van 
zowel dragers als niet dragers zijn vergelijkbaar. Dat suggereert dat er geen sprake is 
geweest van een virulente S. aureus kloon die door kruisbesmetting infecties heeft 
veroorzaakt in niet-dragers. 
2. S. aureus neusdragers met S. aureus infecties zijn beschermd tegen overlijden door 
gedeeltelijke beschermende immuniteit. Eén studie laat zien dat asymptomatische 
dragers antistoffen hebben tegen S. aureus superantigenen, welke afwezig of 
verminderd aanwezig zijn in niet-dragers.21 Onderzoek in een muizenmodel laat zien 
dat intranasale applicatie van S. aureus superantigenen inderdaad beschermt tegen 
overlijden ten gevolge van een S. aureus infectie.22 Ook is het inmiddels bekend dat 
mensen effectief tegen bepaalde virussen en bacteriën kunnen worden gevaccineerd, 
middels het toedienen van het vaccin in de neus.23-25 De aanwezigheid van S. aureus in 
de neus zou op een dergelijke wijze kunnen leiden tot een beschermende 
immunologische respons. Dit dient nader te worden onderzocht. Aangezien meer dan 
80 procent van de S. aureus infecties bij dragers van endogene oorspong is, lijkt het 
zeer waarschijnlijk dat er een mate van beschermende immuniteit van dragerschap uit 
gaat, met een lagere mortaliteit tot gevolg. 
  
In hoofdstuk 6 wordt een onderzoek beschreven waarin invasieve en niet-invasieve S.  aureus 
stammen met elkaar worden vergeleken middels genotypering (MLST). Op een dergelijke 
wijze kan men nagaan of bepaalde genotypes vaker of minder vaak worden aangetroffen bij 
invasieve infecties. In dit onderzoek is een prevalente S. aureus kloon (CC45) geïdentificeerd 
onder niet invasieve stammen. Er waren geen S. aureus kloons die significant meer voor 
kwamen onder invasieve stammen. Hoewel 50 procent van de invasieve stammen tot CC30 
behoorde, was dit niet significant. Verder is bestudeerd of welke genotypes aan elkaar 
verwant zijn en een zogeheten klonaal complex vormen. Patiënten die waren geïnfecteerd met 
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een genotype behorend tot een klonaal complex hadden een hoger overlijdensrisico, dan 
patiënten die waren geïnfecteerd met een stam die niet tot een klonaal complex behoorde. 
Stammen die tot een klonaal complex horen, zijn in het algemeen prevalent en daarom 
waarschijnlijk beter aangepast aan de mens.  
 
Neuspeuteren en S. aureus neusdragerschap 
Aangezien S. aureus neusdragerschap een belangrijke risicofactor is voor het krijgen van een 
S. aureus infectie, is het belangrijk het mechanisme dat leidt tot dragerschap op te helderen 
om zodoende effectieve preventieve maatregelen te kunnen ontwikkelen. Het is reeds bekend 
dat dragerschap van S. aureus in de neus en op de handen en vingers sterk met elkaar zijn 
gecorreleerd.26 Daarom hebben wij een onderzoek gedaan naar een mogelijke associatie 
tussen neuspeuter gedrag en dragerschap van S. aureus (hoofdstuk 7). 
Wij vonden een significante associatie tussen S. aureus dragerschap en deelnemers die waren 
geclassificeerd als neuspeuteraar volgens standaard criteria. Ook onder deelnemers waarvan 
de KNO-arts van mening was dit een neuspeuteraar betrof, vond men significant vaker S. 
aureus in de neus. Tevens was er een significante positieve correlatie tussen de frequentie van 
neuspeuteren en het relatief aantal positieve neuskweken met S. aureus. De frequentie van 
neuspeuteren en de hoeveelheid S. aureus in de neus waren ook positief met elkaar 
gecorreleerd. Deze zogenaamde ‘dosis-respons’ relatie duidt op een causaal verband tussen 
mate van neuspeutergedrag en S. aureus neusdragerschap. Neuspeuteren of het hebben van 
lesies in de neus alleen is echter niet voldoende om vaker S. aureus drager te zijn. Het is 
mogelijk de combinatie van zowel het introduceren van S. aureus in de neus met de vinger 
door neuspeutergedrag en het hebben van lesies dat tot S. aureus dragerschap van de neus 
leidt. 
Het neusslijmvlies is de eerste barrière voor microbiële invasie. Lesies in dit slijmvlies zorgen 
ervoor dat extracellulaire matrix moleculen geëxposeerd worden waaraan S. aureus zich kan 
hechten, waaronder fibronectine en collageen.2,27,28 Echter, recente in-vitro studies laten zien 
dat clumping factor B en teichoinezuur, beide S. aureus producten, in staat zijn zich aan 
epitheliale cellen te hechten. Dit suggereert dat de expositie van extracellulaire eiwitten niet 
echt nodig is voor S. aureus om zich in de neus vestigen.29-32 Echter, het is bekend dat S. 
aureus in grote hoeveelheden kan worden gekweekt uit huidlesies, zoals bij eczeem patiënten. 
Dit laat zien dat in-vivo, S. aureus een hoge affiniteit heeft voor extra-cellulaire matrix 
moleculen.28 Of neuspeuteren nu een gevolg is van S. aureus dragerschap of een oorzaak 
daarvan dient nader te worden onderzocht. 
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Meticilline-resistente S. aureus (MRSA) 
Om infecties met MRSA te voorkomen, is het essentieel om de prevalentie van MRSA 
dragerschap laag te houden. Infecties door MRSA, in vergelijking met meticilline-gevoelige 
S. aureus (MSSA), kunnen meestal alleen worden behandeld met minder effectieve en 
duurdere antibiotica. Daarenboven, hebben patiënten met een MRSA infectie een slechtere 
prognose dan patiënten met een MSSA infectie.3 In Nederland worden patiënten met 
risicofactoren voor MRSA dragerschap volgens een nationale richtlijn gescreend op MRSA 
en geïsoleerd verpleegd totdat de MRSA screeningskweken negatief zijn.33 Bij vastgesteld 
MRSA dragerschap blijft de patiënt in isolatie en wordt een MRSA eradicatiekuur ingesteld. 
Deze strategie staat ook bekend als het ‘search and destroy’ beleid. Onder meer door dit 
beleid is de prevalentie van meticilline resistentie onder klinische S. aureus isolaten 
vooralsnog onder de één procent.4 Gezien deze lage prevalentie is het van belang een 
sensitieve en specifieke test te hebben voor het screenen op MRSA. 
In hoofdstuk 8 wordt een nieuwe gevoelige methode beschreven voor het kweken van MRSA. 
In de tijd dat deze studie plaatsvond was het voor de detectie van MRSA meestal gebruikelijk 
om patiëntenmonsters op vaste media te enten, zoals bloedplaten. De resultaten van deze 
studie laten zien dat het gebruiken van een selectief ophopingsmedium (phenyl mannitol 
bouillon) met antibiotica (aztreonam en ceftizoxime), twee keer zoveel MRSA wordt 
gedetecteerd dan met vaste media alleen. Ceftizoxime is gebruikt omdat dit middel 
phenotypisch het expressie niveau van meticilline resistentie kan verhogen. Aztreonam is 
toegevoegd ter onderdrukking van gram-negatieve staven. Deze kweekmethode wordt 
inmiddels in meerdere Nederlandse ziekenhuizen naar tevredenheid gebruikt. 
Sinds 1995 zijn enkele meldingen geweest van MRSA uitbraken in Nederlandse 
zorginstellingen die niet konden worden gerelateerd aan een patiënt met risicofactoren, zoals 
vastgesteld in de richtlijn van de Werkgroep Infectiepreventie (WIP).34,35 Dit kan betekenen 
dat ongemerkt MRSA dragers worden opgenomen in Nederlandse ziekenhuizen. Om dit te 
onderzoeken hebben wij 10 duizend patiënten zonder risicofactoren voor MRSA dragerschap 
bij opname gescreend op MRSA neusdragerschap in vier verschillende Nederlandse 
ziekenhuizen (Hoofdstuk 9). Deze screening laat zien dat onder patiënten zonder 
risicofactoren voor MRSA dragerschap de prevalentie van MRSA neusdragerschap bij 
opname zeer laag is (0,03%). De risicofactoren zoals vastgelegd in de WIP richtlijn hoeven 
vooralsnog niet te worden aangepast. Deze lage prevalentie ondersteunt het huidige ‘search en 
destroy’ beleid in combinatie met het restrictieve antibioticagebruik. Dit beleid kan worden 
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verbeterd door het implementeren van snelle MRSA detectie technieken wat grote voordelen 
heeft voor de patiënt (kortere isolatieduur) en ziekenhuis (kosten).36 
 
Conclusies en aanbevelingen voor de clinicus 
 Het screenen van niet-chirurgische patiënten op S. aureus neusdragerschap bij opname 
middels kweek en het vervolgens toedienen van mupirocine neuszalf bij gevonden dragers, is 
niet effectief in het voorkomen van ziekenhuisinfecties met S. aureus, en wordt daarom niet 
aanbevolen. 
 De behandeling van S. aureus neusdragerschap dient te worden vervolgd met 
neuskweken omdat rekolonisatie frequent kan voorkomen. 
 Neusdragers van S. aureus hebben een drievoudig verhoogd risico op het krijgen van 
een ziekenhuis bloedbaaninfectie met S. aureus, in vergelijking met niet-dragers. 
 Niet dragers van  S. aureus in de neus, die wel een ziekenhuis bloedbaaninfectie 
oplopen, hebben een viervoudig verhoogd risico op overlijden, in vergelijking met S. aureus 
neusdragers die eenzelfde infectie doormaken.  
 Neuspeuteren en S. aureus neusdragerschap zijn geassocieerd. Deze associatie is 
waarschijnlijk causaal omdat er een positieve correlatie bestaat tussen de frequentie van 
neuspeuteren en het aantal positieve kweken of de hoeveelheid van S. aureus in de neus. 
 Clinici dienen het ‘search en destroy’ MRSA beleid te ondersteunen. Nederland is de 
last van endemisch aanwezige MRSA tot op heden bespaard gebleven, en dat moet zo blijven.  
 
Conclusies en aanbevelingen voor de onderzoeker 
 Voor nieuwe studies gericht op het voorkomen van S. aureus infecties, is het aan te 
bevelen om van de deelnemers snel een testresultaat van S. aureus dragerschap te hebben en 
snel te starten met behandeling, bij voorkeur op de dag van opname.  
 Dergelijke studies dienen zich ook te richten op patiënten met een verhoogd risico op 
S. aureus bloedbaaninfecties, waaronder patiënten met een verwachte lange opnameduur.  
 De rol van S. aureus dragerschap op plekken buiten de neus op het ontstaan van S. 
aureus infecties behoeft nader onderzoek. 
 De hogere mortaliteit onder niet dragers versus dragers van S. aureus met een S. 
aureus bloedbaaninfectie behoeft confirmatie en het onderliggende mechanisme dient te 
worden onderzocht. 
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 De immunologische respons op S. aureus neusdragerschap behoeft grondig 
onderzoek. Het menselijke model die wordt gebruikt op onze afdeling leent zich hier 
uitstekend voor (niet beschreven in dit proefschrift). 
 Indien men beoogt  S. aureus neusdragerschap te behandelen, is mogelijk het advies 
om niet meer in de neus te peuteren een waardevolle aanvulling op het eradicatieschema. 
 Voor het screenen van MRSA moet altijd een ophopingsmedium te worden gebruikt. 
 Een snelle sensitieve en specifieke test moet worden ontwikkeld voor het screenen van 
patiënten op zowel meticilline-resistente als gevoelige S. aureus (uitslag binnen enkele uren). 
 
Aanbevelingen voor de beleidsmaker 
 Meer geld moet worden besteed aan onderzoek die zich richt op het voorkomen van S. 
aureus infecties want dit is naar alle waarschijnlijkheid kosten-effectief. In Nederland zijn er 
1.6 miljoen ziekenhuisopnames per jaar (Prismant). Ongeveer 0.1 procent van deze patiënten 
(n=1600) zullen ziekenhuis bloedbaaninfectie met S. aureus oplopen tijdens de 
ziekenhuisopname. Zo’n S. aureus bloedbaaninfectie kost gemiddeld 10.000 euro, en heeft 
een mortaliteit van 25% (400 doden/jaar).1,37 In Nederland kosten deze S. aureus 
bloedbaaninfecties de samenleving 16 miljoen euro per jaar. Bij dit bedrag dient ook nog de 
kosten van andere S. aureus te worden opgeteld, waaronder chirurgische wondinfecties, 
urineweginfecties, osteomyelitis, en luchtweginfecties. 
 Meer energie moet worden gestoken in het promoten van het Nederlandse ‘search and 
destroy’ MRSA beleid, zowel op nationaal als op internationaal niveau. Dit beleid is al 20 jaar 
effectief, terwijl minder streng beleid in andere landen ten aanzien van MRSA hebben 
gefaald. 
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presentation for the ‘9th international symposium on Staphylococci’, Kolding (Denmark), 
2000. 
 Antibiotica resistentie en de DNA chip. Wetenschapsdag Arts-Assistenten Vereniging 
Erasmus MC, Rotterdam (The Netherlands), 2000. 
 Nosepicking and nasal carriage of Staphylococcus aureus. Oral presentation for the ‘42nd 
International Conference on Antimicrobial Agents and Chemotherapy’, San Diego (USA), 
2002 
 Does application of mupirocin in the nose prevent nosocomial Staphylococcus aureus 
infections? A placebo controlled trial. Oral presentation for the ‘42nd International 
Conference on Antimicrobial Agents and Chemotherapy’, San Diego (USA), 2002 
 Nosepicking and nasal carriage of Staphylococcus aureus, part two. Poster presentation for 
the 10th International Symposium on Staphylococci and Staphylococcal Infections, 
Tsukuba (Japan), 2002. 
 Application of mupirocin in the nose postpones nosocomial Staphylococcus aureus 
infections. Poster presentation for the 10th International Symposium on Staphylococci and 
Staphylococcal Infections, Tsukuba (Japan), 2002. 
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 Low prevalence of MRSA carriage at hospital admissions in The Netherlands. Poster 
presentation for the 10th International Symposium on Staphylococci and Staphylococcal 
Infections, Tsukuba, Japan, 2002. 
 Low prevalence of methicillin-resistant Staphylococcus aureus nasal carriage in hospital 
admissions in The Netherlands. Oral presentation for the Wetenschappelijke 
Voorjaarsvergadering van de Nederlandse Vereniging voor Medische Microbiologie, 
Arnhem (The Netherlands), 2003. 
 LCI richtlijn community onset MRSA. Oral presentation for the Wetenschappelijke 
Voorjaarsvergadering van de Nederlandse Vereniging voor Medische Microbiologie, 
Arnhem (The Netherlands), 2005. 
 Staphylococcus aureus infections. Lead by the nose. Seminar for the department of 
Immunology, University of Greifswald, Greifswald (Germany), 2005. 
 Risk and outcome of nosocomial Staphylococcus aureus bacteremia in nasal carriers versus 
non-carriers. Oral presentation for the Internistendagen of the Nederlandse Internisten 
Vereeniging, Maastricht (The Netherlands), 2005. 
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 4 ziekenhuizen 
 16 auteurs 
 5.000 S. aureus stammen 
 14.500 neuzen 
 18.000 wattenstokken 
 25.000 formulieren 
 370.000 euro 
 
Dit groots opgezette onderzoek had ik uiteraard niet kunnen uitvoeren en voltooien zonder de 
medewerking, inzet en steun van een hele reeks personen. Graag wil ik alle mensen die op een 
of andere wijze een bijdrage hebben geleverd aan mijn onderzoek bedanken en niet in de 
laatste plaats alle patiënten en vrijwilligers die hun neuzen beschikbaar hebben gesteld voor 
de wetenschap.  
 
Een persoonlijk woord van dank wil ik richten tot: 
 
Henri Verbrugh: Beste Henri, zeer veel dank voor jouw vertrouwen in mij. Je hebt mij de 
vrijheid gegund om de dingen ook op mijn manier te doen, maar was tevens altijd bereikbaar 
als klankbord en graag bereid constructief mee te denken. Ik vind het inspirerend om met jou 
van gedachten te wisselen over nieuwe onderzoeksavonturen (Brazilië?). 
  
Greet Vos:  Ha Greet, je bent een heerlijke collega en de meest enthousiaste copromotor die ik 
me had kunnen wensen. Jouw aanstekelijke enthousiasme voor het vak gaf mij zeven jaar 
geleden een extra impuls om arts-microbioloog te worden. Fantastisch hoe je ruim de tijd nam 
om mij met raad en daad bij te staan. 
 
Alewijn Ott: Beste Alewijn, het merendeel van de eerste analyses en interpretaties heb ik 
samen met jou gedaan. Jouw diepgaande kennis en ervaring in de epidemiologie en statistiek 
zijn voor mij, en eigenlijk voor de hele afdeling, goud waard. Voor mij was je als het ware 
een tweede ‘copromotor’.  
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Alex van Belkum: Beste Alex, jou ‘no nonsense’ instelling werkt verfrissend. Het is altijd 
snel en goed ‘zaken’ doen met jou. Neusdragerschap studies nemen een hele andere wending 
nu wij COGEM toestemming hebben verkregen om recombinant Stafylokokken in neuzen te 
gaan smeren. Het zal me benieuwen. 
 
Jan Kluytmans: Beste Jan, stafylokokken-in-de-neus goeroe, jouw voorwerk heeft dit 
proefschrift mede mogelijk gemaakt. Ik vind het bewonderenswaardig hoe jij jouw 
‘onderzoeksterrein’ en kennis deelt en uitbouwt met anderen vanuit een niet-academische 
setting.  
 
Christina Vandenbroucke-Grauls: Beste Christina, jouw kritische commentaren op het 
onderzoeksprotocol en uiteindelijke manuscripten hebben mij zeer geholpen scherp te blijven 
en helder te formuleren. Ik hoop dat de ‘koek en zopie’ tijdens de MUP meetings jouw 
treinreizen naar Rotterdam enigszins hebben verzacht. 
 
Andreas Voss: Beste Andreas, door jouw expertise en andere kijk op wetenschappelijk 
onderzoek was het leerzaam en door je gevoel voor humor ook ontzettend leuk om samen met 
jou onderzoek te doen. Gelukkig heeft jouw overstap naar het Canisius ziekenhuis verdere 
samenwerking niet belemmerd. 
 
Peter van Keulen: Beste Peter, dank je wel voor jouw deelname aan en inzet voor de MUP-
studie en de spin-off studies. Als enig deelnemend perifeer ziekenhuis hebben jullie een zeer 
groot deel van de  patiënten data verzameld. Daarvoor ben ik ook mijn dank verschuldigd aan 
Annie Antonissen, Geert van de Sanden, Melanie Srodzinsky, en Laura Verputten. 
 
Marlene Meester: Beste Marlene, jouw jarenlange ervaring in de infectiepreventie is zeer 
waardevol gebleken. Zo had jij ook ‘antieke’ proefschriften over stafylokokken in jouw bezit, 
welke mij een historisch perspectief ten aanzien van dit onderzoek hebben gegeven. Ook Joke 
van Wegen wil ik hier bedanken voor haar inzet voor de MUP-studie.  
 
Wilma Kraak: Beste Wilma, jij was de stille kracht uit Nijmegen. Hoofdzakelijk in je eentje 
heb jij honderden patiënten ‘geronseld’ voor de MUP-studie en duizenden formulieren 
ingevuld. Grandioos! 
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Roel Verkooyen: Beste Roel, dankjewel voor jouw onmisbare hulp bij het ontwikkelen van de 
‘case record forms’ die door een computer konden worden ingelezen. Ik zou niet weten hoe ik 
zonder jouw hulp 25.000 formulieren in een database zou hebben gekregen. Je know-how 
wordt nu weer gebruikt voor de vervolg studie. 
 
Marius Vogel en Arjen van Vliet: Beste Marius en Arjen, de computer experts, wat moet onze 
afdeling zonder jullie? Verloren bestanden of ‘verzoekjes’ worden door jullie ergens uit een 
server tevoorschijn getoverd. Geweldig! Dank dank dank!  
 
Wytske Fokkens: Beste Wytske, ik mis je hier wel in Rotterdam. Waren we eindelijk op dreef 
met het onderzoek, ging je naar Amsterdam! Met plezier denk ik terug aan onze neuspeuter 
brainstorm sessies op jouw oude kamer in de ‘ivoren toren’.  
 
Willem van Leeuwen: Beste Willem, jouw MLST-chip voorwerk kwam goed van pas. Hele 
stammencollecties zijn door deze chip geanalyseerd, waaronder de MUP collectie, met leuke 
resultaten. Jammer dat het maken van een eigen virulentie-chip met Susan is mislukt om de 
karakterisering van invasieve versus niet invasieve stammen te completeren.  
 
Susan Snijders: Beste Susan, jouw handen zijn onmisbaar gebleken, onder andere voor het 
‘chippen’. Samen hebben we nog kunnen ploeteren met een virulentie-chip, echter zonder 
resultaat. Volgende keer beter met een gekochte chip. 
 
Hélène Boelens: Beste Hélène, zonder jouw hulp zou ik heel wat minder artikelen hebben 
geproduceerd en pas jaren later zijn gepromoveerd. Honderden stammen heb jij met 
verschillende apparaten geanalyseerd. Veel dank. 
 
Jan Nouwen, beste Jan, dank je wel voor het helpen schrijven van het protocol voor de MUP-
studie (7 jaar geleden alweer). Uniek dat wij, na zeven jaar werken op dezelfde afdeling en 
aan hetzelfde micro-organisme, nul publicaties samen hebben. Wellicht komt daar binnenkort 
verandering in. 
 
Marian Humphrey and Paula Jansen: lieve dames, dank voor al jullie steun en het mij wegwijs 
maken in de administratieve wirwar van het Erasmus MC. 
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Verder wil ik graag drie medische studenten bedanken voor hun hulp: Menno van Kleef, 
Jeroen Verveer en Jilling Bergman. Beste Menno, jij nam het werk wel heel serieus door 
neuswattenstokken als corsages op een studentengala uit te delen. Beste Jilling, bedankt voor 
de eerste typeringen en opzet database die hebben geleid tot het ‘relatief risico’ artikel. Beste 
Jeroen, het kweken van bijna tweehonderd studenten was een hele klus die je toch mooi hebt 
geklaard.   
 
Unit Infectiepreventie: Myra, Cindy, Carol, Marja, en Gerard. Dank voor het includeren van 
patiënten op dagen dat ik met vakantie of cursus was (niet te vaak?). Margreet Filius, als 
enige niet-hygiënist, deed ook mee aan deze pool. Succes met het afronden van je boekje! 
Myra Behrendt wil ik nog in het bijzonder bedanken voor het mij wegwijs maken in de 
wereld van infectiepreventie en sepsis registratie. Cindy van Pelt en Peter de Man wil ik extra 
bedanken voor al het werk rondom het ontwikkelen en valideren van de MRSA bouillon. 
 
Verder heeft iedereen van de afdeling Medische Microbiologie en Infectieziekten wel een 
keer op persoonlijke wijze een bijdrage geleverd aan mijn onderzoek: stafleden, analisten, en 
arts-assistenten. Bedankt! Nogmaals wil ik alle analisten bedanken voor het verwerken van al 
die duizenden neuswattenstokken en het bewaren van de ‘kokken uit de gokken’.  
 
Wim Ang: Beste Wim, paranimf, dank je wel voor het kritisch lezen van bijna al mijn 
manuscripten. Heerlijk hoe jij genadeloos strepen zet door hele alinea’s. 
Bernard Jan Verkoren, de andere paranimf, en dat zegt genoeg. L’Chaim!  
 
Lieve ouders, dank voor een heerlijke jeugd en al jullie onvoorwaardelijke steun daarna. De 
gevleugelde woorden van vroeger: ‘heb je snot, doe het vlug in een pot’, neem ik nog steeds 
letterlijk. 
 
Lieve Sigrid, met jou is het leven vurrukkulluk.  
Lieve Lara en Peer, nu hebben jullie ook een boekje van papa voor het ‘slapen gaan’. 
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Geboortedatum  7 december 1970 te ‘s-Gravenhage 
Nationaliteit Nederlandse 
Burgerlijke staat Gehuwd met Sigrid Heck 
Kinderen Lara (30-11-2001) en Peer (21-11-2004) 
 
Opleiding: 
1998-2005 AGIKO medische microbiologie, Erasmus MC, Rotterdam.  
1998-2002 Klinische epidemiologie, Netherlands Institute for Health Sciences, Rotterdam. 
1989-1997 Geneeskunde, Rijksuniversiteit Leiden. 
1985-1989 International school, Hilversum, Nederland. 
1983-1985 Curundu Junior High School, Panama. 
1982-1983 Collegio Episcopal, Panama. 
 
Werk ervaring 
Vanaf juli 2005 Arts-microbioloog, Erasmus MC, Rotterdam. 
2004 Waarnemend arts-microbioloog als senior arts-assistent, RDGG, Delft. 
1998-2005 AGIKO medische microbiologie, Erasmus MC, Rotterdam.  
1997-1998 AGNIO pediatrische intensive care, Sophia Kinderziekenhuis, Rotterdam. 
1992-1995 Coördinator weefseltransplantaties; Bio Implant Services / Eurotransplant, 
 Leiden. 
 
Onderzoek 
1998-2005 Promotieonderzoek. ‘Staphylococcus aureus infections. Lead by the  
 nose.’ Erasmus MC, Rotterdam (verdediging op 17 juni 2005). 
2001 Proteomics of Staphylococcus aureus nasal carriage, UCLA, Los Angeles,  
 U.S.A. 
1998 Septische complicaties van enteraal versus parenteraal gevoede neonaten  
 aan de hart-long machine, Sophia Kinderziekenhuis, Rotterdam. 
1995 Testen nieuwe bottransplantaten in ratten, Osteotech Inc., New Jersey, U.S.A. 
1994-1995 Preventie van bacteriële contaminatie van non-heart beating donor  
 hartkleppen, Hartkleppenbank, Rotterdam. 
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Cursussen 
2004  Management Cursus, St. Management Scholing Medische Specialisten, 
 Utrecht. 
2003 Molecular Medicine, Josephine Nefkens Institute, Rotterdam. 
2003 Medical Mycology, Centraalbureau voor Schimmelcultures, Utrecht. 
2002 Virologie, Erasmus MC, Rotterdam. 
2002 Medische Parasitologie, Boerhaave Commissie, Leiden.  
2001 (Na)scholingscursus Infectieziekten. Boerhaave Commissie, Leiden. 
    
Nevenactiviteiten: 
2004-heden Lid werkgroep “MRSA in de openbare gezondheidszorg”, Landelijk  
 Coördinatiecentrum Infectieziekten (LCI). 
2004-heden Redactielid Nederlands Tijdschrift voor Medische Microbiologie. 
2003-2004  Organisatie eerste “get out of your lab days”, Molecular Medicine Postgraduate 
 School, Rotterdam. 
2003-2004 Lid Postdoctorale student commissie Molecular Medicine Postgraduate  
 School, Rotterdam. 
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Wetenswaardigheden: 
2004-heden Oprichter werkgroep ‘Stront aan de Knikker’, aanpak hondenpoep overlast  
 Den Haag. 
2004-heden Fietser ROPARUN, Parijs-Rotterdam. 
1999-heden Drumles van de ‘beste drumleraar in de Benelux’. 
1994-1995 Producent musical Anatevka, Fiddler on the Roof; acht voorstellingen in de 
 Leidse Schouwburg. 
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